CLINICAL STUDY PROTOCOL
Study Title: A Phase 2/3, Open -Label Study of the Pharmacokinetics, Safety, and Antiviral 
Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) Single Tablet Regimen (STR) in HIV -1 Infected Antiretroviral 
Treatment -Naive Adolescents and Virologically Suppressed Children
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_993186] 
Foster City, CA [ZIP_CODE]
IND No.:
EudraCT Number:
Clinicaltrials.gov 
Identifier:[PHONE_15111]-002780-26
[STUDY_ID_REMOVED]
Indication: HIV-1
Protocol ID: GS-US-292-[ADDRESS_993187] 
Information: The medical monitor name [CONTACT_3669] [CONTACT_727403].
Protocol 
Version/Date:Original: 04 February 2013
Amendment 1: 22 March 2013
Amendment 2: 09 January 2015
Amendment 3: [ADDRESS_993188] 2016
Amendment 4: 11 June 2018
Amendment 5: [ADDRESS_993189] 2018
Amendment 6: 21February [ADDRESS_993190] or Independent Ethics Committee. The information is only  to be 
used by  [CONTACT_82226]. You will not disclose any of the information to others without 
written authorization from [COMPANY_009] Sciences, Inc., except to the extent necessary  to obtain 
informed consent from those persons to whom the drug may  be administered.
(rJ GILEAU 
EVG /COBI/FfCffAF 
Protocol GS-US-[ADDRESS_993191] OF IN-TEXT FIGURES .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 4 
PROTOCOL SYNOPSIS .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ....... 5 
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ............ ................ .......... ........ ................ ...... 17 
1. INTRODUCTIO N ............ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 21 
1.1. Backgrowid .......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 21 
1.1.1. Elvitegra vir/Cobici stat/Emtricitabine/Tenofo vir Alafenamide 
(E/C/F/TAF ) ................ ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 23 
1.2. Rationale for the Cwl'en t Study ............ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... [ADDRESS_993192] POP ULATION ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 39 
4.1. Number of Subjects and Subjec t Selec tion .. .......... ........ ................ ................ .......... ........ ................ ...... 39 
4.2. Inclu sion Criteria .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 39 
4.3. Exclusion Criteria ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 42 
5. INVESTIGATIONAL MED ICINAL PROD UCTS ............. ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 45 
5.1. Rando1niza tion and Blinding ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 45 
5.2. Description and Handling ofE/C /F/TAF STR ............... ........ ......... ........ ........ ......... ........ ........ ......... .... .45 
5.2.1. Foimulation ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 45 
5.2.2. Packaging and Labeling .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 46 
5.2.3. Storage and Handling .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 46 
5.3. Dosage and Ad1nini strntion ofE/C/F/TAF STR ............ ................ ................ .......... ........ ................ ...... [ADDRESS_993193] Enrollment and Treatment Assignment ............. ........ ......... ........ ........ ......... ........ ........ ......... ..... 55 
Screening Visit ............. ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 55 
Treatment Assess1nent s ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 57 
6.3.1. Baseline/Day 1 Assessment s ................ ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 57 
6.3.2. Treatment Assessments through 48 Week s (Week s 1 (Day 7) -48) .................... .......... ..... 59 
6.3.3. Inten sive PK Evaluation a11 A sub·ects onl , inclusi ve of Coho113 .......... ................ ...... 62 
6.3.6. Eary Stu y Drng D1scontmuahon ESDD ........ .......... ........ ................ ................ .......... ..... 65 
6.3.7. 30-Day Follow -Up Visit .............. ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 66 
Bone Evaluations ......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 67 
Bone and Renal Safe ......... ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 68 
Cntena or D1scontmuahon o Stu y Treatmen t. ........... ........ ......... ........ ........ ......... ........ ........ ......... ..... 68 
Virologic Failw·e .......... ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ........ ........ ......... ..... 69 
6.8.1. Management of Subop timal Virologic Response (Coho1 1 1 only) ........ ................ .......... ..... 69 
CONFIDENTIAL Page2 2 1 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences, Inc. Final 
Amendment6 
6.8.2. Manage1nent ofVirologic Rebound ............. ........ ......... ........ ........ ......... ........ ........ ......... ..... 70 
6.8.3. Subjects with e:: 400 copie s/mL of HIV- I in Absence of SVR orVR ............ ................ ...... [ADDRESS_993194] (IRB)/Independent Ethics Committee 
(IEC)/Research Ethic s Board (REB ) Appro val .................... ......... ................ ......... ........ ...... 93 
CONFIDENTIAL Page3 2 1 Febma1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 4 21 February [ZIP_CODE].1.3. Informed Consent ................................................................................................................. 94
9.1.4. Confidentiality ...................................................................................................................... 94
9.1.5. Study Files and Retention of Records .................................................................................. 94
9.1.6. Electronic Case Report Forms (eCRFs) ............................................................................... 96
9.1.7. Drug Accountability ............................................................................................................. 96
9.1.8. Inspections ............................................................................................................................ 96
9.1.9. Protocol Compliance ............................................................................................................ 96
9.2. Sponsor Responsibilities ........................................................................................................................ 96
9.2.1. Protocol Modifications ......................................................................................................... 96
9.2.2. Study Report and Publications ............................................................................................. 97
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... [ADDRESS_993195] OF IN -TEXT TABL ES
Table 1-1. Pooled Virologic Outcomes of Studies 104 and 111 at Weeks 48a and144b........................ 24
Table 1-2. Measures of Bone Mineral Density in Studies 104 and 111 (Week 144Analysis) ................ 26
Table 1-3. Change from Baseline in Renal Laboratory Tests in Studies 104 and 111 (Week 144
analysis) .................................................................................................................................. [ADDRESS_993196] OF IN -TEXT FIGU RES
Figure 1-1. Predicted EVG AUC in Children Following Administration of E/C/F/TAF 
90/90/120/6 mg ....................................................................................................................... 31
Figure 1-2. Predicted COBI AUC in Children Following Administration of E/C/F/TAF 
90/90/120/6 mg ....................................................................................................................... 32
Figure 1-3. Predicted FTC AUC in Children Following Administration of E/C/F/TAF 
90/90/120/6 mg ....................................................................................................................... 32
Figure 1-4. Predicted TAF AUC in Children Following Administration of E/C/F/TAF 
90/90/120/6 mg ....................................................................................................................... 33
Figure 1-5. Predicted TFV AUC in Children Following Administration of E/C/F/TAF 
90/90/120/6 mg ....................................................................................................................... 33
Figure 3-1. Study Schema ......................................................................................................................... 38
Figure 6-1. Suboptimal Virologic Response Schema (Cohort 1 only) ...................................................... 70
Figure 6-2. Virologic Rebound Schema .................................................................................................... 71
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993197]
Foster City, CA [ZIP_CODE]
Study Title: A Phase 2/3, Open -Label Study  of the Pharmacokinetics, Safet y, 
and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/ 
Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) 
in HIV -1 Infected Antiretroviral Treatment -Naive Adolescents and 
Virologically  Suppressed Children
IND Number: 
EudraCT Number: 
ClinicalTrials.gov 
Number:111,007
2013-002780-26
[STUDY_ID_REMOVED]
Study Centers
Planned:Approximately  15 centers in North America, Africa, and Thailand
Objectives: Cohort 1
The primary  objectives of this study  are:
Part A:
To evaluate the steady state pharmacokinetics (PK) for 
elvitegravir (EVG) and tenofovir alafenamide (TAF) and 
confirm the dose of the elvitegravir/cobicistat/emtricitabine/ 
tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) 
in HIV -1 infected, an tiretroviral (ARV) treatment- naive 
adolescents
Part B:
To evaluate the safet y and tolerability  of the E/C/F/TAF STR 
through Week 24 in HIV -1 infected, ARV treatment- naive 
adolescents
The secondary  objectives of this study  are:
To evaluate the safet y and to lerability  of the E/C/F/TAF STR 
through Week 48 in HIV -1 infected, ARV treatment- naive 
adolescents
To evaluate the antiviral activity  of the E/C/F/TAF STR through 
Week 48 in HIV -1 infected, ARV treatment- naive adolescents
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 6 21 February 2020Cohort 2
The primary  objectives of this study  are:
Part A:
To evaluate the PK of EVG and TAF in virologically  suppressed 
HIV-1 infected children 6 to < 12 y ears of age weighing ≥ 25 kg 
administered E/C/F/TAF STR
Part B:
To evaluate the safet y and tolerability  of E/C/F/TAF STR 
through Wee k 24 in virologically  suppressed HIV -
1infected 
children 6 to < 12 years of age weighing ≥ 25 kg
The secondary  objectives of this study  are:
To evaluate the antiviral activity  of switching to E/C/F/TAF 
STR through Week 48 in virologicall y suppressed HIV -1 
infected children 6 to < 12 y ears of age weighing ≥ 25 kg
To evaluate the safet y and tolerability  of E/C/F/TAF STR 
through Week 48 in virologically  suppressed HIV -1infected 
children 6 to < 12 years of age, weighing ≥ 25 kg
Cohort 3
The primary  objectives of this study  are:
To evaluate the PK of EVG and TAF and confirm the dose of 
the STR in virologically  suppressed HIV -1 infected children
≥ 2years of age weighing ≥ 14 to < 25 kg administered 
E/C/F/TAF low dose (LD) (90/90/120/6 mg) STR
To evaluate the saf ety and tolerability  of E/C/F/TAF LD STR 
through Week 24 in virologically  suppressed HIV -1 infected 
children ≥ 2 y ears of age and weighing ≥ 14 to < 25kg
The secondary  objectives of this study  are:
To evaluate the antiviral activity of switching to E/C/F/ TAF LD 
STR through Week 48 in virologicall y suppressed HIV 1 infected 
children ≥ 2 y ears of age and weighing ≥ 14 to < 25kg
To evaluate the safet y and tolerability  of E/C/F/TAF LD STR 
through Week 48 in virologically  suppressed HIV -1 infected 
children ≥ 2 years of age and weighing ≥ 14 to < 25kg
EVG/COBI/FfCffAF 
Protocol GS-US-292-0106 
[COMPANY_009] Sciences , Inc. 
Study Design: 
CONFIDENTIAL All Cohorts 
I 
I Final 
Amendment6 
Open-label , multi center, multi- coho1i, single-ann study of the 
phaimacokinetics, safety, tolerability, and antiviral activity of the 
E/C/F/TAF STR in HIV-1 infected ARV treatment-naive 
adolescents and virologically sup pressed children. 
A total of 50 adolescents (12 to< 18 years of age), and upto 
75 children (2 to< 12 years of age) of either sex will be enrolled to 
receive the E/ C/F/TAF STR once daily with food as follows: 
Part A 
Intensive PK samples will be anal yzed once they are available from 
18 subjects regai·d less of age distribu tion (Coho1is 1 and 2 only). 
Coho1i 1, Paii A: EVG, TAF and C OBI exposures will be compai·ed 
to historical data from adult HIV-1 infected subjects. T AF data will 
also be compar ed to HIV-n egative subjects from 292-010 3 study. 
FTC and TFV expos ures will be compar ed to historical data in 
HIV-infe cted adults and available data in adolescent subj ects. 
Coho1i 2 Paii A and Coho1 i 3: EVG, TAF, COBI, FTC and TFV 
expos ures will be compar ed to historical adult data. 
EVG and TAF dose confnm ation w ill be established if the 90% CI 
of geometric me an ratios for AUC in adolescents and children 
(respect ively) versus those in adults are w ithin the e quivalency 
bounds of 70-14 3%. 
Following completion of the Intensive PK visit, subjects will 
continue to receive the E/ C/F/TAF STR and return for scheduled 
study visits through Week 48. 
Cohort 1 (Adole scents 12 to< 18 year s of age) 
• Eighteen to 24 eligible subjects will be initially enrolled to 
evaluate the steady state phaim acokinetics, and confnm the dose 
of the E/C/F/T AF STR. 
• Pa1i A will aim to enroll at least 6 subj ects 12 to< [ADDRESS_993198] 6 subjects 15 to < 18 yeai·s of age. 
Page7 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 8 21 February 2020If at least 6 subjects ages 12 to < 15 y ears and 6 subjects ages 
15to < [ADDRESS_993199] not been enrolled at the time of the Intensive PK 
analysis, Part A enrollment will remain open in order to enroll 
sufficient subjects to meet the minimum enrollment of the 2 age 
subgroups.
Subjects enrolled in Part A will participate in an Intensive PK 
evaluat ion at Week 4. Samples will be collected at 0 (pre-dose, 
≤ 30 minutes prior to dosing), [ADDRESS_993200] -dose.
Cohort 2 (Children 6 to < 12 years of age and weigh ≥ 25 kg)
Eighteen to 24 eligible subjects will be i nitially  enrolled to 
evaluate the EVG and TAF plasma PK and confirm the dose of 
EVG and TAF.
Subjects enrolled in Part A will participate in an Intensive PK 
evaluation at Week 4. Samples will be collected at 0 (pre -dose, 
≤ 30 minutes prior to dosing), 0.[ADDRESS_993201] -dose.
Cohort 3 (Children ≥ 2 years of age and weighing ≥ 14 to 
< 25 kg)
Approximately  25 eligible subjects will be initially  enrolled to 
evaluate the EVG and TAF plasma PK and confirm the dose of 
EVG and TAF.
Subjects enrolled in Part A will participate in an Intensive PK 
evaluation at Week 2. Samples will be collected at 0 (pre -dose, 
≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 
8hours post -dose.
Part B
Cohort 1 (Adolescents 12 to < 18 years of age)
Screening will be initiated into Cohort 1, Part B following 
confirmation of EVG and TAF exposure in at least 18 subjects from 
Cohort 1, Part A. The additional 26 –32 subjects will be enrolled in 
Cohort 1, Part B to evaluate the safet y, toler ability and antiviral 
activity  of the E/C/F/TAF STR in at least 50 patients, including all 
subjects enrolled in Cohort 1 (Parts A and B combined).
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 9 21 February 2020Cohort 2 (Children 6 to < 12 years of age and weigh ≥ 25 kg)
Screening will be initiated into Cohort 2, Part B based on exposure 
data from at least 18 subjects from Cohort 2, Part A. The additional 
26 – 32 subjects will be enrolled in Cohort 2, Part B to evaluate the 
safety , tolerabilit y and antiviral activity  of the E/C/F/TAF STR in at 
least 50 patients, in cluding all subjects enrolled in Cohort 2 (Parts A 
and B combined).
Cohort 3 (Children 
≥ 2 years of age and weighing ≥ 14 to 
< 25 kg)
No Part B for this cohort. All subjects will be enrolled in Part A 
and will complete an Intensive PK evaluation.
Number of Subjects 
Planned:Cohort 1
50 subjects
Part A: Eighteen to 24 subjects representing 2 age subgroups 
(atleast [ADDRESS_993202] be 12 to <[ADDRESS_993203] be 15 to < 18 y ears of age)
Part B: Twent y-six to 32 subjects between 12 to <18years of age 
(dependent upon enrollment in Part A)
Cohort 2
50 subjects
Part A: Eighteen to 24 subjects between 6 to < 12years of age 
weighing ≥ 25 kg
Part B: Twent y-six to [ADDRESS_993204] be 6 to < 12years of age 
and weigh ≥ 25 kg (dependent up on enrollment in Part A)
Cohort 3
Approximately  25 subjects ≥ 2 y ears of age and weighing ≥ 14 to 
< 25 kg
Target Population: Cohort 1
Antiretroviral treatment- naive, HIV -1 infected adolescents (12 to 
<18 years of age) of either sex with plasma HIV -1 RNA levels 
≥1,000 copi[INVESTIGATOR_014]/mL
Cohort 2
Virologically  suppressed, HIV -1 infected children (6 to < 12years 
of age and screening weight ≥ 25 kg) of either sex with plasma 
HIV-1 RNA levels < 50 copi[INVESTIGATOR_014]/mL  for ≥ 6 consecutive months prior 
to screening on a stable an tiretroviral regimen, with no documented 
history  of resistance to any  component of E/C/F/TAF STR.
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
Dmati onof 
Treatment: Cohort 3 Final 
Amendment6 
Virolog ically suppre ssed, HIV-1 infected children (:::: 2 years of age 
and screen ing weig ht of:::: 14 to< 25 kg) of either sex with plasma 
HIV-1 RNA levels < 50 copi[INVESTIGATOR_014]/mL for :::: 6 consecutive month s prior 
to scree ning on a stable antiretroviral regime n, with no documented 
histo1y of resistance to any compone nt of E/C/F IT AF STR. 
48 weeks 
Diagnosis and Main HIV-1 infected subjects who meet the following criteria: 
Eligibility Criteria: Cohort 1 
CONFIDENTIAL • Age at Baseline: 12 to< 18 years old 
• Weig ht at Scree ning::::: 35 kg (77 lbs) 
• Plasma HIV-1 RNA :::: 1,000 copi[INVESTIGATOR_014]/mL at Scree ning 
([COMPANY_002] COBAS TaqMan v2.0) 
• Screening genotype repo1i shows sensitivity to EVG, FTC and 
TFV (Monogram Bioscience s, Inc.) 
• S ubjects with HIV subtype AE who meet all inclu sion/exclusio n 
criteria and who h ave a non-repo1iable integra se genotype result 
may proceed with study emollme nt. (For Thailand only) 
• No prior u se of any approved or exper imental anti-HIV-I dmg 
for any length of time ( other than that given for prevention of 
mother-to-child transm ission) 
Cohort2 
• Age at Baseli ne: 6 to< 12 years old 
• Weig ht at Scree ning: :::: 25 kg (55 lbs) 
Page 10 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 11 21 February 2020Plasma HIV -1 RNA: < 50 copi[INVESTIGATOR_014]/mL  (or undetectable HIV -1 
RNA level according to the local assay  being used if the limit of 
detection is > 50 copi[INVESTIGATOR_014]/mL ) for ≥ 6 months prior to screening 
on a stable antiretroviral regimen, without prior history  of 
resistance to an y component of E/C/F/TAF STR
Unconfirmed HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  after previously  
reaching virologic suppression (transient detectable viremia, or 
“blip”) and prior to screening is acceptabl e
Currently  receiving an antiretroviral regimen that has been stable 
for at least 6 months or has been newly  initiated within 6 months 
for reasons other than virologic failure.
Cohort 3
Age at Baseline: ≥ 2 y earsold
Weight at Screening: ≥ 14 kg (31 lbs) t o < 25 kg (55 lbs)
Plasma HIV -1 RNA: < 50 copi[INVESTIGATOR_014]/mL  (or undetectable HIV -1 
RNA level according to the local assay  being used if the limit of 
detection is > 50 copi[INVESTIGATOR_014]/mL ) for ≥ 6 months prior to screening 
on a stable antiretroviral regimen, without document edhistory  
of resistance to an y component of E/C/F/TAF STR
Unconfirmed HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  after previously  
reaching virologic suppression (transient detectable viremia, 
or “blip”) and prior to screening is acceptable
Currently  receiving an antiretrov iral regimen that has been stable 
for at least 6 months or has been newly  initiated within 6 months 
for reasons other than virologic failure.
Study  Procedures/ 
Frequency :All Subjects (All Cohorts unless specified):
At the Screening, Baseline/Day  1, and all subsequent study  visits 
laboratory  anal yses (hematology , chemistry  and urinaly sis), HIV-1 
RNA, vital signs, and complete or sy mptom -directed phy sical 
examinations and estimated GFR using the Schwartz formula will 
be performed.
At Screening, HIV -1 prote ase, reverse transcriptase and integrase 
genot ype will be anal yzed (for Cohort 1 onl y).
HBV and HCV serologies will be analy zed and supi[INVESTIGATOR_727366].
Blood samples will be collected for full flow cy tometry  panel testing 
at Screening, Baseline a nd Weeks 2 - 48.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 12 21 February 2020Adverse events and concomitant medications will be assessed at 
each visit.
Subjects will return for study  visits at Weeks 1 (Day  7), 2, 4, 8, 12,
16, and then every  8 weeks through Week 48.
Subjects enrolled in Part A will participate in a n Intensive PK 
Evaluation at Week 2 (Cohort 3, all subjects) or Week 4 (Cohorts 1 
and 2). Subject diary  cards will be provided to all Part A subjects to 
record administration of study  drugs prior to the Intensive PK visit.
For subjects in Cohort 1 and 2, a trough PK sample ([ADDRESS_993205]-dose) will be collected at Weeks 1, 2, and 24. For Cohort 1, a 
trough PK sample will also be collected at Week 48. For subjects in 
Cohort 3, a trough sample will be collected at Weeks [ADDRESS_993206] -dose at Week 4 (Cohort 1 
PartB subjects onl y) and at Week 12 (all Cohort 1) . For subjects in 
Cohort [ADDRESS_993207]-dose at Weeks 8, 12 ,and 16.
Fasting glucose and lipid panel (total choleste rol, HDL, direct LDL, 
and trigl ycerides) will be collected at Baseline, Week 24, and
Week 48.
The following serum bone safet y parameters will be collected at 
Screening (Cohort 3), Baseline (Cohorts 1 and 2) , Week 8 (Cohort 1 
only), and Weeks 12, 24, and 48 :
Cohorts 1 and 2: bicarbonate, N -telopeptide, C -telopeptide 
(CTX), osteocalcin, and procollagen t ype 1 N -terminal 
propeptide (P1NP).
For all cohorts: bone specific alkaline phosphatase, parath yroid 
hormone (PTH), 25OH Vitamin D, and 1,25OH Vitamin D.
The following urine bone safet y parameters will be collected at 
Baseline, Weeks 8, 12, 24, and 48 :
Cohorts 1 and 2: bicarbonate and N -telopeptide.
Urine will be collected for renal safet y parameters at Screening 
(Cohort 3), Baseline (Cohorts 1 and 2) , Weeks 8, 12, 24, and 48.
For all cohorts: urine chemistry , retinol binding protein, and 
beta-2-microglobulin.
EVG /COBI/FfCffAF 
Protocol GS-US-[ADDRESS_993208] , Dose, 
and Mode of 
Adminis tration: 
Reference Therap y, 
Dose, and Mode of 
Adminis tration: 
CONFIDENTIAL Final 
Amendment6 
Tanner stage will be assessed for subj ects::::: 6 yea rs of age at 
Baseline, Weeks 24 and 48 or until subj ects reach Tanner Stage 5, 
after which point Tanner assess ments will no longer be perfo1med. 
For all coho1ts, dual en ergy x-ray abso rptiometiy (D XA) scans of 
the lumbar spi[INVESTIGATOR_727367]1 med at Baseline, 
Weeks 24 and 48 to measure spi[INVESTIGATOR_1928] (BMD) and 
total body BMD. 
Resis tance testing will be perfo1med using the RT/P R PhenoSense 
GT assay, the IN GeneSeq assay, and the IN PhenoSense assay 
(Monogram Biosciences , Inc.) in subjects who expe rience 
suboptimal virologic response or virologic rebound, if H IV-I RNA 
is ::::: 400 copi[INVESTIGATOR_014]/mL. 
Palatab ility and Acce ptability assess ment will be perfo1med at 
Baseline and Week 4 for Coho1 t 2 su bjects , and Ba seline, Week 4, 
Wee k 24, and Week 48 for Coho1t 3 subjects. For Cohort 1 subj ects 
cmTently on study, it will be perfonned at their next scheduled visit. 
Subjects who are pe1ma nently discontinued from the s tudy before 
Wee k 48 and subjects who do not wish to continue on the study 
after completing Week 48 will be required to return to the clinic 
30 days after the comple tion of study dmg for a 30-Day Follow-Up 
Visit. 
Cohort s 1 and 2: 
Elvitegravir 150 mg/cob icistat 150 mg/emti·icitabine 200 mg/ 
tenofovi r alafenamide 10 mg STR admin istered orally once daily 
with food 
Cohort 3: 
Elvitegravir 90 mg/cob icistat 90 mg/emti·icitabine 120 mg/ tenofovir 
alafenamide 6 mg STR low dose tablet admin istered orally 
once daily with food 
None 
Page 13 2 1 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences, Inc. 
Criteria for 
Evaluation: 
Safety: 
Efficacy: 
PK: 
Statistical Method s: 
CONFIDENTIAL Final 
Amendment6 
Adve rse events, clinical laborato1y tests, Tanner stage assessme nt 
(subjects ~ 6 years of age), selected bone bioma rkers, renal safety , 
and BMD to evaluate the safety and tolerabi lity of the treatment 
regimen. 
Cohort 1 
The efficacy endpoints are: 
• 
• 
• The percentage of subjects with plasma HIV -1 RNA 
< 50 copi[INVESTIGATOR_014] /mL at Weeks 24 and 48 as defined by [CONTACT_727404] -1 RNA 
< 400 copi[INVESTIGATOR_014] /mL at Weeks 24 and 48 as defined by [CONTACT_727405]10 HIV -1 RNA 
( copi[INVESTIGATOR_014]/mL) and in CD4 + cell count ( cells/ µL) and perce ntage at 
Weeks 24 and 48 
Cohorts 2 and 3 
• The percentage of subjects with plasma HIV -1 RNA 
< 50 copi[INVESTIGATOR_014] /mL and < 400 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 by [CONTACT_727406] 
• The chan ge from baseli ne in CD4 + cell count (cells /µL) and 
perce ntage at Weeks 24 and 48 
The following plasma phannaco kinetic parameters will be 
calcu lated for EVG, COBI, FTC, TAF and TFV, as applicable: 
AUCtau , AUC 1ast, Ctau, Cmax , C1ast, Tmax, T1ast, 1,.,z, CL/F, VJF , and T½ 
(where possib le) 
PK Anal yses 
PK parameters (AUCtau , Ctau, and Cmax) ofEVG and PK parameters 
(AUC and Cma.x) ofTAF will be summa rized and compa red to 
histor ical adult data. Plasma concentratio n and parameter data of 
EVG , COBI , FTC , TAF , and TFV will be summar ized using 
descr iptive statistics . 
Page 14 2 1 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 15 21 February 2020An anal ysis of variance (ANOVA) using a mixed -effects model for 
appropriate parallel group design will be fitted to natural- logarithm 
transformed AUC for TAF and AUC tau for EVG to evaluate whether 
the exposures of these two anal ytes achieved in adolescent 
(Cohort 1) or children (Cohorts 2 and 3) are similar to the exposure 
achieved in adult subjects. An appropriate adult comparator 
database will be identified and integrated as historical control dat a. 
For each cohort, two one -sided tests with each performed at an alpha
level of 0.05 andaboundary of70% to143% willbeused for 
exposure equivalence assessment.
Efficacy Analyses
The percentage of subjects who achieve HI V-1 RNA < 50copi[INVESTIGATOR_014]/mL  
and < 40 0 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as defined by  [CONTACT_727407]. The 95% 
confidence intervals will also be presented.
The change from baseline in log 10 HIV-1 RNA (Cohort 1 only ) and 
CD4+ cell count and percentage at Weeks 24 and 48 will be 
summarized by  [CONTACT_38071].
Sample Size and Power
Cohorts 1 and 2
A minimum of 18 Part A subjects from each cohort compared to 51 
HIV-infected adult subjects in GS -US-292- 0102 and HIV -negative 
adult subjects in GS -US-292- 0103 combined, will provide 92% 
power to conclude exposure equivalence of TAF AUC last in 
adolescent subjects and children, respectively  vs in adult subjects, 
assuming the expected geometric mean ratio is 1, equivalency
 
boundary  is 70% to 143%, two one -sided tests are each performed at 
an alpha level of 0.05, and the standard deviation of AUC last is 
0.37 ng•hr/mL (natural log scale).
A minimum of 18 Part A subjects from each cohort will also provide 
> 99% power to target a 95% conf idence interval within 60% and 
140% of the geometric mean estimate of clearance and volume of 
distribution of TAF respectively, assuming a coefficient of variation 
(CV) of 38% for clearance and 42% for volume of distribution 
(GS-US-292- 0102 and GS -US- 292-0103 combined).
For each cohort, with a total of [ADDRESS_993209] 1 SAE is 92%, assuming 
the SAE incidence rate is 5% (observed in GS -US-
292-0102). After 
amendment [ADDRESS_993210] become available and will be used 
as historical control for comparison for Cohort 2 (ie, intensive PK 
data from 19 HIV -1 infected adults in Study  GS-US-292- 0102 for 
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993211]). Given the actual number of enrollments in Cohort 
2 Part A was 23, a total of 23
subjects would provide 90% power for 
EVG AUC tauand 88% power for TAF AUC lastto conclude exposure 
equivalence between children and adults, assuming the expected 
geometric mean ratios was 1, equivalency  boundary  was 70% to 
143%, two one -sided tests were each performed at an alpha level of 
0.05, and the intersubject standard deviation (na tural log scale) of 
EVG AUC tauand TAF AUC lastwas 0.34 ng•hr/mL and 0.52 
ng•hr/mL, respectivel y.
A total of 23 subjects from Cohort 2 Part A would also provide 86% 
power to target a 95% confidence interval within 60% and 140% of 
the geometric mean estimate of clearance and volume of distribution 
of TAF respectively, assuming a CV of 53% for clearance and 76% 
for volume of distribution (based on population PK data from 
GS US -292- 0104 and GS -US- 292-0111 combined).
Cohort 3
Twenty -five evaluable subjects compared to historical adult data 
will provide 90% power for each of EVG AUC tau and TAF AUC tau 
to conclude exposure equivalence between children and adults. In 
this power anal ysis, it is assumed that the expected geometric me an 
ratios is 1, equivalency  boundary  is 70% to 143%, two one -sided 
tests are each performed at an alpha level of 0.05, and the 
intersubject standard deviations (natural log scale) of EVG AUC tau 
and TAF AUC tau are 0.34 ng•hr/mL and 0.52 ng•hr/mL . For 
histor ical adult data, we used intensive PK data from 19 HIV -1 
infected adults in Study  GS-US-292- 0102 for EVG AUC tau and 
population PK data from Studies GS -US-
292-0104 and
GS-US-
292-0111 combined for TAF AUC tau.
Twenty -
five evaluable subjects will also provide > 99% power to 
target a 95% confidence interval within 60% and 140% of the 
geometric mean estimate of apparent clearance and volume of 
distribution of TAF respectively , assuming the standard deviation 
natural log scale is 0.51 for CL  and 0.54 for V z(based on population 
PK data from Studies GS -US-292- 0104 and GS -US- 292-0111 
combined).
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 17 21 February 2020GLOSSARY OF ABBREVIATIONS AND DEF INITION OF TERMS
°C degrees Celsius
°F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ARV Antiretroviral
AST Aspartate aminotransferase
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
AUC last the area under the concentration versus time curve from time zero to the last 
quantifiable concentration
AUC tau the area under the concentration verses time curve over the dosing interval AV
BMD bone mineral density
BUN blood urea nitrogen
CBC complete blood count
CDC centers for disease control
CI confidence interval
AUC last the area under the concentration versus time curve from time zero to the last 
quantifiable concentration
CL cr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
Clast the last observed quantifiable concentration of the drug in plasm a
COBI cobicistat (GS-9350)
CNS central nervous system
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRO contract (or clinical) research organization
CYP cytochrome P450
DAVG average area under the dosing interval
DXA dual energy x -ray absorptiometry
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DRV darunavir
DSPH Drug Safety and Public Health
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 18 21 February 2020E/C/F/TDF Single tablet regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 
mg/ tenofovir disoproxil fumarate 300 mg
EC Ethics Committee
ECG Electrocardiogram
eCRF electronic case report form(s)
EFV Efavirenz, Sustiva®
EFV/FTC/TDF Single tablet regimen of efavirenz 600 mg/emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg, Atripla®
EU European Union
EVG elvitegravir (GS-9137)
EVG/COBI/FTC/TAF, 
E/C/F/TAFSingle tablet regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 
mg/ tenofovir alafenamide 10 mg
FDA ([LOCATION_002]) Food and Drug Administration
FTC emtricitabine, Emtriva®
FTC/RPV/TDF emtricitabine 200mg/rilpi[INVESTIGATOR_12979] 25mg/tenofovir disoproxil fumarate 300mg,
Com plera® FTC/TDF
GCP Good Clinical Practice (Guidelines)
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GLP Good Laboratory Practices
GSI [COMPANY_009] Sciences, Inc.
GS-9137 elvitegravir, EVG, 6-(3-Chloro -2-fluorobenzyl) -1-[(2S)-1-hydroxy -3-methylbutan -
2-yl]- 7-methoxy -4-oxo- 1, 4-dihydroquinoline -3-carboxylic acid
GS-9350 cobicistat, COBI, 1,3 -Thiazol -5-ylmethyl (2 R,5R)-(5-(((2S) -2-((methyl((2-(propan -
2-yl)-1,3-thiazol -4-yl(methyl(carbamoyl)amino(( -4-(morpholin -4-yl)butanamido
FDA ([LOCATION_002]) Food and Drug Administration
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HCV hepatitis C virus
HDPE high-density polyethylene
hERG human Ether -à-go-go Related Gene
HIV Human Immunodeficiency Virus
HMG- CoA 5-hydroxy -3-methylglutaryl -coenzyme A
IB Investigator’s Brochure
ICH International Conference on Harm onisation
ID Identification
IDMC Independent Data Monitoring Committee
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 19 21 February 2020IgG Immunoglobulin
IND investigational New Drug (Application)
INH isonicotinylhydrazine, Isoniazid (Laniazid, Nydrazid)
INSTI integrase strand transfer inhibitor
IRB Institutional Review Board
ITT intent -to-treat (analysis or subset)
IV Intravenous
KS Kaposi’s sarcoma
LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
Mg Milligram
Min Minute
mmHg millimeters mercury
NNRTI non-nucleoside reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NOEL no observable effect levels
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
OTC over the counter
PAH Pulmonary arterial hypertension
PBMC Peripheral blood mononuclear cell
PI [INVESTIGATOR_727368]/r riton avir boos ted-protease inhibitor
PK Pharm acokinetic
PR pulse rate
PT preferred term (in Secti on8)
PT prothrombin time (in Appendix 4)
PVE Pharm acovigilance and Epi[INVESTIGATOR_727369] X receptor
QD once daily
QTc corrected QT
RAL Raltegravir
REB Research Ethics Board
RNA ribonucleic acid
RTV ritonavir, Norvir®
SAE serious adverse event
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993212] operating procedure
Spo4 serum phosphate concentration
STR Single Tablet Regimen
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
SVR suboptimal virologic response
T½ halflife
TAF tenofovir alafenamide (GS-7340)
TDF tenofovir disoproxil fumarate, Viread®
TFV Tenofovir
TFV -DP Tenofovir diphosphate
TLOVR time to loss of virologic response
tmax the time (observed time point) of Cmax
TPV/r ritonavir -boosted tipranavir
TSH thyroid stimulating horm one
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US [LOCATION_002]
Upo4 urine phosphate concentration
VR virologic rebound
RPV Rilpi[INVESTIGATOR_12979]
λz terminal elimination rate constant, estimated by [CONTACT_727408]/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 21 21 February [ZIP_CODE]. INTRODUCTION
1.1. Background
Human immunodeficiency virus -1 (HIV -1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.1 million people in 
North America and Western and Central Europe living with HIV -1 and 36.7 million people 
worldwide {Joint United Nations Programme on HIV/AIDS (UNAIDS) 2016 }, including
2.1million children under 15 y ears of age 
{Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 2016 }. This figure is likel y to underestimate the HIV disease burden in the pediatric 
population using the European Medicin es Agency (EMA) categorization of adolescence as from 
12 to 16 or 18 y ears, depending on the region (EMA, Note for Guidance CPMP/I CH/2711/99). 
The infection, if left untreated or suboptimall y treated, is characterized by [CONTACT_580877], u ltimately  resulting in death. Therapeutic strategies for the treatment of HIV -
[ADDRESS_993213] been significantly  advanced by  [CONTACT_727409] y (HAART); the introduction of HAART was associated with a dramatic decrease in 
acquired immune deficiency  syndrome (AIDS) -related morbidity and mortality  {Mocroft 1998, 
Palella 1998 , Sterne 2005 }.
Disease Pathophysiology
The pathogenesis of HIV -1 infection and the general virologic and immunologic principles 
underly ing the use of ARV therapy  are similar between HIV -1 infected adult and pediatric 
patients. However, there are some important and unique issues for HIV -1 infected infants, 
children, and adolescents, including the following {Panel on Antire troviral Therap y and Medical 
Management of HIV -infected Children 2011}:
Acquisition of infection through perinatal exposure for man y infected children
In utero, intrapartum, and/or postpartum neonatal exposure to zidovudine and other ARV 
medications in most perinatally  infected children
Age-specific differences in CD4+ cell counts and percentages
Changes inpharmacokinetic parameters with agecaused by[CONTACT_727410] s ystems involved in drug metabolism and clearance
Differences in the clinical and virologic manifestations of perinatal HIV -1 infection 
secondary  to the occurrence of primary  infection in growing, immunologically  immature 
persons
Special considerations associated with adherence to ARV treatment for infant s, children, and 
adolescents
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 22 21 February 2020Need for longer duration of therap y, with potentially  greater implications than in adults for 
long-term toxicity  and development of resistance
Differences in ph ysiological development of certain body  systems, including the skeletal 
system, where peak bone mass is not achieved until early adulthood
Treatment
The goal of ARV therap y for HIV -1 infection is to delay  disease progression, improve immune 
function, and increase the duration of survival b y achieving maximal and prolonged suppression 
of HIV -1 replication. The availability  of highl y active antiretroviral therap y (HAART) 
combinations for the treatment of HIV- 1 infection has resulted in a dramatic reduction in 
Acquired Immunodeficiency  Syndrome (AIDS) related morbidity and mo rtality  in the US and 
Europe {Mocroft 1998, Palella 1998 , Sterne 2005}. However, eradication of the virus is not 
possible with therapi[INVESTIGATOR_727370]. These therapi[INVESTIGATOR_727371], metabolic abnormalities, hematologic toxi cities, and 
allergic reactions.
The 2018 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection generall y 
recommend the use of 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in 
combination with a 3rd agent (a non -nucle oside reverse transcriptase inhibitor [NNRTI ], a 
boosted protease inhibitor [PI ] or an integrase strand transfer inhibitor [INSTI ]) for treatment of 
children and adolescents with HIV infection depending on age and sexual maturity  rating for 
adolescents (DH HS gui delines May  2018). The choice of a regimen, including the 3rd agent, is 
individualized based on a number of factors including characteristics of the proposed regimen, 
patient characteristics and results of resistance testing {Department of Health and Human 
Services (DHHS) 2018 }.
Studies have shown that a once -daily  STR significantly  improved adherence, treatment 
satisfaction, and virologic outcomes for patients infected with HIV -
1 {Airoldi 2010 , Bangsberg 
2010, Dejesus 2009, Hodder 2010, Sax 2015 }. Due to a longer duration of high adherence, 
patients taking STRs also have better clinical outcomes, such as fewer hospi[INVESTIGATOR_602], 
compared with multiple- tablet regimens {Sax 2010 }. The following STRs are currentl yapproved 
for once -daily administration in the treatment of H IV-1 infection in adolescents and/or children: 
EFV/FTC/TDF (Atripla®), FTC/RPV/TDF (Complera®/Eviplera®), EVG/COBI/FTC/TDF 
(Stribild®), EVG/COBI /FTC/TAF (Genvoy a®), BIC/FTC/TAF (Biktarvy®), R/F/TAF (Odefsey®)
and Triumeq®.
Tenofovir disoproxil fumarate (TDF) is a preferred NRTI  among recommended regimens for 
treatment -naive HIV -infected adults and adolescents, but is associated with nephrotoxicity  and 
reduced bone mineral density  {Panel on Antiretroviral G uidelines for Adults and Adolescents 
2012}. L ifelong antiretroviral treatment and the increasing comorbidities being recognized and 
treated in HIV -infected patients creates an urgent need to improve the safety  profile of regimens 
that most effectivel y suppress HIV replication.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 23 21 February 2020Tenofovir alafenamide (TAF, also known as GS -7340) is an oral prodrug of tenofovir (TFV), a 
nucleotide analog that inhibits HI V-1 reverse transcription. [COMPANY_009] has coformulated TAF with 
the integrase strand transfer inhibitor EVG, COBI, and FTC into a STR. Compared to TDF, the 
use of TAF in the E/C/F/TAF STR provides enhanced l ymphatic delivery  of TFV, resulting in 
higher intracellular levels of the active phosphory lated moiety  tenofovir -diphosphate (TFV -DP), 
and lower s ystemic circ ulating levels of TFV. These features are hy pothesized to translate into 
more effective suppression of viral replication, and an improved tolerability and safet y profile. 
FTC/TAF (Descov y), Genvoy a,R/F/TAF (Odefsey ), and GS-9883/Emtricitabine/Tenofovir 
Alafenamide (Biktarv y)are all FDC’s containing TAF that have been approved in adolescents 
(US and EU) and children 6 to <12 y ears of age weighing 
≥ 25 kg (GEN in the US and EU and 
DVY in the US only ).
EVG can be dosed once daily  when used with a pharmacoenhancing (boosting) agent like 
ritonavir 100 mg or cobicistat (COBI, GS -9350). COBI is devoid of anti -HIV activity , may  have 
less adverse biochemical effects (e.g., effect on adipocy te functions such as lipid accumulation) 
relative to ritonavir, and can be coformulated as a tablet with other ARV agents that require 
boosting. [COMPANY_009] Sciences has coformulated a single tablet regimen of COBI with EVG, FTC and 
TAF. This STR may  be an attractive option for adolescents and children with HIV -[ADDRESS_993214] use of the E/C/F/TAF STR in adolescents and children 6 to 
<
12years of age. E/C/F/TAF was approved in adults and pediatric patients [ADDRESS_993215] recentl y for 6 to < 12 year olds > or equa l to 25 kg. 
Please refer to the E/C/F/TAF local labeling and the investigator brochure for contraindications, 
warnings and precautions, and interactions.
1.1.1. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
A brief summary  of the clinica l trials of E/C/F/TAF STR for the treatment of HIV -1 infection are 
below. Please refer to the E/C/F/TAF IB for additional details:
The efficacy  and safet y of E/C/F/TAF (GENVOYA) in HIV -1 infected, treatment -naïve adults 
are based on 144-week data from two randomized, double -blind, active- controlled studies,
GS-US-292- 0104 (“Study  104”) and GS -US- 292-0111 (“Study  111”) (N=1733).
The efficacy  and safet y of GENVOYA in virologically -suppressed HIV -1 infected adults are 
based on 96- week data from a randomized, open -label, active -controlled study , GS-US-292-0109 
(“Study  109”) (N=1436).
The efficacy  and safet y of GENVOYA in HIV -1 infected, virologically -suppressed patients with 
mild to moderate renal impairment is based on 144 -week data from an open-label stud y,
GS-US-292- 0112 (“Study  112”) (N=242).
The efficacy  and safet y of GENVOYA in HIV -1 infected pediatric patients are based on
48-week data in treatment -naïve patients between the ages of 12 to < 18 years (≥ 35kg) (N=50) 
and 24- week data in virologically  suppr essed patients between the ages of 6 to < 12 years
(≥ 25 kg) (N=23) from cohort 1 and 2, respectively , of this study  (GS-US-292- 0106).
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 24 21 February 2020Treatment -Naïve Patients
Inboth Study 104andStudy 111, patients were randomized ina1:1ratio toreceive either 
GENVOYA (N = 866) once dail y or STRIBILD (elvitegravir 150 mg/cobicistat 150 mg/ 
emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg; N = 867) once daily .
InStudies 104and111, themean agewas36years(range 18 -76),85% were male, 57% were 
White, 25% were Black, and 10% were Asian. Nineteen percent of patients identified as 
Hispanic/Latino. The mean baseline plasma HIV -1 RNA was 4.5 log 10copi[INVESTIGATOR_014]/mL
(range 1.3-7.0). The mean baseline CD4+ cell count was 427 cells/mm3 (range 0 -1360) and 13% 
had CD4+ cell counts less than 200 cells/mm3. Twenty -three percent of patients had baseline 
viral loads greater than 100,000 copi[INVESTIGATOR_014]/mL .
In both studies, patients were stratified b y baseline HIV -1 RNA (less than or equal to
100,000 copi[INVESTIGATOR_014]/mL , greater tha n 100,000 copi[INVESTIGATOR_014]/mL to less than or equal to 400,000 copi[INVESTIGATOR_014]/mL , 
or greater than 400,000 copi[INVESTIGATOR_014]/mL ), by [CONTACT_398]4 count (less than 50 cells/μL , 50-199 cells/μL , or 
greater than or equal to 200 cells/μL ), and b y region (US or ex -US).
Treatment outcomes of Studies 104 and 111 through 48 and 144 weeks are presented in
Table 1-1.
Table 1-1. Pooled Virologic Outcomes of Studies 104 and 111 at Weeks 48a and
144b
Week 48 Week 144
GENVOYA
(N = 866)STRIBILD
(N = 867)GENVOYA
(N = 866)STRIBILD
(N = 867)
HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL 92% 90% 84% 80%
Treatment Difference 2.0% (95% CI = −0.7% to 4.7%) 4.2% (95% CI = 0.6% to 7.8%)
HIV-1 RNA ≥50 copi[INVESTIGATOR_014]/mLc 4% 4% 5% 4%
No Virologic Data at Week 48 or 144 
Window4% 6% 11% 16%
Discontinued Study Drug Due to 
AE or Deathd1% 2% 1% 3%
Discontinued Study Drug Due to 
Other Reasons and Last Available 
HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mLe2% 4% 9% 11%
Missing Data During Window but 
on Study Drug1% <1% 1% 1%
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 25 21 February 2020Week 48 Week 144
GENVOYA
(N = 866)STRIBILD
(N = 867)GENVOYA
(N = 866)STRIBILD
(N = 867)
Proportion (%) of Patients with HIV-1 RNA <50 copi[INVESTIGATOR_014]/ mL by [CONTACT_727411]
< 50 years
≥ 50 years716/777 (92%)
84/89 (94%)680/753 (90%)
104/114 (91%)647/777 (83%)
82/89 (92%)602/753 (80%)
92/114 (81%)
Sex
Male
Female674/733 (92%)
126/133 (95%)673/740 (91%)
111/127 (87%)616/733 (84%)
113/133 (85%)603/740 (81%)
91/127 (72%)
Race
Black
Nonblack197/223 (88%)
603/643 (94%)177/213 (83%)
607/654 (93%)168/223 (75%)
561/643 (87%)152/213 (71%)
542/654 (83%)
Baseline Viral Load
≤ 100,000 copi[INVESTIGATOR_014]/mL
100,000 copi[INVESTIGATOR_014]/mL629/670 (94%)
171/196 (87%)610/672 (91%)
174/195 (89%)567/670 (85%)
162/196 (83%)537/672 (80%)
157/195 (81%)
Baseline CD4+ cell count
< 200 cells/mm3
≥ 200 cells/mm396/112 (86%)
703/753 (93%)104/117 (89%)
680/750 (91%)93/112 (83%)
635/753 (84%)94/117 (80%)
600/750 (80%)
a Week 48 window was between Day 294 and 377 (inclusive).
b Week 144 window was between Day 966 and 1049 (inclusive).
c Includes patients who had ≥ 50 copi[INVESTIGATOR_014]/mL in the Week 48 or 144 window; patients who discontinued early due to lack or 
loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and 
at the time of discontinuation had a vira l value of ≥ 50 copi[INVESTIGATOR_014]/mL.
d Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted 
in no virologic data on treatment during the specified window.
e Includes patients who discontinued for rea sons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, 
loss to follow -up, etc.
At Week 144, GENVOYA demonstrated statistical superiority  (p = 0.021) in achieving HIV-1 
RNA < 50 copi[INVESTIGATOR_014]/mL when compared to STRIBILD.
In Studies 104 and 111, the mean increase from baseline in CD4+ cell count at Week 144 was 
326 cells/mm3 in GENVOYA -treated patients and 305 cells/mm3 in STRIBILD -treated patients 
(p=0.06).
Bone Mineral Density: In a pooled anal ysis of Studies 104 and 111, the effects of GENVOYA 
compared to that of STRIBILD on bone mineral density (BMD) change from baseline to
Week 144 were assessed by  [CONTACT_751] -energy  X-ray absorptiometry  (DXA). As shown in Table 1-2, 
in patients who had both baseline and Week 144 measurements (N = 690 and 702 in the 
GENVOYA group and N = 683 and 686 in the STRIBLD group, for hip and spi[INVESTIGATOR_050], respectively ) 
there were smaller
decreases in BMD in the GENVOYA group as compared to STRIBILD.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 26 21 February 2020Table 1-2. Measures of Bone Mineral Density in Studies 104 and 111 (Week 144
Analysis)
GENVOYA STRIBILD Treat ment Difference
Hip DXA Analysis N=690 N=683
Mean Percent Change in BMD −0.8% −3.4%2.6%
p < 0.001
Patients with Categorical Change:
3% Decrease in BMD
3% Increase in BMD28%
13%55%
6%--
Patients with No Decrease ( ≥ zero % change) in BMD 40% 19% --
Lumbar Spi[INVESTIGATOR_727372] N=702 N=686
Mean Percent Change in BMD −0.9% −3.0%2.0%
p < 0.001
Patients with Categorical Change:
3% Decrease in BMD
3% Increase in BMD30%
13%49%
7%--
Patients with No Decrease ( ≥ zero % change) in BMD 39% 22% --
Changes in Renal Laboratory Tests: Laboratory  tests were performed in Studies [ADDRESS_993216] of TAF, administered as a component of GENVOYA, to that of TDF, 
administered as a component of STRIBILD, on renal laboratory  parameters. As shown in
Table 1-3, statistically  significant differences were observed between treatment groups that 
favored GENVOYA. In these studies, there were statistically  significant differences between 
treatment groups for increases in serum creatinine and changes in proteinuria, including Urine 
Protein to Creatinine Ratio (UPCR), Urine Albumin to Creatinine Ratio (UACR), urine retinol 
binding protein (RBP) to creatinine ratio, and u rine beta -2-microglobulin to creatinine ratio that 
favored GENVOYA.
Table 1-3. Change from Baseline in Renal Laboratory Tests in Studies 104 and 
111 (Week 144 analysis)
GENVOYA N=866 STRIBILD N=867 Treatment Difference
Serum Creatinine (mg/dL)a 0.04 ± 0.12 0.07 ± 0.13−0.04
p < 0.001
Proteinuria by [CONTACT_727412] 40% 45% p = 0.027
Urine Protein to Creatinine Ratio [UPCR]c −10.5% 25.2% p < 0.001
Urine Albumin to Creatinine Ratio [UACR]c,d −5.2% 5.2% p < 0.001
Urine RBP to Creatinine Ratioc 34.8% 111% p < 0.001
Urine Beta -2-Microglobulin to Creatinine Ratioc −25.7% 53.8% p < 0.001
a Mean change ± SD
b Includes all severity grades (1-3).
c Median percent change.
d Week 96 analysis.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 27 21 February 2020Virologically Suppressed Patients
In Stud y 109, the efficacy and safet y of switching from either ATRIPLA, TRUVADA plus 
atazanavir (boosted b y either cobicistat or ritonavir), or STRIBILD to GENVOYA were 
evaluated in a randomized, open -
label stud y of virologicall y-suppressed (HIV -1RNA
< 50 copi[INVESTIGATOR_014]/mL) HIV -1 infected adults (N = 1436). Patients must have been stably  suppressed 
(HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on their baseline regimen for at least 6 months and had no 
resistance mutations to any  of the components of GENVOYA prior to study  entry. Patients were 
randomized in a 2:1 ratio to either switch to GENVOYA at baseline (N = 959), or stay  on their 
baseline antiretroviral regimen (N = 477). Patients had a mean age of 41 years (range 1-77), 89% 
were male, 67% were White, and 19% were Black. The mean baseline CD4+ cell count was
697cells/mm3 (range 79 -
1951)
Patients were stratified by [CONTACT_598579]. At screening, 42% of patients were receiving 
TRUVADA plus atazanavir (boosted by [CONTACT_727413]), 32% of patients wer e 
receiving STRIBILD, and 26% of patients were receiving ATRIPLA.
Pediatric Patients
In this stud y (GS -US-292-0106), the efficacy , safety , and pharmacokinetics of GENVOYA in 
HIV-1- infected patients were evaluated in open -label studies in treatment -naïve pa tients between 
the ages of 12 to < 18 years (≥ 35 kg) (N=50) and in virologicall y suppressed patients between 
the ages of 6 to < 12 years (≥ 25 kg) (N=23).
Cohort 1: Treatment
-naïve adolescents (12 to < 18 y ears; ≥ 35 kg), Week 48 Analy sis
Patients in Coho rt 1 had a mean age of 15 years (range: 12 to 17), 44% were male, 12% were 
Asian, and 88% were black. At baseline, mean plasma HIV- 1 RNA was 4.6 log 10copi[INVESTIGATOR_014]/mL, 
median CD4+ cell count was 456 cells/mm3 (range: 95 to 1110), and median CD4% was 23% 
(range: 7% to 45%). 22% had baseline plasma HIV -1 RNA > 100,000 copi[INVESTIGATOR_014]/mL .
Among the patients in C ohort 1 treated with GENVOYA, 92% (46/50) achieved HIV -1 RNA
< 50 copi[INVESTIGATOR_014]/mL at Week 48. The mean increase from baseline in CD4+ cell count at Week 48 
was 224 cells/mm3. Three of 50 patients had virologic failure at Week 48; no emergent resistance 
to GENVOYA was detected through Week 48.
Among the patients in C ohort 1 who had both baseline and Week 48 measurements (N=47 and 
44 for the lumbar spi[INVESTIGATOR_727373] [TBLH], respectivel y), mean BMD increased 
from baseline to Week 48, +4.2% at the lumbar spi[INVESTIGATOR_20793] +1.3% for TBLH.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 28 21 February 2020Cohort 2: Virologicall y suppressed children (6 to < 12 y ears; ≥ 25 kg), Week 24 Anal ysis
Patients in Cohort 2, Part A had a mean age of 10 years (range: 8 to 11), a mean baseline weight 
of 31.6 kg (range: 26 to 58), 39% were male, 13% were Asian, and 78% were black. At baseline, 
median CD4+ cell count was 969 cells/mm3 (range: 603 to 1421), and median CD4% was 39% 
(range: 30% to 51%).
After s witching to GENVOYA, 100% (23/23) of patients in Cohort 2 remained suppressed 
(HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL ) at Week 24. The mean change from baseline in CD4+ cell count 
at Week 24 was - 150 cells/mm3. No patient qualified for resistance anal ysis through Week 24.
Among the patients in C ohort 2 who had both baseline and Week 24 measurements (N=21 and 
23, for lumbar spi[INVESTIGATOR_727374], respectivel y), mean BMD increased from baseline to Week 24,
+2.9% at the lumbar spi[INVESTIGATOR_20793] +1.7% for TBLH.
For further information, including the results of studies of GENVOYA in adults and adolescents, 
please refer to the current 
GENVOYA Investigator’s Brochure.
1.2. Rationale for the Current Study
The success of HAART and the apparent benefits of maximally  suppressed viremia has shifted 
clinical attention towards antiretroviral agents that optimize long -term safety and tolerability . 
Young, newl y infected patients are diagnosed earlier, initiate therap y earlier, and look ahead 
towards lifelong therap y, often greater than fifty  years {Prejean 2011}. Renal and bone health, in 
both of these contexts, are increasingl y important {Capeau 2011}.
Based on the data from this study  and extrapolation to adult efficacy  and safet y data, 
GENVOYA was approved in adults and pediatric patients 12 y ears of ag e and older in the US 
and EU in 2016 and approved in 2017 for use in pediatric patients 6 to < 12 y ear of age weighing 
≥25 kg.
HIV
-infected children ages ≥ 2 y ears of age will benefit from the availability  of an age-
appropriate formulation containing TAF, which has the potential for an improved renal and bone 
safet y profile relative to TDF, an important consideration for a population in which peak bone 
mass has not y et been achieved and for whom HIV treatment is anticipated to be life -long.
The objective of this study  is to characterize the pharmacokinetics (PK), and confirm the dose of 
E/C/F/TAF and to evaluate the safet y, tolerability and antiviral activit y of E/C/F/TAF as an STR 
in treatment -naive HIV -1 infected adolescents 12 to less than 18 y ears of a ge and in virologicall y 
suppressed HIV -1 infected children 2 to < 12 y ears of age.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 29 21 February [ZIP_CODE].3. Rationale for Dose Selection
The proposed E/C/F/TAF doses for this stud y are expected to provide plasma exposures in the 
pediatric population that are comparable to those as sociated with safet y and efficacy  in adults.
E/C/F/TAF Dose in Adolescents 12 to < 18 years old, weighing ≥ 35 kg
The FDA -approved dose of E/C/F/TAF in adolescents 12 to < 18 y ears, ≥ 35 kg is the adult 
strength STR (150/150/200/10 mg).
E/C/F/TAF Dose in C hildren ≥ 2 years old weighing ≥ 25 kg, and weighing ≥ 14 to < 25 kg
The FDA -approved dose of E/C/F/TAF in children weighing ≥ 25 kg is the adult strength STR 
(150/150/200/10 mg). For children weighing ≥ 14 to ˂ 25 kg, a low dose E/C/F/TAF tablet of 
90/90/ 120/6 mg is proposed for evaluation. The observed exposures following administration of 
E/C/F/TAF 150/150/200/10 mg in children weighing ≥ 25 kg or predicted exposures of 
E/C/F/TAF 90/90/120/6 mg in children weighing ≥ 14 to ˂ 25 kg are comparable to those
observed in adults for all anal ytes (EVG, COBI, FTC, TAF and TAF- metabolite TFV). The 
dosing nomogram is structured to avoid subtherapeutic dosing in a population requiring lifelong 
therap y from a young age, in which the implications of virologic failure may be greater than in 
adults.
Rationale for E/C/F/TAF Dose in Children weighing ≥ 25 kg 
EVG:
EVG is differentially  dosed in adults in order to achieve comparable EVG exposures depending 
on the co- administered regimen: 85 mg with L PV/r or ATV/r; EVG 150 m g with COBI and 
other boosted PI s.
Preliminary  data are available in treatment- experienced children 6 to < 12 y ears old on a regimen 
containing LPV/r or ATV/r from Study  GS-US-183-0160. Of 14 participants who completed the 
PK substudy , 6 were taking the ad
ult strength EVG 85 mg (bod yweight ≥ 30 kg) and 8 were 
taking a reduced strength EVG 50 mg (bod y weight 17 to < 30 kg). Plasma exposures of EVG 
were similar to those previously  observed in adolescents, and higher than in adults (GMR AUC 
1.36; GMR C trough 1.29) with all participants having an EVG C trough above the protein -binding 
adjusted I C95 of 44.5 ng/mL . Plasma exposures support using the adult EVG dose in 6 to 
< 12 years olds ≥ 30 kg. Simulation for children with a body weight between 25 and < 30 kg 
demonstrated that when combined with LPV/r, administration of the higher dose (85 mg) would 
result in slightly  higher, but acceptable EVG exposures. EVG was well -tolerated in this study , 
with no related SAEs or AEs leading to EVG discontinuation (with one related AE of mild 
dizziness). Therefore, the adult 150 mg dose of EVG is proposed for use in children 6 to 
<
12years old weighing ≥ 25 kg.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 30 21 February 2020COBI:
The 150 mg dose of COBI is the adult dose, selected for its efficacy  in boosting EVG exposures. 
COBI dose selecti on was guided b y dose/data available for ritonavir boosting in various pediatric 
weight bands and similarities in observed dose- dependent PD effects (CYP3A inhibition) for 
COBI versus RTV in adults. Comparison of ritonavir (RTV) and COBI dose -ranging PK an d PD 
(Studies GS- US-183- 0113, GS -US- 216-0101, GS -US- 216-0110, and GS -US-236-0101) indicate
comparable CYP inhibition/boosting of probe/other substrates, including ARVs. The proposed 
COBI doses generally  represent a higher dose on a mg/kg basis relative to the adult dose, and are 
expected to provide sufficient boosting activity  within the context of E/C/F/TAF STR. The adult 
150 mg dose of COBI is proposed for administration to pediatric subjects ≥ 25 kg.
FTC:
Emtricitabine is approved to be dosed at ≤ 6.1 mg/kg in children with either a capsule or oral 
solution formulation {EMTRI VA® 2012 }. Per the current Emtriva label, the approved dose of 
200mgFTC canbeadministered inadults with normal renal function andthose with mild renal 
impairment (50-
80mL/min), inwhom FTC exposures were shown tobeapproximately 70%
higher than adults with normal renal function {EMTRI VA® 2012 }.Inaddition, aproposal for
FTC/TDF low-dose tablets from theWHO Paediatric Antiretroviral Working Group {World 
Health Organization (WHO) 2011 }allows FTC doses upto8.57 mg/kg (corresponding to a 40% 
increase in dose over 6.1 mg/kg) for use in children. Given the approved doses for FTC and its 
dose-proportional pharmacokinetics, a modest increase of FTC dose in children is expected to
result inexposures intherange ofthose providing afavorable risk:benefit profile. The E/C/F/TAF
(150/150/200/10 mg)adult
-strength STR foruseinpatients 6to< 12 years ofage≥ 25 kg 
provides a range of FTC doses comparable to the approved doses, and does not exceed
8.57 mg/kg.
TAF:
The TAF dose selection in children 6 to < 12 years of age is based on the established TDF dose 
to exposure relationship in children and adults, where it has been shown that administration of 
TDF doses at approximately  twice the average adult dose (on a mg/kg basis) result in TFV 
exposures in children within the range observed in adults { [COMPANY_009] Sciences Inc 2012 }.
The TAF dose proposed for a 75 kg adult is 0.13 mg/kg when used with boosted regimens such 
as E/C/F/TAF STR. For a subject ≥ 25 kg to < 35 kg, administration of TAF 10 mg (in the 
context of E/C/F/TAF STR) corresponds to a range of TAF dose per bod y wei ght of 0.29 to 
0.40 mg/kg (approximately  2 to 3 times the adult dose). This is predicted to result in TAF 
exposures in children within the range observed in adults and to y ield maximum exposures in the 
lowest weight ranges of each band less than 2 -fold abo ve mean TAF exposure in adults.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 31 21 February 2020Rationale for E/C/F/TAF Dose in Children weighing ≥ 14 to < 25kg
For dose selection in children weighing ≥ 14 to < 25 kg, EVG, COBI, FTC, TAF and TFV 
exposures were predicted by  [CONTACT_727414] y weight and clearance (CL) capacity. Model -predicted s ystemic exposures of EVG, 
COBI, FTC, TAF and TFV in children weighing ≥ 14 to < 25 kg administered the low dose 
E/C/F/TAF STR (90/90/120/6 mg) are presented in Figure 1-1, Figure 1-2, Figure 1-3, 
Figure 1
-4and Figure 1-5, respectivel y. These simulations indicate that the predicted exposure 
ranges of EVG, COBI, FTC, TAF and TFV in children 2 to < 12 y ears weighing ≥ 14 to < 25 kg 
following administration of E/C/F/TAF 90/90/120/6 mg are comparable to those observed in the 
adult Phase 2/3 population, and in children 6 to < 12 years weighing ≥ 25 kg who received th e 
adult strength STR.
Figure 1-1. Predicted EVG AUC in Children Following Administration of 
E/C/F/TAF 90/90/120/6 mg
The adult exposures for EVG were the population PK predicted exposures from the STB Phas e 2/3 program 
(Stribild NDA 203100 SN 0000, m5.3.3.5, COBI -boosted EVG Population PK report)
::r 
E -C, 
C • .c 
u ::::, 
<C [ZIP_CODE] 
~[ZIP_CODE]· 
w E/C/F/TAF 90/90/120/6 mg 
:':" ... - · -.... _ ·.;. ·;.; · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph2/3 Adult Max ------ .. ,. ~-------------------
[.-:-: .. .. : .. :-'.'. - ~ -~ -.:': .. ~ . - ~--~ -:":'. - ~ -_......, __ ,,_ . ..,. ·;.;.· ~ -· .:.;,--~ · ·.:.;· - ~--:.:,· :_:,· ·.:,:--.:_:· ·.:_· - ~ -~--~ -- ~ -- ~--~ -- ~ · ~ -- ~--~ -- ~--~ -~ -· ~ -- ~ -- ~ -- ~--J · Ph2/3 Adult 95th % 
,------- -------- . ........... ........... ..................... _ ,_,_. ........................................... . ---------- ------Ph2/3 Adult Median 
Ph2/3 Adult 5th % 
-
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph 2/3 Adult Min . . . 
14 15 16 17 18 19 20 21 22 23 24 25 
Weight (kg) 
Predicted AUC : - Median - -5th/95th percentile 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 32 21 February 2020Figure 1-2. Predicted COBI AUC in Children Following Administration of 
E/C/F/TAF 90/90/120/6 mg
The adult exposures for COBI were the population PK predicted exposures from Phase 2/3 studies with Stribild (STB) or 
ATV/co + Truvada (ATV/co + TVD) (Studies GS -US-236-0102, GS -US-236-0103, GS -US-236-0104, GS -US-216-0105, and 
GS-US-216-0114)
Figure 1-3. Predicted FTC AUC in Children Following Administration of 
E/C/F/TAF 90/90/120/6 mg
The adult exposures for FTC were the exposures from Phase 2/3 studies with STB (Studies GS -US-236-0101, GS -US-236-0102, 
GS-US-236-0103, GS -US-236-0104, and GS -US-236-0110)
[ZIP_CODE] E/C/FITAF 90/90/120/6 mg 
Ph2/3 Adult Max 
::f [· ~··~··~ ·~··~··~··:"!"'· · ~ ·""· ---- .......... · ·.,.··;.;.·:.:.··~··.:.;··.:;··:.:.·;.;,· ·.:.;··.:.:··:.;_··:.:,·:.:,··.:_:··_;,;··:.:_·:,:_··:_:··.:_:··.:_:· · ~ ·~··::··.:_:··.:.··~ ·~··~··~··j· Ph2/3 Adult 95th % 
E [ZIP_CODE] -- - - - - - - - -__ _ c3, ................................. -~ .• . [ZIP_CODE] - · ·- _ . .., ... -w ·• ·:.; ·..;,·:..: ·..:.·;.: - ~ - ·_:·:_: :.:,·:: :.:,·: 
C: • .c: Ph2/3 Adult Median 
-u 
:::> 
<( 
iii 
0 u 
:J" 
E -C) 
C: • :S u 
:::> Ph 2/3 Adult 5th % 
1000 
· · · · · · · · · · · · · · · · · · · · .... · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph2/3 Adult Min 
14 15 16 17 18 19 20 21 
Weight (kg) 22 23 24 25 
Predicted AUC: -Median - - 5th/95th percentile 
E/C/FITAF 90/90/120/6 mg 
[ZIP_CODE] 
· · · · · · · · · · · · · · · · · · · · · · · • · · · · · · · · · · · · · • · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · .. · · • · · · · · Ph2/3 Adult Max ----------------- -------- ------ ------
[~ · ·~ · - ~ -· ~ · · ~ .. ~ · .. .. ':°: .. ".': .. "'.°'. •• :"." •• :":'. :":' •• •• ":": .. .,.,. --- · -· ·-.· ·:.:.· :.:,· • ;.;,· ·.:,:· ·.:_:· ·..:_: .. .:;· ·:.:_· :.:_· ·:_:· ·:: .. .:_:· ·.:.· - ~ · · ~ · ~ · ·~ · ·~ · - ~ -· ~ · · ~ · ~ -• J · · Ph2/3 Adult 95th % ----------------......................................... ::.~.:":.":"'.:-:-.~. -· -- · ··--······················ Ph2/3 Adult Median 
<( [ZIP_CODE] u ---------
I-
LL Ph2/3 Adult 5th % 
· · · · · · · · · · · · · · · · · · · · · · · • · · · · · · · · • · · · · · · · · · · · · · · · · · · · · · · · • · · · · · · · .. • · · · • · · · · • · · · · · · · · · · · · · · Ph2/3 Adult Min 
14 15 16 17 18 19 20 21 
Weight (kg) 22 23 
Predicted AUC : - Median (60%) - -5th/95th percentile 24 25 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 33 21 February 2020Figure 1-4. Predicted TAF AUC in Children Following Administration of 
E/C/F/TAF 90/90/120/6 mg
The adult exposures for TAF were the population PK predicted exposures from the GEN Phase 2/3 program
(Genvoya NDA 207561, m5.3.3.5, Population PK Analysis of TAF and TFV following Administration of E/C/F/TAF STR)
Figure 1-5. Predicted TFV AUC in Children Following Administratio n of 
E/C/F/TAF 90/90/120/6 mg
The adult exposures for TFV were the population PK predicted exposures from the GEN Phase 2/3 program
(Genvoya NDA 207561, m5.3.3.5, Population PK Analysis of TAF and TFV following Administration of E/C/F/TAF STR)
E/C/F/TAF 90/90/120/6 mg 
4000 
~1000 . ________________ _ 
E ------------------- -C) 
C: • .c -u ·-----------------<( 100 ------------------• 
LL Ph2/3 Adult Max 
Ph2/3 Adult 95th % 
Ph2/3 Adult Median 
Ph2/3 Adult 5th % 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph2/3 Adult Min 
10+--------,--...-.- ....... -----,--...---,..-- ........ ---.---..---+ 
14 15 16 17 18 19 20 21 22 23 24 25 
Weight (kg) 
Pred icted AUC : - Median - -5th/95th percentile 
E/C/F/TAF 90/90/120/6 mg 
2000 
Ph2/3 Adult Max 
-1000 • ----- - -------------E -----------------0, 
C: • :S 
(.J 
<( 
> LL .... Ph2/3 Adult 95th % 
":::-.:-:. ~ ---• - •,..•a.:· ~ ·:.:· . : :;,;· ~ ·:,:·············································· ········ Ph2/3 Adult Median ----------------------· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph 2/3 Adult 5th % 
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · Ph2/3 Adult Min 
100+---.------- ....... -....... ---,,.....-..---.-- ....... --,......-+ 
14 15 16 17 18 19 20 21 22 23 24 25 
Weight (kg) 
Pred icted AUC : - Median - -5th/95th percentile 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 34 21 February [ZIP_CODE]. OBJECTIVE S
Cohort 1
The primary  objectives of this study  are:
Part A:
To evaluate the stead y state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir 
alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir 
alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV -1 infected, antiretroviral 
(ARV) treatment -naive adolescents
Part B:
To evaluate the safet y and tolerability  of the E/C/F/TAF STR through Week 24 in HIV -1 
infected, ARV treatment -naive adolescents
The secondar y objectives for Cohort 1 for this study are:
To evaluate the safet y and tolerability  of the E/C/F/TAF STR through Week 48 in HIV -1 
infected, ARV treatment -naive adolescents
To evaluate the antiviral activity  of the E/C/F/TAF STR through Week 48 in HIV-1i nfected, 
ARV treatment -naive adolescents
Cohort 2
The primary  objectives of this study  are:
Part A:
To evaluate the PK of EVG and TAF in virologically  suppressed HIV -1 infected children 
6to < 12 y ears of age, weighing ≥ 25 kg, administered E/C/F/TAF STR
Part B:
To evaluate the safet y and tolerability  of E/C/F/TAF STR through Week 24 in HIV -1 
infected children 6 to < 12 y ears of age
The secondary  objectives for this study  are:
To evaluate the antiviral activity  of switching to E/C/F/TAF STR through Week 48 in 
virologicall y suppressed HIV -1 infected children 6 to < 12 y ears of age weighing ≥ 25 kg.
To evaluate the safet y and tolerability  of E/C/F/TAF STR through Week 48 in virologicall y 
suppressed HIV -1 infected children 6 to < 12 y ears of age, weighing ≥ 25 kg
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
Cohort 3 
The p rima1 y objectives of this study are: Final 
Amendment6 
• To evaluate the PK ofEVG and TAF and confnm the dose of the STR in virologica lly 
suppressed HIV-I infecte d children 2 years of age weighing 14 to < 25 kg admini stered 
E/C/F IT AF LD STR 
• To evaluate the safety and tolerability ofE/C/F/TAF LD STR through Week 24 in 
virolog ically suppressed HIV-I infected children ~ 2 years of age and weig hing~ 14 to 
<25 kg 
The secondaiy objectives of this study are: 
• To evaluate the antiviral activ ity of switc hing to E/C/FffAF LD STR through Week 48 in 
virolog ically suppressed HIV-I infected children ~ 2 years of age and weigh ing~ 14 to 
<25 kg 
• To evaluate the safety and tolerability ofE/C/F/TAF LD STR through Week 48 in 
virolog ically suppressed HIV-I infected children ~ 2 yeai·s of age and weighing ~ 14 to 
<25 kg 
All Cohort s 
I 
CONFIDENTIAL Page 35 2 1 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 36 21 February [ZIP_CODE]. STUDY DESIGN
3.1. Treatment Plan and Regimen
This protocol describes an open- label, multicenter, multi -cohort, single -arm study  of the 
pharmacokinetics (PK), safet y, tolerability , and antiviral activity  of the E/C/F/TAF STR in 
HIV
-1 infected ARV treatment- naive adolescents and virologically suppressed children.
A total of 50 adolescents (12 to < 18 years of age) and up to 75 children (6 to < 12years of age) 
of either sex will be enrolled to receive the STR of E/C/F/TAF once dail y with food as fol lows:
Part A
Intensive PK samples will be anal yzed for Cohort 1 and 2 once they  are available from 
18 subjects regardless of age distribution and for all Cohort 3 subjects.
Cohort 1, Part A: EVG, TAF and COBI exposures will be compared to historical data from adult 
HIV-1 infected subjects. TAF data will also be compared to HIV- negative subjects from
292-0103 study . FTC and TFV exposures will be compared to historical data in HIV - infected 
adults and available data in adolescent subjects. Cohort 2, Part A: EV G, TAF, COBI, FTC and 
TFV exposures will be compared to historical adult data.
EVG and TAF dose confirmation will be established if the 90% confidence intervals of 
geometric mean ratios for AUC in adolescents and children (respectivel y) versus those in adults 
are within the equivalency bounds of 70 -143%.
Following completion of the I ntensive PK visit, subjects will continue to receive E/C/F/TAF 
STR and return for scheduled study  visits through Week 48.
Cohort 1 (Adolescents 12 to < 18 years of age)
Eighteen to 24 eligible subjects will be initially  enrolled to evaluate the steady  state PK, and 
confirm the dose of the E/C/F/TAF STR.
Part A will aim to enroll at least 6 subjects 12 to < [ADDRESS_993217] 6 subjects 
15to < 18 y ears of age.
If at lea st 6 subjects ages 12 to < 15 y ears and 6 subjects ages 15 to < [ADDRESS_993218] not been 
enrolled at the time of the Intensive PK analy sis, Part A enrollment will remain open in order 
to enroll sufficient subjects to meet the minimum enrollment of the 2 age subgroups.
Subjects enrolled in Part A will participate in an Intensive PK evaluation on Week 4. 
Samples will be collected at 0 (pre -dose, ≤ 30 minutes prior to dosing), [ADDRESS_993219]-dose.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 37 21 February 2020Cohort 2 (Children 6 to < 12 years of age and weight ≥ 25 kg)
Eighteen to 24 eligible subjects will be enrolled to evaluate the EVG and TAF plasma PK 
and confirm the dose of EVG and TAF.
Subjects will participate in an Intensive PK evaluation on Week 4.
Cohort 3 (Children 
≥ 2 years of age and weighing ≥ 14 to < 25 kg)
Up to 25 eligible subjects will be enrolled to evaluate the EVG and TAF plasma PK and 
confirm the dose of EVG and TAF.
Subjects will participate in an Intensive PK evaluation on Week 2.
Part B 
Cohort [ADDRESS_993220] 18 subjects from Cohort 1, Part A. The additional 26 – 32 subjects will be 
enrolled in Cohort 1, Part B to evaluate the safet y, tolerability  and antiviral activity of the 
E/C/F/TAF STR in at least 50 patients, including all subjects enrolled in Cohort 1 (Parts A and 
Part B combined).
Cohort 2
Screening will be initiated in subjects 6 to < [ADDRESS_993221] 18 subjects from Cohort 2, Part A. The additional 26 – 32 subjects 
will be enrolled in Cohort 2, Part B to evaluate the safet y, tolerabilit y and antiviral activity of the 
E/C/F/TAF STR in at least 50 patients, including all subjects enrolled in Cohort 2 (Part s A and B 
combined).
Cohort 3
No Part B for this cohort. All subjects will be enrolled in Part A and will complete an Intensive 
PK evaluation.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 38 21 February 2020Figure 3-1. Study Schema
Cohort 1:
a
Screening for Part B will commence after the PK data from Part A confirms the adolescent dose of the E/C/F/TAF STR
Cohort 2:
Cohort 3:
Screening 
:, 35 days prior B~" 
to Baseline (Day l} Pan A: E/C/F/T AF QD 
N=IS -2~ 
PK \Veek 24 \Veek 48 
Screening" 
'.':: 35 daF pria,- B~" Week24 
to Baseline (Day l) 
Screening 
-:, 35 days prior B~ 
to Baseline (Day ]) Part A E/C/Fc AF QD 
N=18 -H 
PK Week24 Week48 30Dayf -
We<!k 48 30 Day F1 U 
30Dayf -
( creeningH .___ P _art_ . B_ : --- ....... ~--# .... m ....... 
1----- ---- --------1 
-:, 35 days prior &:,eliru, Week48 30Day F/U 
to Baseline (Day I) 
( ScreeningH .__ __ ~ - / ~;.;....;!_j!_:m Q;._,H _ __.~ ...... ....... ...... " ....... 
'.':: 3.> day~ prior Baseiin,, PK 
to Baseline (Day I) \Veek24 W'"'148 30Dayf -
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993222] Selection
A total of 50 adolescents (12 to < 18 years of age) and up to 75 children (2 to <12years of age) 
who meet the eligibility criteria will be enrolled into this study .
Replacement subjects may be enrolled if subjects do not complete all Intensive PK procedures or 
if PK data are incomplete. Replacement subjects will not be enrolled i n Part A for subjects who 
discontinue the study  due to treatment- related toxicity .
Cohort 1:
Part A
Eighteen to 24 subjects representing two age strata (at least [ADDRESS_993223] be 12 to < 15years 
of age and at least [ADDRESS_993224] be 15 to < 18 years of age).
Part B
Twenty -six to 32 subjects between 12 to < 18 y ears of age (dependent upon enrollment in 
PartA).
Cohort 2:
Part A
Eighteen to 24 subjects 6 to < 12 y ears of age and weigh ≥ 25 kg.
Part B
Twenty -six to 32 subjects 6 to < 12 y ears of age and we igh ≥ 25 kg.
Cohort 3:
Approximately  25 subjects ≥ 2 y ears of age and weighing ≥ 14 to < [ADDRESS_993225] meet all of the following inclusion criteria, as well as the Cohort specific criteria 
listed below, to be eligible for participation in this study . Subjects with screening results that do 
not meet eligibility  criteria will not be allowed to rescreen:
CD4+ cell count ≥ 400 cells/ μL and CD4+ percentage of 20%
Adequate renal function: estimated glomerular filtration rate ≥ 90 mL /min/1.73m2
Estimated Glomerular Filtration Rate (eGFR) using Schwartz Formula (mL/min/1.73m2)
= k L/Scr [(k is a proportionality  constant, for females ≥ 2 years old is 0.55; and for 
males ≥ 12 y ears old is 0.70) and males and females 2to ≤ 11 y ears old is 0.55; L  is 
height in centimeters (cm); and S cr is serum creatinine (mg/dL)]
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 40 21 February 2020Clinically  normal ECG (or if abnormal, determined by  [CONTACT_727415])
Documented screening for active pulmonary  tuberculosis per local standard of care within 
6 months of a Screening visit.
Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)
Total bilirubin ≤ 1.5 mg/dL , or normal direct bilirubin
Adequate hematologic function:
Absolute neutrophil count ≥500/mm3
Platelets ≥50,000/mm3
Hemoglobin ≥ 8.5 g/dL
Note that subjects with chronic neutropenia, defined as having an ANC of < 500/mm3
documented at least twice within 6 months of screening, and in whom, according to the 
investigator, there isnoevidence ofactive opportunistic orserious infection canenroll inthe 
study  contingent upon approval from the [COMPANY_009] study  Medical Monitor.
Negative serum pregnancy  test for all female subjects
Females of childbearing potential (as defined in Appendix 5) must have a negative serum 
pregnancy  test at screening and Baseline/Day  1
Male subjects and female subjects of childbearing potential who engage in heterosexual
intercourse mus
t agree to use protocol specified method(s) of contraception as described in 
Appendix 5
Subjects able to give written assent prior to an y screening evaluations
Parent orguardian able togive written informed consent prior toanyscreening evaluations 
and willing to compl y with study requirements
Able to swallow oral tablets
Must be willing and able to comply  with all study requirements
Life expectancy  > 1year
Cohort 1
12 to < 18 y ears of age at Baseline
Weight ≥ 35 kg (77 lbs) at Screening
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 41 21 February 2020Plasma HIV -1 RNA levels of > 1,000 copi[INVESTIGATOR_014]/mL at Screening ([COMPANY_002] COBAS TaqMan v2.0)
Screening genot ype report shows sensitivity  to EVG, FTC and TFV (Monogram Biosciences,
Inc.)
Subje ctswith HIVsubtypeAEwho meet allinclusion/exclusion criteria andwho have a 
non-reportable integrase genot ype result may  proceed with study enrollment
(Thailand only)
No prior use of an y approved or experimental anti- HIV-1 drug for an y length of time 
(other than that given for prevention of mother- to-child transmission)
Cohort 2
6 to < 12 y ears of age at Baseline
Weight ≥ 25 kg (55 lbs) at Screening
Plasma HIV -1 RNA: < 50 copi[INVESTIGATOR_014]/mL  (or undetectable HIV -1 RNA level according to the 
local assay  being use d if the limit of detection is > 50 copi[INVESTIGATOR_014]/mL ) for ≥ 180 consecutive day s 
(6 months) prior to Screening on a stable antiretroviral regimen, without documented history  
of resistance to an y component of E/C/F/TAF STR
Unconfirmed HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  after previously  reaching virologic 
suppression (transient detectable viremia, or“blip”) prior toScreening isacceptable
Currently  receiving an antiretroviral regimen that has been stable for at least
180consecutive day s (6 months) or has been newly  initiated within 6 months for reasons 
other than virologic failure.
Cohort 3
≥ 2 y ears of age at Baseline
Weight ≥ 14 to < 25 kg (≥ 31 to < 55 lbs) at Screening
Plasma HIV -1 RNA: < 50 copi[INVESTIGATOR_014]/mL  (or undetectable HIV -1 RNA level according to the 
local assay  being used if the limit of detection is > 50 copi[INVESTIGATOR_014]/mL ) for ≥ 180 consecutive days 
(6 months) prior to Screening on a stable antiretroviral regimen, without documented history  
of resistance to an y component of E/C/F/TAF STR
Unconfirmed HIV -1 RNA ≥ 50 copie s/mL  after previously  reaching virologic 
suppression (transient detectable viremia, or“blip”) prior toScreening isacceptable
Currently  receiving an antiretroviral regimen that has been stable for at least 180 
consecutive day s (6 months) or has been newl y initiated within 6 months for reasons 
other than virologic failure.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 42 21 February [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
A new AIDS -defining condition diagnosed within the 30 day s prior to Scr eening (Refer to
Appendix 6).
Positive Hepatitis C antibody
. Note: Subjects with false positive hepatitis antibody confirmed 
by [CONTACT_727416] C PCR are permitted to enroll.
Positive Hepatitis B surface antigen or ot her evidence of active HBV infection.
Note: Subjects with positive HBV surface antibody and no evidence of active HBV infection 
are permitted to enroll.
Prior treatment with an y approved or investigational or experimental anti HIV -1 drug for an y 
length of time (other than that given for prevention of mother -to-child transmission)
(Cohort 1 only )
Evidence of active pulmonary  or extra -pulmonary  tuberculosis disease within 3 months of 
the Screening visit.
Anticipated to require rifamy cin treatment for mycobact erial infection while participating in 
the study . Note: proph ylactic INH therap y for latent TB treatment is allowed.
Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
Pregnant or lactating subjects
Have an implanted defibrillator or pacemaker
Have an y serious or active medical or ps ychiatric illness which, in the opi[INVESTIGATOR_684], would interfere with subject treatment, assessment, or compliance with the 
protocol. This would include uncontrolled renal, card iac, hematological, hepatic, pulmonary  
(including chronic asthma), endocrine (e.g., diabetes), central nervous, gastrointestinal 
(including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, o r malignancy  that are clinically  significant or 
requiring treatment within 30 day s prior to the study dosing.
Current alcohol orsubstance abuse judged by[CONTACT_727417].
Have history  of significant drug sensitivity or drug allergy .
Known hy persensitivity  to the study  drugs, the metabolites or formulation excipi[INVESTIGATOR_840] 
(seeSection 5.2)
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 43 21 February 2020Have been treated with immunosuppre ssant therapi[INVESTIGATOR_10793] 
3months of study  Screening or expected to receive these agents during the study
(e.g., immunoglobulins, and other immune- or cy tokine -based therapi[INVESTIGATOR_014]).
A history  of malignancy  within the past 5 y ears (prior to Screening) or ongoing malignancy  
other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive 
cutaneous squamous carcinoma. Subjects with cutaneous KS are eligible, but must not have 
received an y systemic therapy  for KS within [ADDRESS_993226] not be anticipated 
to require s ystemic therapy  during the study .
Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within 30 day s prior to Baseline.
Have previously  participated in an investigational trial involving administration of any  
investigational agent within 30 day s prior to the study dosing.
Participation in any  other clinical trial (including observational trials) without prior approval 
from spons or is prohibited while participating in this trial.
Subjects receiving ongoing therap y with an y of the medications in the table below, including 
drugs not to be used with EVG, COBI, FTC, TDF and TAF (For EVG, COBI, and FTC refer 
to the individual agents Pr
escribing Information; for EVG, and TAF refer to the E/C/F/TAF 
STR I nvestigator’s Brochure); or subjects with any  known allergies to the excipi[INVESTIGATOR_22880] 
E/C/F/TAF STR tablets.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 44 21 February 2020Drug Class Agents Disallowed*
Alpha Adrenergic Receptor Antagonists Alfuzosin
Antibacterials Telithromycin
Anticonvulsants Phenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_727375], Terfenadine
Antimycobacterials Rifampin, Rifapentine, Rifabutin
Antiplat elets Clopi[INVESTIGATOR_727376], Ergonovine Dihydroergotamine 
Methylergonovine Ergometrine
Direct Acting Anticoagulants Api[INVESTIGATOR_3822], Rivaroxaban
GI Motility Agents Cisapride
Herbal Supplements St. John’s Wort, Echinacea
HMG- CoA Reductase Inhibitors Simvastatin, Lovastatin
Neuroleptics Pi[INVESTIGATOR_727377]/Hypnotics Midazolam, Triazolam
Systemic** Corticosteroids with the exception of
short -term (≤ 1 w eek) use of prednisone as a steroid burstAll agents, including dexamethasone
* Administration of any of the above medications must be discontinued at least 21 days prior to the Baseline/Day 1 visit and 
for the duration of the study.
** Systemic use defined as intravenously or orally administered corticosteroid.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 45 21 February [ZIP_CODE]. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization and Blinding
This is an open -label, non -blinded study . All eligible subjects will receive open -label E/C/F/TAF 
STR.
Once eligibility  is confirmed, the Sponsor will assign a unique subject num ber for each eligible 
subject and provide the subject number information to the study  site.
The subject number assignment may  be performed up to [ADDRESS_993227] is eligible for the study  prior 
to enrollment.
5.2. Description and Handling of E/C/F/TAF STR
5.2.1. Formulati on
E/C/F/TAF 150/150/200/10 mg
E/C/F/TAF 150/150/200/10 mg STR tablets are capsule -shaped, film -coated green tablets and 
are debossed with “GSI” on one side of the tablet and “510” on the other side of the tablet.
E/C/F/TAF STR tablets contain 150 mg of EVG, 150 mg of COBI, 200 mg of FTC, and 10 mg 
of TAF (as 11.2 mg of TAF fumar ate). The E/C/F/TAF 150/150/200/10 mg STR tablet cores 
contain silicon dioxide, croscarmellose sodium, hydrox ypropyl cellulose, lactose monohy drate, 
magnesium stearate, microcry stalline cellulose, and sodium laury l sulfate as inactive ingredients 
and are f ilm
-coated with indigo carmine aluminum lake, poly ethylene gl ycol, poly vinyl alcohol, 
talc, titanium dioxide, and yellow iron oxide.
E/C/F/TAF 90/90/120/6 mg (Low Dose)
E/C/F/TAF LD STR tablets are capsule -shaped, film -coated green tablets and are debossed with 
“GSI” on one side of the tablet and “306” on the other side of the tablet. E/C/F/TAF LD STR 
tablets contain 90 mg of EVG, 90 mg of COBI, 120 mg of FTC, and 6 mg of TAF (as 6.7 mg of 
TAF fumarate). The E/C/F/TAF LD STR tablet cores contain silicon dioxide, croscarmellose 
sodium, hy droxyprop yl cellulose, lactose monohydrate, magnesium stearate, microcry stalline 
cellulose, and sodium laury l sulfate as inactive ingredients and are film- coated with poly ethylene 
glycol, pol yvinyl alcohol, talc, titanium dioxide, black iron oxide, and y ellow iron oxide.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 46 21 February [ZIP_CODE].2.2. Packaging and Labeling
E/C/F/TAF 150/150/200/10 mg tablets are packaged in white, high density  poly ethylene (HDPE) 
bottles. Each bottle contains 30 tablets, a silica gel desiccant canister and poly ester coi l fiber.
Each bottle is enclosed with a white, continuous thread, child -resistant polypropy lene screw cap 
fitted with an induction- sealed, aluminum- faced liner.
E/C/F/TAF LD tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each 
bottle contains 30 tablets, a silica gel desiccant canister and polyester coil fiber. Each bottle is 
enclosed with a white, continuous thread, child- resistant poly propy lene screw cap fitted with an 
induction- sealed, aluminum -faced liner.
All labels for study  drug bottles to be distributed to centers in all countries will meet all 
applicable requirements of the FDA and Annex 13 of Good Manufacturing Practices: 
Manufacture of investigational medicinal products (July  2010) and/or other local regulations as 
applicable.
5.2.3. Storage and Handling
The E/C/F/TAF STR tablets should be stored at a controlled room temperature of 25°C (77°F); 
excursions are permitted between 15°C and 30°C (59°F and 86°F). To ensure the stability  of the 
tablets, the drug product should not be dis pensed into a container other than the container in 
which it is supplied. Measures that minimize drug contact [CONTACT_122029] y should alway s be 
considered during handling, preparation, and disposal procedures.
All study  medications should not be stored in any containers other than the container in which it 
is supplied.
5.3. Dosage and Administration of E/C/F/TAF STR
The E/C/F/TAF STR tablets will be provided by  [CONTACT_727418] , 
once dail y with food at approximately  the same time each day.
In-clinic dosing will be performed at Baseline/Day 1 and Weeks 1, 2, 4, 12, 24, and 48. For 
those subjects that take their medication in the evening, the in -clinic dosing will not be 
performed.
Subjects in Part A (inclusive of Cohort 3) will be admin istered their dose of study 
medication intheclinic with food during theIntensive PKvisit, atWeek 4(Cohorts 1and2) 
orWeek 2(Cohort 3).Inorder toallow forease ofPKsampling over a 24-hour period, subjects 
should be instructed to take their dose of E/C/F/TAF STR together with food at the same time 
every dayinthemorning (breakfast) ,during thedaysleading uptoIntensive PKassessments.
Prior to the scheduled trough and Intensive PK visits, subjects should fast overnight (a minimum 
of 8 hours).
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. Final 
Amendment6 
Subjects will be instructed to bring all study medicatio n in the original container at each study 
visit for drng acco untability (unless othe1wise spec ified in Section 6 ). The Investigato r will be 
responsib le for maintaining accurate records for all study drng bottles dispensed and tablets 
returned. The invento1 y and dispe nsing logs must be available for inspectio n by [CONTACT_8760]. Study medicatio n supp lies, including paiiially used or empty bottles, must be accounted 
for by [CONTACT_727419]1 1ction or return. 
For subjects in Cohort 3 unable to swallow the tablet whole, it is acceptable to split the tablet in 
two and administer both palis seque ntially. 
5.4. Prior and Concomitant Medication s 
• Conce nti·ations of ethinyl estradiol may decrease and progest in level may increase on 
coadm inisu-atio n of honnonal conti·aceptives with study diug. Please see the table below and 
refer to Appendix 5 for guidance on the use of conti·aception methods . 
• Coadinin isti·ation of GENVOY A with diugs that have active metabolite(s) fonned by 
[CONTACT_097]3A may result in reduced plasma concenti ·ations of the active metabolite(s) . 
• D rngs that induce CYP3A activity ai·e expected to increase the clearance ofEVG and COB! , 
resulting in decreased plasma conce nti·ation of COB !, and thus that of EVG , which may lead 
to loss of therape utic effect of GENVOY A, and deve lopment of resistance. 
• Med icatio ns listed in the following table and u se of herbaVnat ural supp lements are excluded 
or shou ld be used with caution while su bjects ai·e participating in the study due to potential 
diug -diug interact ions with the study diug. Inclusion of medicat ions in this list does not 
imply approva l for use in pediatric populations. 
• The list below shou ld be utilized in jurisdictions in which E/C/FffAF has NOT been 
approved. 
CONFIDENTIAL Page 47 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993228] and 
not to changes in gastric pH. It is recommended to 
separate E/C/F/TAF STR and antacid administration 
by [CONTACT_2669] 2 hours.
Alpha- 1 Adrenoreceptor 
AntagonistAlfuzosin
AntiarrhythmicsAmiodarone, Bepridil, Digoxin, Disopyramide, 
Flecainide, systemic Lidocaine, Mexiletine, 
Propafenone, Quinidine:
Concentrations of these antiarrhythmics may increase 
when coadministered with Cobicistat. Caution is 
warranted and clinical monitoring is recommended 
upon coadministration of these agents with 
E/C/F/TAF STR.
Antibacterials TelithromycinClarithromycin and Telithromycin:
Concentrations of Clarithromycin and/or Cobicistat 
may be alte red when Clarithromycin is 
coadministered w ith E/C/F/TAF STR.
Patients with CL cr greater than or equal to 60 mL/min: 
No dose adjustment of Clarithromycin is required.
Patients with CL cr between 30 mL/min and 
60mL/min: The dose of Clarithromycin should be 
reduced by 50%. Concentrations of Telithromycin 
and/or Cobicistat may be increased when 
Telithromyci nis coadministered w ith E/C/F/TAF 
STR. Clinical monitoring is recommended
upon coadministration with E/C/F/TAF STR.
AnticoagulantsConcentrations of Warfarin may be affected upon 
coadministration with E/C/F/TAF STR. It is 
recommended that the international normalized ratio 
(INR) be monitored upon coadministration with 
E/C/F/TAF STR.
Direct Oral 
Anticoagulants (DOACs)Api[INVESTIGATOR_3822], RivaroxabanDabigatran, Edoxaban: Concentrations may increase 
with study drug(s). Clinical monitoring and/or dose 
adjustment is recommended
AnticonvulsantsCarbamazepi[INVESTIGATOR_050], Phenobarbital, 
Phenytoin,Ethosuximide, Oxcarbazepi[INVESTIGATOR_050],
Coadm inistration of Oxcarbazepi[INVESTIGATOR_050], a CYP3A 
inducer, may decrease Cobicistat and Elvitegravir 
plasma concentrations, which may result in loss of 
therapeutic effect and development of resistance. 
Alternative anticonvulsants should be considered.
Concentrations of Ethosuximide may be increased 
when coadministered with Cobicistat. Clinical 
monitoring is recommended upon coadministration 
with E/C/F/TAF
STR.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 49 21 February 2020Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
AntidepressantsBupropi[INVESTIGATOR_2394]:
Concentrations may increase or decrease w ith study 
drug. Subjects receiving bupropi[INVESTIGATOR_727378].
SSRI dosing should be titrated in conjunction with 
clinical monitoring.
SSRIs except Sertraline, and Trazodone, tricyclic 
antidepressants (TCAs):
Concentrations may increase when coadministered 
with Cobicistat.
Concentrations of Sertraline are no t affected upon 
coadministration with study drug. No dose adjustment 
is required upon coadministration.
Concentrations of other antidepressant agents may be 
increased when coadministered with Cobicistat. Dose 
titration may be required for most drugs of the SSRI 
class. Concentrations of Trazodone may increase 
upon coadministration with Cobicistat. Dose 
reduction should be considered w hen Trazodone is 
coadministered w ith
E/C/F/TAF STR.
AntifungalsConcentrations of ketoconazole, itraconazole and/or 
cobicistat may increase with coadministration of 
E/C/F/TAF STR. When administering with 
E/C/F/TAF STR, the maximum daily dose of 
ketoconazole and itraconazole should not exceed 
200mg per day.
Concentrations of voriconazole may be increased 
when coadminist ered with cobicistat. Clinical 
monitoring may be needed upon coadministration 
with E/C/F/TAF STR.
AntigoutColchicine:
Concentrations may increase with study drug(s). Dose 
reductions of colchicine may be required. Should not 
be coadministered in patients with renal or hepatic 
impairm ent.
Dose reductions of colchicine may be required. 
E/C/F/TAF STR should not be coadministered w ith 
colchicine in patients with renal or hepatic 
impairm ent.
Treatment of familial Mediterranean fever :
Maximum daily dose of 0.6 mg (may be given as 
0.3mg twice a day)
AntihistaminesAstemizole, Terfenadine:
Concentrations of Astemizole and Terfenadine may 
be increased when coadministered with Cobicistat. 
Clinical monitoring is recommended when these 
agents are coadministered with E/C/F/TAF STR.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993229] 
and development of resistance.
Coadm inistration of E/C/F/TAF 
STR w ith rifampin is 
contraindicated.
Coadm inistration of E/C/F/TAF 
STR w ith rifabutin or rifapentine is 
not recommended.
AntiplateletsCoadm inistration of clopi[INVESTIGATOR_727379] a concentrations, 
which may reduce the antiplatelet 
activity of clopi[INVESTIGATOR_7745]. 
Coadm inistration of clopi[INVESTIGATOR_727380].
GENVOYA is not expected to have 
a clinically relevant effect on 
plasma concentrations of the active 
metabolite of prasugrel.
Benzodiazepi[INVESTIGATOR_727381]: Concentrations of other benzodiazepi[INVESTIGATOR_1651], 
including Diazepam and parenterally administered 
Midazolam, may be increased when adm inistered 
with E/C/F/TAF STR. Coadministration should be 
done in a setting that ensures close clinical 
monitoring and appropriate medical management in 
case of respi[INVESTIGATOR_233415]/or prolonged 
sedation. Dose reduction may be necessary.
Based on n on-CYP -mediated elimination pathways 
for Lorazepam, no effect on plasma concentrations is 
expected upon coadministration with E/C/F/TAF 
STR.
β-BlockersConcentrations of beta -blockers may be increased 
when coadministered with Cobicistat. Clinical 
monitoring is recommended and a dose decrease may 
be necessary when these agents are coadministered 
with E/C/F/TAF STR.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 51 21 February 2020Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Calcium Channel 
BlockersAmlodipi[INVESTIGATOR_050], Diltiazem, Felodipi[INVESTIGATOR_050], Nicardipi[INVESTIGATOR_050], 
Nifedipi[INVESTIGATOR_050], Verapamil:
Concentrations of calcium channel blockers may be 
increased when coadministered w ith Cobicistat. 
Caution is warranted and clinical monitoring is 
recommended upon coadministration with E/C/F/TAF 
STR.
Endothelin Receptor 
AntagonistsCoadm inistration of Bosentan with study drug may 
lead to decreased Elvitegravir and/or Cobicistat 
exposures and loss of therapeutic effect and 
development of resistance. Alternative endothelin 
receptor antagonists may be considered.
Ergot DerivativesErgotamine, Ergonovine (known as 
ergometrine in some regions), 
Dihydroergotamine 
Methylergonovine
GI Motility Agents Cisapride
Hepatitis C Virus 
Antiviral AgentsConcentrations of Cobicistat, Ledipasvir, Sofosbuvir, 
and GS -331007 (the predominant circulating 
metabolite of sofosbuvir) are increased when 
ledipasvir/sofosbuvir is coadministered w ith 
Elvitegravir and Cobicistat. The effect of 
coadministration of ledipasvir/sofosbuvir and 
E/C/F/TAF STR on concentrations of all components 
of these fixed -dose combinations is unknown. There 
are insufficient data to make a dosing 
recommendation for coadministration of E/C/F/TAF 
STR w ith ledipasvir/sofosbuvir.
Herbal/Natural 
SupplementsSt. John’s Wort
HMG- CoA Reductase 
InhibitorsSimvastatin, LovastatinConcentrations of Atorvastatin may be increased 
when coadministered with Elvitegravir and 
Cobicistat. Start with the lowest possible dose of 
Atorvastatin with careful monitoring upon 
coadministration with E/C/F/TAF STR.
Concentrations of Rosuvastatin are transiently 
increased when coadministered w ith Elviteg ravir and 
Cobicistat. Dose modifications are not necessary 
when Rosuvastatin is administered in combination 
with E/C/F/TAF STR.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 52 21 February 2020Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Hormonal ContraceptivesDrospi[INVESTIGATOR_187306]: Plasma concentrations may be 
increased when administered with E/C/F/TAF STR. 
Clinical monitoring is recommended due to the 
potential for hyperkalemia.
Coadm inistration ofstudy drug anda
norgestimate/ethinyl estradiol -containing horm onal 
oral contraceptive is expected to decrease plasma 
concentrations of ethinyl estradiol and increase
norgestimate.
Use caution when coadministering study drug and a 
horm onal contraceptive. The hormonal contraceptive 
should contain at least [ADDRESS_993230] of 
coadministration of E/C/F/TAF STR with oral 
contraceptives or hormonal contraceptives containing 
progestogens other than drospi[INVESTIGATOR_187306], norgestimate, 
orless than 25 mcg of ethinyl estradiol, is not known.
ImmunosuppressantsCyclosporine, Rapamycin, Sirolimus, Tacrolimus: 
Concentrations may increase when coadministered 
with Cobicistat. Therapeutic monitoring is 
recommended upon coadministration with E/C/F/TAF 
STR.
Inhaled Beta AgonistSalmeterol:
Coadm inistration with study drug may result in 
increased plasma concentrations of Salmeterol, which 
is associated with the potential for serious and/or
life-threatening reactions. Coadministration of 
Salmeterol and E/C/F/TAF STR is not recommended.
Neuroleptics Pi[INVESTIGATOR_580861], Risperi done, Thioridazine, Quetiapi[INVESTIGATOR_050]:
Consider reducing the dose of the neuroleptic upon 
coadministration with E/C/F/TAF STR.
Phosphodiesterase- 5 
InhibitorsCoadm inistration of E/C/F/TAF 
STR w ith Sildenafil for the 
treatment of pulmonary arterial 
hypertension (PAH) is 
contraindicated.PDE5 inhibitors are primarily metabolized by 
[CONTACT_097]3A. Coadministration with E/C/F/TAF STR may 
result in increased plasma concentrations of Sildenafil 
and Tadalafil, w hich may result in PDE5 
inhibitor -associated adverse reactions.
Caution should be exercised, including consideration 
of dose reduction, when coadministering E/C/F/TAF 
STR w ith Tadalafil for the treatment of pulmonary 
arterial hypertension.
For the treatment of erectile dysfunction, it is 
recommended that a single dose of sildenafil no more 
than 25 mg in 48 hours, vardenafil no more than 
2.5mg in 72 hours, or tadalafil no more than 10 mg in 
72 hours be coadministered with E/C/F/TAF STR.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 53 21 February 2020Drug Class Agents Disallowed Use Discouraged and To Be Used With Caution
Sedatives/Hypnotics Midazolam, TriazolamBuspi[INVESTIGATOR_5331], orally administered Zolpi[INVESTIGATOR_6730]:
With sedative/hypnotics, dose reduction may be 
necessary upon coadministration with E/C/F/T AF 
STR and clinical monitoring is recommended.
Corticosteroids: SystemicSystemic Dexamethasone, a CYP3A inducer, may 
decrease Elvitegravir and Cobicistat plasma 
concentrations, which may result in loss of 
therapeutic effect and development of resistance. 
Alternative systemic corticosteroids should be 
considered.
Corticosteroids: (all 
routes excluding 
cutaneous)Betam ethasone, Budesonide, Fluticasone, 
Mom etasone, Triamcinolone:
Coadm inistration with corticosteroids that are 
sensitive to CYP3A inhibition can increase the risk 
for Cushing’s syndrome and adrenal suppression, 
which have been reported during postmarketing use 
ofcobicistat -containing products. Consider the risk of 
systemic corticosteroid effects if E/C/F/TAF STR is 
coadministered w ith corticosteroids that are sensitive 
to CYP3A inhibition.
Alternative corticosteroids should be considered, 
particularly for long -term use.
In jurisdictions in which E/C/F/TAF has been approved, consult the local prescribing 
information for E/C/F/TAF dose recommendations with concomitant medications.
Should subjects have a need to initiate treatment with any  excluded concomitant medication, the 
[COMPANY_009] Science Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify  [COMPANY_009] Sciences as soon as he/she is aware of the use of the exclu ded 
medication.
5.5. Study Drug Return or Disposal
[COMPANY_009] recommends that used and unused stud y drug supplies be destroyed at the site. If the site 
has an appropriate standard operating procedure ( SOP)for drug destruction as determined b y 
[COMPANY_009], the site may  destroy  used (empt y or partially empt y) and unused study drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for the 
electronic trial master file . If study drug is destroyed on site, the investigato r must 
maintain accurate records for all study  drugs destroy ed. Records must show the identification 
and quantity of each unit destroy ed, the method of destruction, and the person who disposed of 
the study  drug. Upon study  completion, copi[INVESTIGATOR_727382]. Another copy  will be returned to [COMPANY_009]. 
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993231] perform drug accountabil ity 
during an on- site monitoring visit.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993232] enrolled in the study  are presented in 
tabular form in Appendi x 2, and also described in the text that follows.
All subjects will participate in all study  visits and assessments. Additionally, subjects in Part A 
(inclusive of Cohort 3) will complete the I ntensive PK visit at Week 4 (Cohorts 1 and 2) or 
Week 2 (Cohort 3).
Any deviation from protocol procedures should be noted and the Sponsor or Contract Research 
Organization (CRO) should be notified.
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the I nvestigator to ensure that each subject is eligible for the study  
before enrollment.
Please refer to Section 5.1for details about subject number assignment.
6.2.
Screening Visit
Each subject must sign an assent (and parent or legal guardian sign an informed consent form) 
prior to the conduct of any screening procedures. Subjects will be assigned a screening number at 
the time of assent/consent. Screening evaluations are used to determine the eligibility of each 
candidate for study  enrollment.
The following evaluations are to be completed at the Screening visit:
Obtain medical and medication history , including history  of HIV -1 disease -related events, 
and an y other ongoing medications within 30 days of the Screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487] ,andtemperature)
Height and weight
12-lead ECG performed supi[INVESTIGATOR_050]
Urine collection for the following laboratory
procedures:
Urinaly sis
For Cohort 3, urine renal safet y including: urine chemistry, retinol binding protein and 
beta-2-microglobulin. 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 56 21 February 2020Blood sample collection for the following laboratory analy ses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, the 
subject will not be enrolled.
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, CPK, and uric acid
For Cohort 3, metabolic assessments: Fasting (no food or drinks, except water, at least 
8hours prior toblood collection) glucose andlipid panel (total cholesterol, HDL, direct 
LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit may
proceed, but the subject must return within 72 hours in a fasted state to draw blood for the 
metabolic assessments.
Hematology  profile: comple te blood count (CBC) with differential and platelet count
Estimated Glomerular Filtration Rate (GFR) using Schwartz Formula (mL/min/1.73m2)= 
k L/Scr
Plasma HIV -
1 RNA ([COMPANY_002] COBAS TaqMan®v2.0)
Whole blood sample (Cohort 3 only)
Full flow cy tometry  panel testing
HIV-1 genot ype (protease, reverse transcriptase and integrase) testing (Cohort 1only). 
TheHIV-1genot ypemay not be performed forsubjects thatfailtomeet other screening 
laboratory criteria.
Hepatitis B virus (HBV) surface antigen serology (HBsAg)
Hepatitis C virus (HCV) serology (HCVAb)
For Cohort 3, serum bone safet y including: Bone specific alkaline phosphatase, 
parath yroid hormone (PTH), 25OH Vitamin D, and 1,25OH Vitamin D
Review of Adverse Events (AEs) and Concomitant Medications
Historical genot ype report(s) should be collected, if available (Cohorts 2and3only)
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 35 days after the Screening visit for the Baseline/Day 1 assessments. For Cohort 1, 
the Screening window may  be extended to 42 days for subjects who require repeat testing of the 
HIV-1 genot ype.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993233] eligibility  has been confirmed.
6.3. Treatment Assessments
6.3.1. Baseline/Day 1 Assessments
The following evaluations are to be completed at the Baseline/Day  [ADDRESS_993234] received the results from the screening genot ype report before proceeding 
with the Baseline/Day  1 visit.
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1516] r ate,
and temperature)
Height and weight
Tanner Stage assessments ( ≥ 6 y ears of age)
DXA Scan (lumbar spi[INVESTIGATOR_456000] )
The DXA scan will be performed on subjects once eligibility  is confirmed and prior to 
study  drug administration at the Baseline/Day  1visit. The scan may  be performed on the 
morning of the Baseline/Day  1 visit as long as it occurs before dosing.
Urine collection for the following laboratory procedures:
Urinaly sis
For Cohorts 1 and 2, urine renal safet y including: urine chemistry , retino l binding protein 
and beta -2-microglobulin. 
For Cohorts 1 and 2, urine bone safet y including: bicarbonate, N -telopeptide
EVG /COBI/Ff CffAF 
Protocol GS-US-292-[ADDRESS_993235] (female s of childbear ing potential only). If the urine pregnancy test 
is positive at Baseline, study dmg will not be dispensed. The positive result will be 
confmn ed with a s ernm pregnanc y test. If the sennn pregnancy test is positive, the 
subject will not be able to paiticipate . 
• Blood sample collectio n for the following laborato1 y analy ses: 
I Chemistiy profile: alkaline phosphata se, AST , ALT, total bilirnbin, direct and indirect 
bilirnbin , cystatin C for Coho1ts 1 and 2, total protein , albumin , bicai·bonate , BUN , 
calcium , chloride, creatin ine, phosphorns, magne sium, potass ium, sodium, CPK, and uric 
acid 
For Cohorts 1 and 2, metab olic assess ment s: Fasting (no food or drink s, except wate r, at 
least 8 hour s prior to blood collection) glucose and lipid panel (total chol estero l, HDL , 
direct LDL , and ti·iglyceride s). If the s ubject has not fasted prior to the visi t, the visit may 
proceed , but the s ubject must return within 72 hours in a fasted state to draw blood for the 
metab olic assessme nts. 
Hemato logy profile : CBC with differential and platelet count 
Plasma HIV-1 RNA ([COMPANY_002] COBAS TaqMan ® v2.0) 
Full flow cytometiy panel testing 
For Coho1ts 1 and 2, senun bone safety includin g: Bicai ·bonate, N-tel opept ide, C-
telopeptide (C TX), osteocalc in, procoll agen type 1 N-tenninal propeptide (Pl NP), bone 
specific alkaline phosphata se, pai·athyroid honnone (PTH ), 25OH Vitainin D, and 
1,25OH Vitainin D 
Estimated glomernlar filu-ati on rate accord ing to Schwa1tz fonnu la 
• Study diug dispensation. Subjects should initiate dosing of study diug along with food 
in-clinic the day of the Baseline visit. 
• Subjects should be instiucted to take study mugs with food . The subject should be counsel ed 
regardin g the impo1tance of adhe rence and taking their study medicati on at appro ximately 
the s ame time each day as directed by [CONTACT_737]. Sites sho uld consider individual 
subject study diug dosing schedule while scheduling study visits requiring collect ion of 
ti· ough PK sainple s. 
CONFIDENTIAL Page 58 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 59 21 February 2020The PK study  of Part A (inclusive of Cohort 3) is designed to assess the PK of and 
confirm the doses of E/C/F/TAF STR. Therefore, all subjects must take their dose of 
study  medication with food at approximately the same time every morning at all visits 
prior to the Intensive PK visit.
Palatability  and Acceptability  assessment (Cohorts 2 and 3)
The Investigator will ask if the study  drug was palatable and if the subject was able to 
take the dosage form.
Subjects should be reminded to bring the required drug bottles of the E/C/F/TAF STR with 
them for in- clinic dosing and drug accountability  at the Week 1/(Day  7)visit.
6.3.2. Treatment Assessments through 48 Weeks (Weeks 1 (Day 7) – 48)
The following eval uations are to be completed at the end of Weeks 1, 2, 4, 8, 12, 16, 24, 32, 40 
and 48 unless otherwise specified.
All study visits are to be scheduled relative to the Baseline/Day 1 visit date . The Week 1 
(Day  7) visit should occur on the protocol- specifie d visit date based on the Baseline/Day 1 visit. 
Study  visits at Weeks 2 through 8 are to be completed within ± 2 day s of the protocol -specified 
visit date based on the Baseline/Day  1 visit and completed within ± 4 day s of the
protocol -specified visit date at Weeks 12 through Week 48, unless otherwise specified.
Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
Review of AEs and changes in concomitant medications
Complete phy sical examination ( Weeks 24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom -directed phy sical examination as 
needed ( all other visits)
Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature)
Height and Weig ht
Tanner Stage assessments for ≥ 6 y ears of age ( Weeks 24 and 48 − except for subjects 
documented to have achieved Tanner Stage 5)
DXA scan (lumbar spi[INVESTIGATOR_456000] ) (Weeks 24 and 48 ± 10 days)
Urine collection for the following laboratory procedures:
Urinaly sis and urine chemistry
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. Final 
Amendment6 
Urine renal safety includin g: urine chemi stry, retinol binding protein and 
beta-2-microglob ulin (Weeks 8, 12, 24 and 48) 
For Coho1ts 1 and 2, urine bone safety including: bicarbo nate, N-telopeptide (Weeks 8, 
12, 24 and 48) 
Urine pregnancy test (females of childbear ing potential only). If the urine pregnancy test 
is positive, study drng will not be dispense d. The positive result will be confnm ed with a 
sernm pregnancy test. If the sennn pregnancy test is positive , the subj ect will be 
discontinued 
• Blood sample collectio n for the following laborato 1 y analyses: 
Chemistry profile: alkalin e phosphatase , AST , ALT, total bilirnbin, direct and indirect 
bilirnbin, cystatin C (Weeks 2 [Cohort 1 only], 4, 24, and 48 [Cohorts 1 and 2 only]. 
Cystatin C will not be done for Cohort 3 to reduce blood draw volumes), total protein , 
albumin , bicarbonate , BUN, calcium, chloride, creatinine, glucose, phosp horns, 
magnesium, potassium , and sodium, CPK , and uric acid. At Weeks 24 and 48, analyses of 
glucose will be done as pait of the fasting metabolic assessments and not as pa1t of the 
chemistry profile . 
Metabolic assessme nts: Fasting (no food or drinks , except wate r, at least 8 hours prior to 
blood collectio n) glucose and lipid panel (total cholestero l, HDL , direct LDL , and 
tr·iglycerides) . If the subject has not fasted prior to the visit, the visit may proceed , but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments (Weeks 24 and 48 only ). 
Hemat ology profile : CBC with differential and platelet count 
Plasma HIV-1 RNA ([COMPANY_002] COBAS TaqMan v2.0) 
Full flow cytometiy panel testing (Weeks 2 -48) 
Sernm bone safety including: 
Coho1ts 1 and 2: bicarbonate, N-telopeptide , CTX, osteocalcin , PlNP 
For all coho1ts: bone specific alkaline phosp hatase, PTH , 25OH Vitamin D, and 1,25OH 
Vitam in D (Weeks 8 [Cohort 1 only], 12, 24 and 48) 
CONFIDENTIAL Page 60 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 61 21 February 2020Estimated glomeru lar filtration rate according to Schwartz formula
HIV-1 genot ype/phenot ype testing for subjects with suboptimal virologic response or 
virologic rebound (as needed)
Pharmacokinetic (PK) blood collection:
Cohort 1
Trough PK sample ([ADDRESS_993236]- dose) (Weeks 1 (Day 7), 2, 24 and 48).*
Timed Single PK sample collected between 0.[ADDRESS_993237]- dose ( Week 4 [PartB 
subjects only ]and at Week 12 only )*
Random Single PK sample taken an ytime in relationship to last dose of study  drug ( all 
other visits )*
Cohort 2
Trough PK sample ([ADDRESS_993238]- dose) ( Weeks 1, 2, and 24 )
Timed Single PK sample collected between 0.[ADDRESS_993239]- dose ( Week 12only)*
Random Single PK sample taken an ytime in relationship to last dose of study  drug 
(Weeks 8 and 16 )
Cohort [ADDRESS_993240]- dose ( Weeks 8, 12 ,and 
16)*
Trough PK sample ([ADDRESS_993241]
-dose). Subjects should be reminded not to take 
their study  medication on the morning of these visits. The time of last dose prior to the 
PK draw should be documented. ( Weeks 4 and 24
)
* For subjects who take their medication in the evening, a Random Single PK sample taken 
at an y time in relationship to last dose of study drug will be collected in lieu of the 
Trough or Time d Single PK collected between 0.[ADDRESS_993242] 
dose prior to the PK draw should be documented. ( For Uganda only)
Subjects who meet the criteria for suboptimal virologic response or rebound should be 
managed according to Management Virologic Failure Section 6.8.1.
Subjects should be reminded not to take their study  medication on the morning of their 
Week 1 (Day  7), 2, 4, 12, 24, and 48 clinic visits and the visits during which PK trough or 
intensive samples will be collected.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 62 21 February 2020Document study  drug dispensation and accountability  for all study  drugs dispensed. No study  
drug will be dispensed at the Week 2 visit.
Subject dosing diaries sh ould be dispensed at the Week 1 (Cohort 3) or Week 2 (Cohort 1 
and 2) visit (depending upon the timing of the i ntensive PK visit) to subjects in Part A 
(inclusiveof Cohort 3) to capture study drug information prior to the I ntensive PK study visit.
Palatab ility and Acceptability Assessment
For Cohort 1, at the next scheduled visit, the investigator will ask if the study  drug was 
palatable and if the subject was able to take the dosage form. If the subject has passed the 
Week [ADDRESS_993243] discontinues prior to the Week 4 visit, this assessment will be 
captured at the ESDD visit.
6.3.3. Intensive PK Evaluation (Part A subjects only, inclusive of Cohort 3)
The Intensive PK evaluation will occur at the Week 4 (Cohorts 1 and 2) or Week 2 (Cohort 3) 
visit. For the purpose of scheduling the Intensive PK visit, a + 7 day s window may  be used.
Subjects should come in a fasted state (i.e. no food or drink except water at least 8 hours prior). 
Subjects should be instructed that on the day  of the Intensive PK evaluation the dose of 
E/C/F/TAF STR must not be taken prior to the visit.
If the subject has alread y dosed prior to the Intensive PK evaluation visit or is not in a fasted 
state, the Intensive PK assessments must not be completed. The subject should be instructed to 
return in a fasted state within 7 day s of their Week 4 (Cohorts 1 and 2) or Week 2 (Cohort 3) 
visit for the I ntensive PK assessments.
If dosing non -compliance not related to AEs is identified on or prior to the I ntensive PK 
evaluation visit, the I ntensive PK assessments must not be completed. The subject should be 
counseled regarding proper dosing and be scheduled to return for the Intensive PK evaluation 
visit no sooner than three days following compliant dosing and no later than Week 4 (Cohorts 1 
and 2) + 7 day s or Week 2 (Cohort 3) + [ADDRESS_993244] should be reminded to not take the E/C/F/TAF 
STR prior to arriving at the clinic on the day  of the re -scheduled Intensive PK v isit. All Intensive 
PK assessments listed below should be completed when the subject returns:
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
• Su bject dosing diaries will be collected and reviewed. Final 
Amendment6 
• For Coho1t 1 subjects, blood samples will be collected at 0 (pre-dose , ::; 30 minu tes prior to 
dosing). After collection of the pre-dose sample , subjects will be provided a standa rdized 
meal. Within five minute s after consumin g the standardized meal , subjects will be dosed 
with the E/ C/F/TAF STR. Intensive PK sampli ng at the following time-points will occur: 
[ADDRESS_993245]-dose. 
• For Coho1t 2 subjects , blood samples will be collected ::; 30 minutes prior to dosing . After 
collection of the pre-dose sample , subjects will be provided a meal. Within five minutes after 
consuming the meal , subjects will be dosed with the E/ C/F/fAF STR. Intensive PK sampling 
at the following time-points will occur: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and [ADDRESS_993246]-dose . 
Subjects will be restricted from fiuther food intake until afte r the 4 -hour PK blood draw. 
• For Cohort 3 su bjects, blood samples will be collected ::; [ADDRESS_993247] ion of the pre-dose samp le, subjects will be provided a meal. Within five minutes 
after consuming the meal , subjects will be dosed with the E/C/F/fAF STR. Intensive PK 
sampling at the following time-points will occur: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and [ADDRESS_993248]-dose. Subjects will be restricted from fiuther food intake until after the 4-hour PK bl ood 
draw. -
-
I 
CONFIDENTIAL Page 63 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences, Inc. 
I 
I 
I 
I 
I 
I I 
I 
I 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 64 Final 
Amendment6 
21 Febrna1y 2020 
EVG /COBI/Ff CffAF 
Protocol GS-US-292-0106 
[COMPANY_009] Sciences, Inc. 
I 
I 
I 
I I 
I 
6.3.6. Early Study Drug Discontinuation (ESDD) Final 
Amendment6 
If a subject in the treatment phase of the study discontinu es study diug prior to Week 48, the 
subject will be asked to return to the clinic within 72 hour s of stoppi[INVESTIGATOR_727383] s for an ESDD 
Visit. Sub· ects will then be asked to continu e attendin all scheduled stud visits. 
At the ESDD Visit, any evaluations showing abnormal results for which there is a possible 
or probable causal relationship with the study drug, should be repeated weekly ( or as often 
as deemed prudent by [CONTACT_093]) until the abnormality is resolved , returns to 
baseline, or is otherwise explained. 
The following evaluations are to be comp leted at the ESDD visit: 
• Review of AEs and concomita nt medicati ons 
• Complete phys ical examination (urogenital/anorectal exams will be perfonned at the 
discretion of the Investigator) 
• V ital signs (blood press ure, pulse, respi[INVESTIGATOR_39870] n rate, and temperature) 
• Height and Weig ht 
• Urine collectio n for the followingprocedures: 
Urinal ysis 
Urine pregnanc y test (female s of childbear ing potential only). The positive result will be 
confmn ed with a sernm pregnanc y test. 
CONF IDENTIAL Page 65 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
I 
• Blood sample collectio n for the following laborato 1 y anal yses: Final 
Amendment6 
Chemistiy profile: alkaline phosphatase , AST , ALT, total bilirnbin, direct and indirect 
bilirnb in, total prote in, albumin , bicarbonate , BUN , calcium , chloride, creat inine, 
glucose, phosphorns, magnesium , potassi um, and sodium, CPK, and mic acid 
Estimated glomern lar filu-atio n rate according to Schwa1tz fonnula 
Hemato logy profi le: CBC with differe ntial and platelet count 
Full flow cytometiy panel testing 
Plasma HIV-I RNA (Roc he COBAS TaqMan v2.0) 
Plasma storage samples for virology testing , safety or phaimacok inetic testing 
I 
HIV-I genotype /phen otype testing for subjects with su boptimal virologic response or 
virologic rebound 
Single plasma PK sainple taken anytime in relatio nship to last dose of study diug 
• D rng accountability 
• Pal atability and Acceptabi lity assessme nt (if applicable) 
6.3.7. 30-Day Follow- Up Vis it 
Subjects who disco ntinue study diug prior to Week [ADDRESS_993249] one su bseq uent visit after the Eai·ly Study Drng Disco ntinuation visit will not be required 
to complete the 30-Day Follow-Up visit. 
Subjects who complete 48 weeks on study diug will be required to return to the clinic 30 da s 
after com letion of the Week 48 visit for a 30-Day Follow-Up visit 
For the pmpose of scheduling a 30-Day Follow -Up Visi t, a± 6 days window may be used. The 
following evaluations are to be completed at the 30-Day Follow-Up Visit: 
• Review of AEs and concomita nt medicat ions 
• Symptom -directed physical exaininatio n 
CONFIDENTIAL Page 66 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
• Vital signs (blood press ure, pulse, respi[INVESTIGATOR_39870] n rate, and temperat ure) 
• Height and Weight 
• Ur ine collectio n for the followingproced ures: Urinalysis Final 
Amendment6 
Urine pregnancy test (females of childbear ing potentia l only). A posit ive result will be 
confmned with a sernm pregnancy test. 
• Bl ood sample collectio n for the following laborato 1 y an alyses: 
Chemistiy profile: alkaline ph osphatase , AST , ALT, total bilirnbin , direct and indirect 
bilirnb in, total protein , albumin , bicarbonate , BUN , calcium , chloride, creat inine, 
glucose, phosphorns, magnesium , potassium , and sodium, CPK , and uric acid 
Estimated glomern lar filu-atio n rate accord ing to Schwa1tz fo1 m ula 
Hemato logy profi le: CBC with differe ntial and platelet count 
Full flow cytometiy panel testing 
Plasma HIV-I RNA ([COMPANY_002] COBAS TaqMan v2.0) 
• Palatability and Acceptability assessment (if applicab le) 
At the 30-Day Follow -Up visit, any evaluatio ns showing abnonnal results for which there is a 
possible or probable causa l relations hip with the study diug , should be repeated weekly ( or as 
often as deemed prnde nt by [CONTACT_20616] r) until the abno1mality is resolved, returns to 
baseline , or is othe1wise expla ined. 
6.4. Bone Evaluation s 
Dual energy x-ray abso1ptiometiy (DXA) scans of the lumbar spi[INVESTIGATOR_727384]1med prior to study diug adinin isti·ation at the Baseli ne/Day 1, and Weeks 24, [ADDRESS_993250]-Week 48 visits (±10 days) . Scans will measure changes in lumbar spi[INVESTIGATOR_727385] (BM D) and total BMD. DXA scan results will be prov ided to study sites. 
A complete descr iption of the proced ures perfo1med for the DXA scans wi ll be provided in a 
DXAma nual. 
CONFIDENTIAL Page 67 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
6.5. Bone and Renal Safety Final 
Amendment6 
The following semm bone safety paramete rs wi ll be collected at Scree ning (Cohort 3) or 
Baseline (Coho1is 1 and 2) and Weeks 8 (Coho1 i 1 on ly), 12, 24, and [ADDRESS_993251]-Week 48 visits (±6 days): Senun: For Coho1is 1 and 2 only: bi carbonate , N-telopeptide , 
C-telopeptide (CTX) , osteocalc in, and proco llagen type 1 N-tenninal propeptide (PlNP). For all 
coho1is: bone specific alkaline phosphatase, parathyroid honnone (PTH ), 250H Vitamin D, and 
1,250H Vitamin D. 
For Coho1is 1 and 2, the following urine bone safety parameters will be collected at Baseli ne, 
Weeks 8, 12, 24, 48: Urine: bicarbonate , N-telopept ide. 
For all subjects , urine will also be collected for selected renal safety , including urine chemistry, 
retino l binding protein , and beta-2-m icroglobu lin at the Scree ning (Coho1i 3) or Baseli ne 
(Coho1is 1 and 2) visit, and Weeks 8, 12, 24, 48. 
6.7. Criteria for Discontinuation of Study Treatment 
Study medicat ion may be disco ntinued in the following instances : 
• Intercune nt illness that would, in the judgme nt of the investigator , affect assessme nts of 
clinical status to a significa nt degree 
• Un acceptable toxic ity, as defined in the toxicity management section of the protocol , or 
toxicity that, in the judgme nt of the investigato r, compromises the ability to continue 
study -specific proced ures or is considered to not be in the subject's best interest 
• Lack of efficacy (virologic failure) 
• Subject request to discontinue for any reaso n 
• Subject noncomp liance 
• Pr egnancy during the study 
• Discont inuatio n of the study at the r equest of [COMPANY_009], a regulato1y agency, or an IRB/IEC 
CONFIDENTIAL Page 68 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 69 21 February [ZIP_CODE].8. Virologic Failure
Subjects in Cohort 1 who experience suboptimal virologic response (SVR) or subjects in 
Cohorts 1, 2, or 3 who experience virologic rebound (VR), as defined below, will be considered 
to have virologic failure.
Upon confirmation of virologic failure, potential causes should be documented. Assessments 
should include:
Adherence
Concomitant medic ation
Comorbidities (eg active substance abuse, depression, other intercurrent illnesses)
If virologic failure is confirmed and the HIV- 1 RNA value is ≥ 400 copi[INVESTIGATOR_014]/mL , the blood 
samples from the confirmation visit will be used for HIV -1 genot ype/phenotype testing.
Genoty pe/phenot ype resistance testing will be performed using the RT/PR PhenoSense GT 
assay , the IN GeneSeq assay , and the IN PhenoSense assay  (Monogram Biosciences, Inc.) in 
subjects who experience suboptimal virologic response or virologic rebou nd, if HIV -1 RNA is 
≥ 400 c opi[INVESTIGATOR_014] /mL.
If genot ype/phenot ype resistance to study  drug is documented, study  drugs should be 
discontinued.
If no resistance is detected from genot ype/phenot ype testing, the subject may remain on study 
drug and an HIV -[ADDRESS_993252] should be repeated ([ADDRESS_993253] with HI V-1 RNA
≥50 copi[INVESTIGATOR_014]/mL ). Investigators should carefully  evaluate the benefits and risks of remaining on 
study  drug for each individual subject and document this assessment in the on -site medical 
recor d. Investigators who opt to discontinue study  drugs for an individual subject must discuss 
with the Medical Monitor prior to study  drug discontinuation.
6.8.1. Management of Suboptimal Virologic Response (Cohort 1 only)
Subjects who meet the criteria listed below will be considered to have suboptimal virologic 
response:
HIV-1 RNA is < 1 log 10 reduction from Baseline and ≥ 50 copi[INVESTIGATOR_014]/mL  at the Week 8 visit, 
confirmed at Week 12 or Unscheduled visit following Week 8.
Following the unconfirmed suboptimal virologic res ponse at Week 8, HIV- 1 RNA should be 
repeated at a scheduled or Unscheduled visit ([ADDRESS_993254] with 
HIV-1 RNA to ≥ 50 copi[INVESTIGATOR_014]/mL ). If suboptimal virologic response is confirmed, the samples from 
the confirmation visit will be used for HIV -1 genoty pe/phenot ype testing if HIV -1 RNA is
≥ 400 copi[INVESTIGATOR_014]/mL .
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 70 21 February 2020Please refer to Figure 6-1for the management of subjects who meet the criteria for suboptimal 
virologic response.
Figure 6
-1. Suboptimal Virologic Response Schema (Cohort 1only)
a If suboptimal virologic response is confirmed and the HIV- 1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype 
(reverse transcriptase, protease and integrase) will be analyzed.
b If genotype/phenotype results are not available by [CONTACT_56421] 12 visit, an unscheduled visit should be performed when the 
laboratory results are available.
c Based on the results of the genotype/phenotype assays, the subject will remain on study drug or study drug will be 
discontinued at the next scheduled or unschedul ed visit, whichever occurs first. If genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_580868], a repeat 
specimen will be sent for analysis. If repeat genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_727386], study medications can be continued 
or a new ARV regimen can be configured at the discretion of the Investigator, in consultation with the Medical Monitor.
d If no resistance is detected, HIV- 1 RNA will be repeated within 3 -6 weeks. Investigator reviews and document study drug 
continuation/discontinuation options. Investigator must discuss with the Medical Monitor prior to study drug discontinuation
e A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.
6.8.2. Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:
At any  visit, after achieving HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL , a rebound in HIV -1 RNA to
≥ 50 copi[INVESTIGATOR_014]/mL, which is subsequently  confirmed (two consecutive tests) at the following 
scheduled or Unscheduled visit (3- [ADDRESS_993255] with HI V-1 RNA 
to ≥ 50 copi[INVESTIGATOR_014]/mL ) (Cohorts 1, 2, and 3); OR
Figm ie 6-1. Suboptima l Virologi.c Re-sp -0D1se Sdiem.a ,{Cohm · , t 1 oruy) 
Screenrng 
I 
Baiselm Day 1 
BIV-1!:NA < l loglli redud:i:-0 . 
fn>m l:Jas:eline 311.d 
50 ,c;o,pi~iml. 
U11c"Oafimted 
sul:Jo:plliimai 
mologiic: 
r,espo11Se - : i:-tmaia 
oa !fudJ d!m( ; I' .,. 
.f 
I ' .f .f 
I' 
I Tre.atment Pel'iod 
i 
r \\i,eel Uo.-
lm.St.hedu!e d i;:isit 
Repeal Hn'-1 RNA 
ed pote.atw 
geiti!l};p,l!lphmo~ 
, 3,-(i 'l{et!lu :alur W,etik3) 
Confum!d 
mboptim.a] 
. lo • !J Dl'O ~cnspoase 
HIV-l ·goiolype iph.eaolJpt 
if ~00 copn'inL ill t 30-Da, y · F,U 
I 
Unschedu led 
vis:if 
Geaotype,'pllea.otn,e malrsi! r.esolli c.d . . 
f ao :r,e>fl"Se o:a:as;aiip last 
-or iu:ttgn5e reistaaoe -
d.etected, , ,c;ontiJJ11f o study 
dnige 
' l"l!TI!TS:e Ill" 
· u!istaaoe 
mded, ,~ontiJJ11(! study 
mgs aod «nstmd a :ae:w 
"·"'. . . . f :u,. · r,epm,e,.n 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 71 21 February 2020At any  visit, a >1 log 10 increase in HIV -1 RNA from the nadir which is subsequently
confirmed (two consecutive tests) at the following scheduled or Unscheduled visit
(3-6weeks after the date of the original test with HIV -1 RNA to ≥ 50 copi[INVESTIGATOR_014]/mL ) (Cohort 1
only)
Following the unconfirmed virologic rebound, HIV -1 RNA should be repeated at a scheduled or 
unscheduled visit ([ADDRESS_993256] w ith VL ≥ 50 copi[INVESTIGATOR_014]/mL ). If 
virologic rebound is confirmed, the samples from the confirmation visit will be used for HIV -1 
genot ype/phenot ype testing if HIV -1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL .
Please refer to Figure 6-2for the management of subjects who meet the criteria for virologic 
rebound.
Figure [ADDRESS_993257] will remain on their current regimen.
b If virologic rebound is confirmed, and the HIV-1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c Based on the results of the genotype/phenotype assays, the subject will remain on study drug or study drug will be 
discontinued. If genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_580868], a repeat specimen will be sent for analysis. If repeat genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_727387], study medication can be continued or a new ARV regimen can be configured at the discretion of the 
Investigator, in consultation with the Medical Monitor.
d If no resistance is detected. Investigator reviews study drug continuation/discontinuation options and discuss with the 
Medical Monitor prior to study drug discontinuation
e A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study
Screemng Treaitment Period Follow -u_ p 
Baseilme iD.ay 
.~f au. ~ -risit, a.fter .a.duniu g BIV-1 RNA < 50 CAJPi[INVESTIGATOR_143341], a, ubllllll.d lo~ 50 copi[INVESTIGATOR_014].imL 
(Oiboot s l Hli 2} OR> [ log., DICUISf! m HIV- - ] RNIA fr.om lheir nlllfu- (Cdhort I ) 
Unconfirmed 
Tif,lllll<gic 
r,ebo1111.-d : 
. r,ellWl!< ooi 
CIIITffLt 
~1!11 
Iii 1111, nnrse 0-3.lll5cripla.slf or 
iDugra,se , nsilstance defecied, 
C.GDU!llll! OIi sbldJ d!r11gs. d Remm for sd1.edaled. (11.11<sd1ed.aled 
iEln'-1 !R,'lf..'\ and potaitial 
i:e110.type,'pht:11~-pe (3-6 \liffl.:s htK) 
Coomrmedl .irologic 
i:eboud • 
Remam 
, o.a.stud)" Hu.e-rse • lra!IS(ripfMP or 
intep35e i-esm ance 1btfd:ed, 
1limmtinue stod~ • d111~ ad 
r,onstruc t a ntw .UV r•e~11 ·0 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 72 21 February [ZIP_CODE].8.3. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -[ADDRESS_993258] ained at ≥ 400 copi[INVESTIGATOR_014]/mL but do not meet 
either SVR or VR criteria. Subjects in that category  could have an antiviral response that was
1 log 10 HIV-1 RNA reduction from baseline (and therefore did not meet SVR criteria), but did 
not show > [ADDRESS_993259] achieved HIV -1 RNA < 50copi[INVESTIGATOR_014]/mL could 
subsequently  experience unconfirmed blips ≥ 400 copi[INVESTIGATOR_014]/mL  of HIV -[ADDRESS_993260] visit while 
receiving stud y drugs (or within 72 hours of discontinuation of study  treatment). Subjects with
≥400 copi[INVESTIGATOR_014]/mL  of HIV -1 RNA at study  discontinuation (after Week 8) while receiving study  
drugs (or within 72 hours of discontinuation of study  treatment) will be analy zed for resistance.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 73 21 February [ZIP_CODE]. ADVERSE EVENTS AND T OXICITY MANAGEMENT
7.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical investigat ion subject 
administered a medicinal product and which does not necessaril y have a causal relationship with 
this treatment. An AE can therefore be an y unfavorable and unintended sign, s ymptom, or 
disease temporall y associated with the use of a medicinal pr oduct, whether or not considered 
related to the medicinal product.
AEs also include the following:
Pre-or post -treatment complications that occur as a result of protocol mandated procedure 
(e.g. such as venipuncture, biopsy ) during or after Screening (bef ore the administration of 
study  investigational medicinal product).
Any pre-existing condition that increases in severity , or changes in nature during or as a 
consequence ofthestudy investigational medicinal product phase of ahuman clinical trial, 
will also be considered an AE.
Complications and termination of pregnancy  (see Section 7.4for additional information)
All AEs that occur from the Screening visit onwards and throughout the duration of the 
study ,including thefollow -upoffstudy medication period should berecorded as an AE.
An AE does not include the following:
Medical or surgical procedures (e.g., surgery , endoscopy , tooth extraction, transfusion) 
perfor med; the condition that leads to the procedure is an adverse event
Pre-existing diseases or conditions or laboratory  abnormalities present or detected before the 
Screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.4)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before theconsent form issigned andnotrelated toaprotocol -associated procedure isnotan 
AE. It is considered to be pre -existing and should be documented on the medical history  
CRF.
Uncomplicated pregnancy .
An induced elective abortion to terminate a pregnancy  without medical reason.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 74 21 February [ZIP_CODE].2. Assessment of Adverse Events
All AEs will be assessed by  [CONTACT_727420]. The AE entry  should indicate whether or not the AE was serious, the start date (AE onset), 
the stop date (date of AE resolution), whether or not the AE was related to investigational 
medicinal product or to a study  procedur e, the action taken with investigational medicinal 
product due to the AE, and the severit y of the AE. The investigator is responsible for final 
review and confirmation of accuracy  of events, relationship and severit y confirmed b y the 
signature [CONTACT_530127] b ook. The relationship to investigational medicinal product therap y should 
be assessed using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the investigational 
medicinal product. For SAEs, an alternative causality  must be provided (e.g., pre-existing 
condition, underly ing disease, intercurrent illness, or concomitant medication).
Yes: A temporal relationship exists between the AE onset and administration of the 
investigational medicin al product that cannot be readily  explained by  [CONTACT_423]’s clinical 
state or concomitant therapi[INVESTIGATOR_014]. Furthermore, the AE appears with some degree of certainty  to 
be related, based on the known therapeutic and pharmacologic actions or adverse event 
profile of the investigational medicinal product. In case of cessation or reduction of the dose, 
the AE abates or resolves and reappears upon rechallenge.
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the conte xt of adverse event reporting.
The relationship to study  procedures (e.g., invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the 
study procedure.
Yes: The adverse event occurred as a result of protocol- mandated procedures such as 
venipuncture or biops y.
7.3. Serious Adverse Events
A serious adverse event (SAE) is defined as follows:
Any adverse drug experience occurring at any  dose that results in an y of the following outcomes:
Death
Life-threatening situation (subject is at immediate risk of death)
In-patient hospi[INVESTIGATOR_1081] (excluding those for 
study  therapy  or placement of an indwelling cathe ter, unless associated with other SAEs)
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 75 21 February 2020Persistent or significant disability /incapacit y
Congenital anomal y/birth defect in the offspring of a subject who received investigational 
medicinal product
Other: medicall y significant events that may  not be immedia tely life-threatening or result in 
death or hospi[INVESTIGATOR_059], but based upon appropriate medical and scientific judgment, may  
jeopardize the subject or may  require medical or surgical intervention to prevent one of the 
outcomes listed above
Examples of such events are as follows:
Intensive treatment in an emergency  room or at home for allergic bronchospasm
Blood d yscrasias or convulsions that do not result in hospi[INVESTIGATOR_727388]
Death is an outcome of an AE, and not an adverse event in itself. In reports of death due to 
“Disease Progression,” where no other information is provided, the death will be assumed to 
have resulted from progression of the disease being treated with the investigational medicinal 
product(s).
The subject may  not have been on investigational medicinal product at the occurrence of the 
event. Dosing may  have been given as treatment cycles or interrupted temporaril y before the 
onset of the SAE, but may have contributed to the event.
“Life-threatening” means that the subject was at immediate risk of death from the event as it 
occurred. This does not include an event that might have led to death if it had occurred with 
greater severit y.
Complications thatoccur duringhospi[INVESTIGATOR_727389]. Ifa complication prolongs the 
hospi[INVESTIGATOR_059], it is a SAE.
“In-patient hospi[INVESTIGATOR_059]” means the subject has been formally  admitted to a hospi[INVESTIGATOR_99325], for an y length of time. This may  or may  not be overnight. It does not 
include presentation and care within an emergency department.
The investigator should attempt to establish a diagnosis of the event on the basis of signs, 
symptoms and/or other clinical information. In such cases, the diagnosis shoul d be 
documented as the AE and/or SAE and not the individual signs/sy mptoms.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 76 21 February 2020A distinction should be drawn between seriousness and severit y of AEs. An AE that is assessed 
as Grade 4 (potentiall y life -threatening) should not be confused with an SAE. Severity is a 
category  utilized for rating the intensit y of an event; and both AEs and SAEs can be assessed as 
Grade 4. An event is defined as “serious” when it meets one of the predefined outcomes 
described above in Section 7.3.
7.4. Special Situations
7.4.1. Definitions of Special Situations
Special situation reports include pregnancy  reports, reports of medication error, abuse, misuse, or 
overdose, reports of adverse reactions in infants following exposure from breastfeeding, 
occupational exposure with an AE, and reports of adverse reactions associated with product 
complaints.
A pregnancy  report is used to report an y pregnancy that occurs during the study , whether or not 
matern
al exposure to the product occurred.
Medication error is an y unintentional error in the prescribing, dispensing or administration of a 
medicinal product while in the control of the HCP, patient or consumer.
Abuse is defined as persistent, sporadic or inten tional excessive use of a medicinal product by  a 
patient.
Misuse is defined as an y use of a medicinal product in a way  that the product is intentionally  and 
inappropriatel y used not in accordance with the protocol instructions or the local prescribing 
information.
An overdose is defined as a dose taken (accidentally  or intentionall y) exceeding the dose as 
prescribed b y the protocol or the maximal recommended daily dose as stated in the Product 
Labeling (as it applies to the daily  dose for the subject/patien t in question). In cases of a 
discrepancy  in drug accountability , overdose will be established onl y when it is clear that the 
subject has taken the excess dose(s). Overdose cannot be established when the subject cannot 
account for the discrepancy  except in cases in which the investigator has reason to suspect that 
the subject has taken the additional dose(s)
Product complaint is defined as an y written or verbal report arising from potential deviations in 
the manufacture, packaging or distribution of the pro duct.
Occupational exposure is defined as exposure to a medicinal product as a result of one’s 
professional or non- professional occupation.
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
7.4.2. 
[IP_ADDRESS]. Instruction s for Reporting Special Situation s 
Instrnctions for Repo [ADDRESS_993261] consents to pa1ticipate in the study (i e, signing the info1med consent) and 
throughout t he study , including the post-study diug follow-up period, to [COMPANY_009] PVE (fonnerly 
DSPH) using the Pregnancy Repo1 t fo1 m within 24 hours of beco ming aware of the pregnancy. 
Refe r to Section 7.5 and the CRF /eCRF completion guidelines for full instrnctions on the 
mechanism of pregna ncy repo1t ing. 
The pregna ncy itself is not considered an AE nor is an induced elective abo1tion to te1minate a 
pregnancy without m edical reaso ns. 
Any premature te1mination of pregnancy ( eg, a spontaneous abo1t ion, an induced therapeutic 
abo1tion due to complications or other m edical reasons) must be reported within [ADDRESS_993262]-study di11 g follow up period, 
then t he outcome shou ld be repo1ted to [COMPANY_009] PVE (fo1merly DSPH) using the Pr egna ncy 
Outcome Repo1 t fonn. [COMPANY_009] PVE (forme rly DS PH) contact [CONTACT_2997]1mation is as follows: 
Emai l:I[COMPANY_003] andfax: PD 
Refe r to Appendix 5 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contracep tive Reco mmendations. 
[IP_ADDRESS]. Instrnctio ns for Repo1t ing Other Specia l Situ ations 
All other Specia l Situ ation repo1ts must be repo1ted on the Special Situatio ns Repo1t Fo1m and 
fo1warded to [COMPANY_009] PVE (fonnerly DS PH) with in [ADDRESS_993263] of situatio ns that involve study investigatio nal medicinal products 
(IMPs) , but do not apply to conc01nita nt medicat ions (i .e., except for situ ations th at result in 
adve rse events, special situatio ns involving conc01nita nt medicatio ns wi ll not be repo1ted) . Any 
inapprop riate use of non-protocol approved medicat ions should n ot be repo1ted as "inis use" but 
may be more appropr iately documented as a protocol deviatio n if applicable. 
Refe r to Section 7.5 and the C RF/eCRF completion guidelines for full instruct ions on the 
mechanism of special situations repo1t ing. 
CONFIDENTIAL Page 77 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. Final 
Amendment6 
All clinical sequelae in relation to these specia l situ ation repo1is will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE repo1i fonn. Details of the symptoms and 
signs, clinical management and outcome will be repo1ied , when available. 
7.5. 
7.5.1. Serious Adverse Event Reporting Requirements 
All Serious Adverse Events 
[COMPANY_009] Sciences is required to exped ite to worldwide regulato1y author ities repo1is of Serious 
Adverse Dmg Reactions or Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ; 
therefore , [COMPANY_009] Sciences ( or the CRO on the behalf of [COMPANY_009] Sciences) must be notified 
imm ediately regarding the occmTence of any SAE that occurs after the s ubject consents to 
paiiicipate in the study, inclu ding SAEs resultin g from protocol -assoc iated procedures perfo1med 
from Screening onwai·ds. The procedures for reporting all SAEs , regardless of causal 
relationship, ai·e as follows: 
• A ll AEs and SAEs will be recorded in the CRF /eCRF database within the timeli nes outlined 
in the CRF /eCRF completion guideline. 
• At the time of study start, SAEs will be reported using a paper serious adverse event 
repo1iing fo1m (see following bullet). Durin g the study conduct sites may transition to an 
electro nic SAE ( eSAE) system. [COMPANY_009] will notify sites in writing and provide training and 
account infonnation prior to implementing an eSAE system. 
Seriou s Adverse Event Paper Reporting Process 
All SAEs will be recorded on the serious adverse event repo1i fonn and subinitted by [CONTACT_727421]1i fonn within 24 hours of the investigato r's knowledge of the event to the attentio n of 
[COMPANY_009] PVE (fo1merly DSPH) . Contact [CONTACT_2997]1mation is as follows: 
[COMPANY_009] PVE (fo1merly DSPH): 
[COMPANY_009] Sciences Medical Mon itor: Fax: 
E-mail: IPI[INVESTIGATOR_727390] 
T earn Contact [CONTACT_46979]. 
For fatal or life-threaten ing events , also e-mai l or fax copi[INVESTIGATOR_449680]1is , autopsy 
repo1is , and other docume nts when requested and applicable. Transmission of such documents 
should occur with Personal Subject Details de-identified, without losing the traceability of a 
document to the Subject Identifiers. 
[COMPANY_009] Sciences may request additional info1mation from the investigator to ensure the timely 
completion of accurate safety repo1is. 
CONFIDENTIAL Page 78 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993264]’s CRF and the event description section of the SAE form.
Follow -up of adverse events will continue through the last day  on study  (including the follow-up 
off-study  medication period of the study ) and/or until the investigator and/or [COMPANY_009] Sciences 
determine that th e subject’s condition is stable. [COMPANY_009] Sciences may  request that certain adverse 
events be followed until resolution.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] PVE (formerl y DSPH) within 24 hours of the investigator’s knowledge of 
the event. Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electr onically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting form 
and submit within 24 hours to [COMPANY_009] PVE (formerly  DSPH) as described above.
As soon as it is possible to do so, any  SAE reported via paper must be transcribed into the eCRF 
Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
7.5.2. Investigator and Sponsor Report ing Requirements for SAEs
An SAE may  qualify  for reporting to regulatory authorities. Expectedness of SAEs will be 
determined b y [COMPANY_009] Sciences using reference safety information specified in the I nvestigator’s 
Brochure.
All Investigators will receive a s afety letter notifying them of relevant S[LOCATION_003]R reports. The 
Investigator should notify the IRB or IEC as soon as is practical, of serious events in writing 
where this is required b y local regulatory  authorities, and in accordance with the local 
institutiona l policy .
In accordance with the EU Clinical Trials Directive (2001/20/EC), the Sponsor or specified 
designee will notify  worldwide regulatory  authorities and the relevant Ethics Committees in 
concerned Member States of applicable S[LOCATION_003]Rs.
7.5.3. Post-Study Reporting Requirements
All AEs and SAEs including deaths, regardless of cause or relationship, must be reported for 
subjects on study  (including an y protocol -required post -treatment follow -up).
Any SAEs and deaths that occur after the post- treatment follow -up visit but within [ADDRESS_993265], regardless of causalit y, should also be reported.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993266] -treatment 
follow -up; however, i f the Investigator learns of any  SAEs that occur after study  participation 
and the event is deemed relevant to the use of investigational medicinal products, he/she should 
promptly  document and report the event to [COMPANY_009] PVE (formerl y DSPH).
7.6. Clinical Labor atory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (e.g., clinical chemistry , hematology, urinaly sis) independen
t of the underl ying 
medical condition that require medical or surgical intervention or lead to investigational 
medicinal product interruption or discontinuation must be recorded as an AE, as well as an SAE, 
if applicable. In addition, laboratory  or other a bnormal assessments (e.g., electrocardiogram,
X-rays, vital signs) that are associated with signs and/or sy mptoms must be recorded as an AE or 
SAE if they  meet the definition of an AE (or SAE) as described in Sections 7.1and7.3. If the 
laboratory  abnormality  is part of a s yndrome, record the syndrome or diagnosis (i.e., anemia) 
not 
the laboratory  result (i.e., decreased hemoglobin).
Severity  should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the 
grading of 
the laboratory abnormality .
7.7. Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3.
Grade [ADDRESS_993267] 
discontinuation, unless such a delay  is n
ot consistent with good medical practice.
Clinical events and clinically significant laboratory  abnormalities will be graded according to the 
Table for GSI Grading Scale for Severit y of Adverse Events and Laboratory Abnormalities 
(Appendix 4).
When restarting investigational medicinal product following resolution of the adverse event, the 
investigational medicinal product should be restarted at full dose upon discussion with the 
Medical Monitor.
Any recurrence of the investigational medicinal product
-related Grade [ADDRESS_993268].
Any questions regarding toxicity  management should be directed to the Medical Monitor.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 81 21 February [ZIP_CODE].7.1. Management of Changes in Estimated Glomerular Filtration Rate
Estimated glomerular filtration rate (GFR), according to the Schwartz formula, will be followed 
post- baseline during the study . All subjects with estimated GFR < 50 mL /min must have serum 
creatinine and subject’s height and weight measured again within [ADDRESS_993269] has confirmed estimated GFR < 50 mL /min, the Medic al Monitor should be 
notified and investigational medicinal product discontinued.
7.7.2. Management of Posterior Uveitis Cases
In a nine -month toxicology  study  conducted in dogs, some animals administered the highest dose 
of TAF (12- 18 mg/kg) had minimal mononuclear cell infiltration in the posterior uvea, 
considered secondary  to general debilitation; this finding did not occur in animals given lower 
doses and it has not occurred in other animal studies. This pre-clinical finding has also not been 
observed in huma ns where the dose is much lower, nor have there been reports of posterior 
uveitis in human clinical studies.
Across allongoing Phase 2andPhase 3studies inwhich 2,[ADDRESS_993270] received E/C/F/TAF 
STR for up to [ADDRESS_993271] the [COMPANY_009] Medical Monitor to discuss the need for additional ophthalmologic evaluation 
including dilated fundoscopy  and optical coherence tomography  (OCT).
7.7.3. Grades [ADDRESS_993272] should be withheld until the toxicity  returns to ≤ Grade 2.
If a laboratory  abnormality  recurs to ≥ Grade [ADDRESS_993273] may not require permanent discontinuation.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993274] may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (e.g., Grade 4 CK after strenuous exercise or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product .
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 83 21 February [ZIP_CODE]. STATISTICAL CONSIDERA TIONS
8.1. Analy sis Objectives and Endpoints
8.1.1. Analysis Objectives
Cohort 1
The primary  anal ysis objectives are:
Part A:
To evaluate the stead y state PK for EVG and TAF and confirm the dose of the E/C/F/TAF 
STR in HI V-1 infected, ARV treatment- naive adolescents
Part B:
To evaluate the safet y and tolerability  of the E/C/F/TAF STR through Week 24 in HIV -1 
infected, ARV treatment -naive adolescents
The secondary  analy sis objectives are:
To evaluate the safet y and tolerability  of the E/C/F/TAF STR through Week [ADDRESS_993275] ed, ARV treatment -naive adolescents
To evaluate the antiviral activity  of the E/C/F/TAF STR through Week 48 in HIV-1infected, 
ARV treatment -naive adolescents
Cohort 2
The primary  anal ysis objectives are:
Part A
To evaluate the PK of EVG and TAF in virolog ically  suppressed HIV -1 infected children 
6to < 12 y ears of age, weighing ≥ 25 kg, administered E/C/F/TAF STR
Part B
To evaluate the safet y and tolerability  of E/C/F/TAF STR through Week 24 in virologicall y 
suppressed HIV -1 infected children 6 to < 12 y ears of age
The secondary  analy sis objectives are:
To evaluate the antiviral activity  of switching to E/C/F/TAF STR through Week 48 in 
virologicall y suppressed HIV -1 infected children 6 to < 12 y ears of age, weighing ≥ 25 kg.
To evaluate the safet y and tolerability  of E/C/F/TAF STR through Week 48 in virologicall y 
suppressed HIV -1 infected children 6 to < 12 y ears of age, weighing ≥ 25 kg
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences, Inc. 
Cohort 3 
The prim a1 y analysis objec tives are: Final 
Amendment6 
• To evaluate the PK ofEVG and TAF and confnm the dose of the STR in virologica lly 
suppressed HIV-I infecte d children 2 years of age weighing 14 to < 25 kg admini stered 
E/C/F/TAF LD STR 
• To evaluate the safety and tolerability ofE/C/F/TAF LD S TR through Week 24 in 
virolog ically suppressed HIV-I infected children ~ 2 years of age and weig hing~ 14 to 
<25 kg 
The secondaiy analysis objectives are: 
• To evaluate the antiviral activity of switc hing to E/C/FffAF LD STR through Week 48 in 
virolog ically suppressed HIV-I infected children ~ 2 years of age and weigh ing~ 14 to 
<25 kg 
• To evaluate the safety and tolerability ofE/C/F/TAF LD S TR through Week 48 in 
virolog ically suppressed HIV-I infected children ~ 2 yeai·s of age, weig hing~ 14 to< 25 kg 
All Cohort s 
I 
8.1.2. Prima ry Endpoint s. 
Cohort 1 
In Pait A the pr ima1 y endpo ints ai·e PK pai·ameter of AUC1aufor EVG and AUC 1astfor TAF and 
in Pait B the primaiy endpoints inclu de incidence of treatment-emer gent SAEs and a ll 
treatme nt-eme rgent adverse events. 
Cohort 2 
In Pait A the pr ima1 y endpo ints include PK par amete r of AUC1aufo r EVG and AUC1astfor TAF, 
and in Pait B the pr ima1 y endpo ints inclu de incidence of treatme nt-emer gent SAEs and a ll 
treatme nt-emergent adverse events. 
Cohort 3 
The prima1 y endpo ints include PK pai·ameter of AUC tau for EVG and TAF , incidence of 
treatme nt-eme rgent SAEs, and all treatme nt-emer gent adve rse events. 
CONFIDENTIAL Page 84 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 85 21 February [ZIP_CODE].1.3. Secondary Endpoints
Cohort 1
For Part A, the secondary  endpoints include:
PK parameters of C tau, Cmax, apparent CL and apparent V z for EVG, C max, apparent CL and 
apparent V z for TAF, AUC tau, Cmax, and C tau for FTC, TFV and COBI.
For Part B, the secondary endpoints include:
The percentage of subjects with plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as 
defined b y the FDA snapshot analy sis
Thepercentage ofsubjects with plasma HIV
-1RNA < 400 copi[INVESTIGATOR_014]/mL atWeeks 24and48as 
defined b y the FDA snapshot analy sis
The change from baseline in plasma log 10 HIV-1 RNA (copi[INVESTIGATOR_014]/mL) and in CD4+ cell count
(cells/μL ) and percentage at Weeks 24 and 48
Cohort 2
For Part A, the secondary  endpoints include:
PKparameters of C tau, Cmax,apparent CLandapparent VzforEVG, Cmax,apparent CLand 
apparent V z for TAF, AUC tau, Cmax, and C tau for FTC, TFV and COBI.
For Part B, the secondary endpoints include:
The percentage of subjects with plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as 
defined b y the FDA snapshot analy sis
The percentage of subjects with plasma HIV- 1 RNA < 400 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as 
defined b y the FDA snapshot analy sis.
The change from baseline in CD4+ cell count (cells/μL ) and percentage at Weeks 24 and 48
Cohort 3
The secondary  endpoints include:
PKparameters of C tau, Cmax,apparent CLandapparent VzforEVG, Cmax,apparent CLand 
apparent V z for TAF, AUC tau, Cmax, and C tau, for FTC, TFV and COBI.
The percentage of subjects with plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as 
defined b y the FDA snapshot analy sis.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 86 21 February 2020The percentage of subjects with plasma HIV -1 RNA < 400 copi[INVESTIGATOR_014]/mL at Weeks 24 and 48 as 
defined b y the FDA snapshot analy sis.
The change from baseline in CD4+ cell count (cells/μL ) and percentage at Weeks 24 and 48
8.2. Analysis Conventions
8.2.1. A nalysis Sets
[IP_ADDRESS]. Full Anal ysisSet
The full anal ysis set will include all subjects who received at least one dose of study  drug.
[IP_ADDRESS]. Safety  Anal ysisSet
The safet y analysis set will include all subjects who received at least one dose of study  drug.
All the data co llected up to 30 day s after subjects permanentl y discontinue their study regimen 
will be included in the safety  summaries.
[IP_ADDRESS]. BMD Anal ysisSets
[IP_ADDRESS].1. Spi[INVESTIGATOR_727391], had nonmissing spi[INVESTIGATOR_727392].
[IP_ADDRESS].2. Total Bod y Anal ysisSet
The total body  less head BMD analy sis set will include all subjects who received at least one 
dose of study  drug, had nonmissing total body  less head BMD value for the Baseline visit and at 
least one postbaseline visit.
[IP_ADDRESS]. Pharmacokinetics (PK) Analy sisSets
[IP_ADDRESS].1. Intensive PK Anal ysisSet
The Intensive PK analy sis set will include all subjects who received at least one dose of study  
drug and for whom steady -state pharmacokinetic profiles at Intensive PK visit are evaluable. The 
Intensive PK anal ysis set will be used for detailed PK analy sis of EVG, COBI, FTC, TAF, and 
TFV b y cohort.
[IP_ADDRESS].2. PK Analy sisSet
The PK anal ysis set will include all subjects wh o received at least one dose of study  drug and for 
whom at least one observed concentration data of any  anal yte of interest is available. The PK 
analysis set will be used for anal ysis of general PK and trough blood concentrations by  [CONTACT_9084].
EVG /COBI/FfCffAF 
Protocol GS-US-[ADDRESS_993276] descriptive 
methods. Demographic summ aries will inclu de sex, race/ethnicity , and age. 
Baseline data including body weight, heigh t, body mass index, HIV-1 infection, and emolhnent 
distribution w ill be summ arized. 
8.4. Efficac y Anal ysis 
The perce ntage of subjects with H IV-1 RNA < 50 copi[INVESTIGATOR_014]/mL at Wee k 24 (Windows: Study 
Days 140-195) as defined by [CONTACT_1622]- defined snapshot algorithms ai· e described below. 
Viro logic outco me at Week 24 for the Cohort 1 (treatment-na'ive) subjects will be defined into 
the following 3 catego ries: 
• H IV-1 RNA < 50 copi[INVESTIGATOR_014]/mL: this includes subjects who h ave the last available on-treatment 
HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL in the Week 24 analysis window; 
• H IV-1 RNA::::: 50 copi[INVESTIGATOR_014]/mL: this includes subjects who h ave the last available on-treatment 
HIV-1 RNA::::: 50 copi[INVESTIGATOR_014]/mL in the Week [ADDRESS_993277] available on-t reatme nt HIV-1 RNA ::::: 50 copi[INVESTIGATOR_014] /mL; 
• No Virologic Data in the Week 24 Analysis Window: this includes subjects who do not have 
on-treatment H IV-1 RNA at Week 24 window beca use of the follow ing: 
Discont inuation of study diug prior to or in the Week 24 analysis window due to AE or 
death; or 
Discont inuation of study diug prior to or in the Week [ADDRESS_993278] available on-treatment H IV-1 RNA 
< 50 copi[INVESTIGATOR_014] /mL; or 
Miss ing data in the Wee k 24 window but on s tudy diug 
CONFIDENTIAL Page 87 2 1 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 88 21 February 2020Virologic outcome at Week 24 for the Cohort 2 and Cohort 3 (treatment suppressed) subjects 
will be defined similarly  with the exception of classify ing subjects who discontinue study  drug 
due to AE or death and have the last available on -treatment HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  into the 
“HIV -1 RNA ≥ 50 copi [INVESTIGATOR_014]/mL ” category .
Virologic outcomes will be summarized using frequency  counts and percentages based on the 
Full anal ysis set.
The percentage of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 (Windows: Study  
Days 308- 377) and the percentage of subjects with HIV -1 RNA < 400 copi[INVESTIGATOR_014]/mL  at Weeks 24 
and 48 will be summarized in the same manner as described above.
The changes from baseline in plasma log 10 HIV
-1 RNA (Cohort 1 only ) and in CD4+ cell count 
will be summarized using descriptive statistics.
8.5. Safety A nalysis
All safet y anal yses will be performed using the safety  anal ysis set.
8.5.1. Extent of Exposure
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the study regimen, inclusive, regardless of tempo rary interruptions in study  
regimen administration.
Dosing information for individual subjects will be listed.
8.5.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High- Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Adverse events meeting the following criteria are defined as treatment -emergent AEs.
1)Any AEs with onset date of on or after the stud y drug start date and no later than 30 days 
after permanent discontinuation of study drug
2)Any AEs leading to premature discontinuation of study drug.
Summaries (number and percentage of subjects) of treatment -emergent adve rse events (b y SOC 
and PT) will be provided. Additional summaries will include summaries for adverse events b y 
grade, Investigator’s assessment of relationship to study  drug, and effect on study  drug dosing.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 89 21 February [ZIP_CODE].5.3. Laboratory Evaluations
Laboratory  results will b e expressed both in the original measurement and in terms of the 
toxicity  grade according to toxicity  grading table attached in Appendix 4. Changes from baseline 
in quan
titative laboratory tests will be summarized by  [CONTACT_765] (including eGFR estimated by  
[CONTACT_196856] C clearance for Cohorts 1 and 2). Cy statin C will not be collected for Cohort 3. The 
maximum toxicity  grade will be summarized by  [CONTACT_10862]. The post -baseline 
laboratory  measurements obtained up to [ADDRESS_993279] dose date of the study  drug will be 
included in the quantitative and qualitative summaries.
8.5.4. Bone Safety
Selected bone safet y, including:
Cohorts 1 and 2: serum bicarbonate, N -telopeptide, C-telopeptide, osteocalcin, procollagen t ype 
1 N-terminal propeptide (P1NP), and urine bicarbonate and N -telopeptide
For all cohorts: bone specific alkaline phosphatase, parath yroid hormone (PTH), 25OH 
Vitamin D, and 1,25OH Vitamin D
All the above will be summarized by  [CONTACT_16750].
8.5.5. Renal Safety
Selected renal safety , including urine chemistry , retinol binding protein, and 
beta-2-microglobulin, will be summarized by  [CONTACT_16750].
8.5.6.
Spi[INVESTIGATOR_727393] e Mineral Density
For all cohorts, the percentage change from baseline in spi[INVESTIGATOR_727394]. BMD z -score will be derived for each BMD measurement if the 
corresponding reference population is available. Z-s cores for spi[INVESTIGATOR_727395] z- scores will also be summarized by  [CONTACT_765].
8.5.7. Tanner Stage Assessment
The Tanner stage score will be summarized by  [CONTACT_154023].
8.5.8. Palatability
Palatability  will be summarized using descriptive statistics by [CONTACT_9084].
8.5.9. Acceptability
Acceptability  will be summarized using descriptive statistics.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 90 21 February [ZIP_CODE].6. Pharmacokinetic Analysis
The concentration data of EVG, COBI, FTC, TAF, and TFV over sampling time will be listed 
and summarized. Pharmacokinetic parameters (e.g., AUC tau, AUC last, Cmax, Tmax, Clast, Tlast, Ctau, 
λz, apparent CL , apparent V z and T ½) will be listed and summarized for analy tes EVG, COBI, 
FTC, TAF, and TFV using descriptive statistics (e.g., sample size, arithmetic mean, geometric 
mean, coefficient of variation %, standard deviation, median, Q1, Q3, minimum, and maximum).
To determine whether the adult dose of TAF in adolescents (Cohort 1) and children (Cohort 2 
and 3), respectivel y, achieves similar TAF s ystemic exposures to that in a dults, an analy sis of 
variance will be carried out for log -transformed AUC as a primary  parameter while other 
pharmacokinetic parameters such as Cmax will be explored. TAF data from the current study  will 
be compared to the integrated historical control da ta using pharmacokinetic equivalence testing 
with an equivalency  boundary  of 70% - 143% for the 90% confidence interval. In addition, the 
95% confidence interval of the geometric mean estimate of apparent CL and V z of TAF will be
provided.
Similar analy siswill be done for log -transformed AUC tau as a primary  parameter to determine 
whether the adult dose of EVG in adolescents and children, respectivel y, achieves similar EVG 
systemic exposures to that in adults. Other pharmacokinetic parameters such as C max and C tau will 
be explored. EVG data from the current stud y will be compared to the integrated historical 
control data using pharmacokinetic equivalence testing with an equivalency  boundary  of70% -
143% for the 90% confidence interval. The 95% confidence interval of the geometric mean 
estimate of apparent CL and V z of EVG will also be provided.
Pharmacokinetic parameters of COBI, FTC, and TFV will be summarized using descriptive 
statistics.
8.7. Independent Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy , 
and safet y data of this study while the stud y is ongoing. No formal stoppi[INVESTIGATOR_328791] b y 
the IDMC for safet y outcomes. Rather, a clinical assessment will be made to determine if the
nature, frequency , and severity  of adverse events associated with a study  regimen warrant the 
early termination of the study in the best interest of the participants. A separate IDMC charter 
will be finalized prior to initiation of dosing.
8.8. Analysis Schedu le
Cohort [ADDRESS_993280] 18 subjects (regardless of age distribution) 
complete the Intensive PK portion of the study  (Part A). With confirmation of TAF exposure 
from the first [ADDRESS_993281] completes 48 weeks on stud y.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 91 21 February 2020Cohort 2
A PK anal ysis will be performed after all subjects complete the Intensive PK portion of the study  
(Part A). The Week [ADDRESS_993282] completes 48 weeks on study .
8.9. Sample Size and Power
Cohort 1 and 2
A minimum of 18 Part A subjects from each cohort will receive E/C/F/TAF STR in this study . 
PK data from these subje cts will have 92% power to conclude exposure equivalence of TAF 
AUC last in adolescents and children, respectivel y vs. 51 HIV -1 infected and HIV- negative adults 
(GS-US-292- 0102 and GS -US- 292-0103 combined) using two one -sided tests with each 
performed at an alpha level of 0.05. In this power anal ysis, it is assumed that the expected 
geometric mean ratios of TAF AUC last between adolescent group and adult group are equal to 1, 
and the inter -subject standard deviation (natural log scale) of TAF AUC last is 0.37 ng•hr/mL, and 
the equivalency  boundary  is 70% to 143%.
A minimum of 18 Part A subjects from each cohort will also provide > 99% power to target a 
95% confidence interval within 60% and 140% of the geometric mean estimate of apparent CL 
and V z of TAF respectively , assuming a coefficient of variation (CV) of 38% for CL and 42% for 
Vz (GS-US-292- 0102 and GS -US- 292-0103 combined).
For each cohort, a total of 50 subjects (subjects from Part A and subjects from Part B combined) 
is planned to study  the safet y of the E/C/F/TAF STR. With this sample size, the present study  
will have 92% chance to observe at least 1 SAE, assuming the SAE incidence rate is 5% 
(observed in GS -US-
292-0102).
After amendment [ADDRESS_993283] become available and will be used as historical control for comparison for Cohort 2
(ie,intensive PK data from [ADDRESS_993284]). Given the actual number of enrollments in 
Cohort 2 Part A is 23, a total of 23 subjects will provide 90% power for EVG AUC tau and 88% 
power for TAF AUC last to conclude exposure equival
ence between adults and children. In this 
power analy sis, it is assumed that the expected geometric mean ratios are equal to 1, the 
intersubject standard deviation (natural log scale) of EVG AUC tau and TAF AUC last is
0.34 ng•hr/mL and 0.52 ng•hr/mL, respec tively, 2 one -sided statistical tests are done at an alpha 
level of 0.05, and the equivalency  boundary  is 70% to 143%.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 92 21 February 2020A total of 23 subjects will also provide > 86% power to target a 95% confidence interval within 
60% and 140% of the geometric mean estimate of CL  and V z of TAF respectively , assuming a 
coefficient of variation (CV) of 53% for CL and 76% for V z (based on population PK data from 
GS-US-292- 0104 and GS -US- 292-0111 combined).
Cohort 3
Twenty -five evaluable subjects compared to historical adult data will provide 90% power for 
each of EVG AUC tau and TAF AUC tau to conclude exposure equivalence between children and 
adults. In this power analysis, it is assumed that the expected geometric mean ratios is 1, 
equivalency  boundary  is 70% to 143%, tw o one- sided tests are each performed at an alpha level 
of 0.05, and the intersubject standard deviations (natural log scale) of EVG AUC tau and TAF 
AUC tau are 0.34 ng•hr/mL and 0.52 ng•hr/mL . For historical adult data, we used intensive PK data 
from 19 HI V - 1 infected adults in Study  GS-US-292-0102 for EVG AUC tau and population PK 
data from Studies GS -US-292- 0104 and GS -US-292-0111 combined for TAF AUC tau.
Twenty -
five evaluable subjects will also provide > 99% power to target a 95% confidence 
interval wit hin 60% and 140% of the geometric mean estimate of apparent CL  and V z of TAF 
respectivel y, assuming the standard deviation in natural log scale is 0.51 for CL  and 0.54 for V z 
(based on population PK data from Studies GS- US-292- 0104 and GS -US-292-0111 combi ned).
Sample size and power calculations were made using the software package nQuery  Advisor 
(Version 6.0) and R.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 93 21 February [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The Investigator will ensure that this study  is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tok yo, Venice, Hong Kong, Washington, 
Seoul, and South Africa), I nternational Conference on Harmonisation (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject. For studies conducted under a [LOCATION_002] I ND, the 
Investigator will ensure that the basic principles of “Good Clinical Practice,” as outlined in
21
CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 
”Protection of Human Subjects”, and 21 CFR, part 56, ”Institutional Review Boards”, are 
adhered to. These standards are consistent with the requirements of the European Community  
Directive 2001/20/EC.
Since this is a “covered” clinical trial, the investigator will ensure that 21 CFR, Part 54, 1998, is 
adhered to; a “covered” clinical trial is any  “stud y of a drug or device in humans submitted in a 
marketing application or reclassification petition subject to this part that the applicant or FDA 
relies on to establish that the product is effective (including studies that show equivalence to an 
effective product) or that make a significant contribution to the demonstration of safet y.” T his 
requires that investigators and all subinvestigators must provide documentation of their financial 
interest or arrangements with [COMPANY_009] Sciences, or proprietary interests in the drug being studied. 
This documentation must be provided before participation of the investigator and an y 
subinvestigator. The investigator and subinvestigator agree to notify  [COMPANY_009] Sciences of any  
change reportable interests during the stud y and for one year following completion of the study. 
Study  completion is defined as the date that the last subject has completed the protocol defined 
activities.
This study  is also subject to and will be conducted in accordance with 21 CFR, part 320, 1993, 
“Retention of Bioavailability  and Bioequivalence Testing Samples.”
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC)/Research Ethics Board (REB) Approval
This protocol and an y accompan ying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study  used to obtain informed 
consent) will be submitted by  [CONTACT_384782] I RB/EC/REB. Approval from the 
IRB/EC/REB must be obtained before starting the study  and should be documented in a letter to 
the investigator specify ing the protocol number, protocol version, pro tocol date, documents 
reviewed, and date on which the committee met and granted the approval.
Any modifications made to the protocol after receipt of I RB/EC/REB approval must also be 
submitted to the I RB/EC/REB for approval before implementation.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993285] utilize an I RB/EC/REB -approved consent form for documenting written 
informed consent. Each informed consent will be appropriatel y signed and dated b y the subject 
or the subject’s legally  authorized representative and the person obtaining consent.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, and an 
identificati on code (i.e., not names) should be recorded on an y form or biological sample 
submitted to the Sponsor, I RB/EC/REB, or laboratory . The investigator must keep a Screening 
log showing codes, names, and addresses for all subjects screened and for all subjects enrolled in 
the trial.
The investigator agrees that all information received from [COMPANY_009] Sciences, including but not 
limited to the I nvestigator Brochure, this protocol, CRFs, the investigational new drug, and any  
other study  information, remain the sole and exclusive propert y of [COMPANY_009] Sciences during the 
conduct of the stud y and thereafter. This information is not to be disclosed to any third part y 
(except employ ees or agents directly  involved in the conduct of the study  or as required by  [CONTACT_2371]) 
without pr ior written consent from [COMPANY_009] Sciences. The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by  [CONTACT_727422] y or otherwise into the public domain.
9.1.5. Study Files and Retent ion of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categ ories: (1) investigator’s study  file, and
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/EC/REB approval with correspondence, informed consent, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include, but is not limited to sequential notes containing at least 
the following information for each subject:
Subject identifica tion (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, i.e., history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Participation in trial (including trial number);
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. 
• Tr ial discussed and date of info1med consent; 
• Dates of all visits ; 
• Docume ntation that protocol specific procedures were perfo1med ; 
• Results of efficacy parameters , as required by [CONTACT_760] ; Final 
Amendment6 
• Staii and end date (including dose regimen) of trial medicatio n (preferab ly drng dispensing 
and r eturn shou ld be documented as well); 
• Reco rd of all adverse events and other safety pai·ameters (staii and end date, and pr eferably 
including causa lity and in tensity) ; 
• Concomita nt medicat ion ( including staii and end date, dose if relevant; dose changes shou ld 
be motivated) ; 
• Date of trial completio n and reason for early discont inuation, if applicab le. 
All clinical study documents must be retained by [CONTACT_20616] r until at least 2 yeai·s after the 
last approval of a marketing applicat ion in an ICH region (i.e., [LOCATION_002] , Europe , or Japan) 
and until there are no pending or conte mplated mai·keting applicat ions in an ICH region; or, if no 
applicat ion is filed or if the applicatio n is not approved for such indicatio n, until [ADDRESS_993286] be made betwee n the investigato r and [COMPANY_009] Sciences 
to store these in sealed containers outside of the site so that they can be returned sealed to the 
investigato r in case of a regulato1y audit. Whe n source docume nts ai·e required for the co ntinued 
cai·e of the su bject, appropr iate copi[INVESTIGATOR_727396]. 
CONFIDENTIAL Page 95 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 96 21 February [ZIP_CODE].1.6. Electronic Case Report Forms (eCRFs)
For each subject enrolled, an eCRF must be completed and signed b y the principal investigator 
[INVESTIGATOR_727397](asappropriate) within areasonable time period after data collection. This also 
applies to records for those subjects who fail to complete the study  (even during a 
prerandomization screening period if an eCRF was initiated). If a subject withdraws from the 
study , the reason must be noted on the eCRF. If a subject is withdrawn from the study  because of 
a treatment -limiting adverse event, thorough efforts should be made to clearly  document the 
outcome.
9.1.7. Drug Accountability
The investigator is responsib le for ensuring adequate accountability  of all used and unused study  
drug kit. This includes acknowledgment of receipt of each shipment of study  drug (quantity  and 
condition). All used and unused study  drug kits dispensed to subjects must be returned to th e site.
Each stud y site must keep accountabilit y records that capture:
The date received and quantity  of study  drug kits 
The date, subject number, and the study  drug kit number dispensed.
The date, quantit y of used and unused study drug kits returned, alo ng with the initials of the 
person recording the information.
All drug supplies and associated documentation will be periodically  reviewed and verified by  [CONTACT_727423] .
9.1.8. Inspections
The investigator should understand that s ource documents for this trial should be made available 
to appropriatel y qualified personnel from [COMPANY_009] Sciences or its representatives, to 
IRB/EC/REBs, or to regulatory  authority  or health authority  inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by [CONTACT_10869]. All protocol modifications must be submitted to the I RB/EC/REB 
in accordance with local requirements. Approval must be obtained before changes can be 
implemented.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 97 21 February [ZIP_CODE].2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency (ies).
[COMPANY_009] Sciences will ensure that the report meets the standards set out in the I CH Guideline for 
Structure and Content of Clinical Study  Reports (ICH E3). Note that an abbreviated report ma y 
be prepared in certain cases.
After conclusion of the study  and without prior written approval from [COMPANY_009] Sciences, 
investigators in this study may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met :
Theresults ofthestudy intheir entiret yhave been publicly disclosed by[CONTACT_727424], manuscript, or presentation form; or
The study  has been completed at all study  sites for at least 2 years.
No such communication, presentation, or publication will include [COMPANY_009] Sciences’ confidential 
information (see Section 9.1.4).
The investigator will submit any  proposed publication or presentation along with the respective 
scientific journal or presentation forum at least 30 day
s before submission of the publication or 
presentation. The investigator will comply  with [COMPANY_009] Sciences’ request to delete r eferences to 
itsconfidential information (other than thestudy results) inanypaper orpresentation andagrees 
to withhold publication or presentation for an additional 60 day s in order to obtain patent 
protection if deemed necessary .
9.3. Joint Investigator/ Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol (eg, attendance at I nvestigator Meetings ). If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies an y 
expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to I nformation for Monitoring
In accordance with ICH Good Clinical Practice (ICH GCP) guidelines, the study  monitor must 
have direct access to the investigator’s source documentation in order to verify  the data recorded 
in the eCRFs for consistency .
The monito r is responsible for routine review of the eCRFs at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRFs. The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected in the course of these monitoring visits are resolved.
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993287] of any  inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilea d Sciences and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. Final 
Amendment6 
10. REFERE NCES 
Airo ldi M, Zaccarell i M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pi [INVESTIGATOR_592419] -a-day 
HAART: a simplificatio n strategy that improves adhere nce and quality of life of 
HIV-infected subject s. Patient prefere nce and adhere nce 2010;4: 115-[ADDRESS_993288], Ragland K, Monk A, Deeks SG. A one-pi [INVESTIGATOR_4382], once-daily , fixed -dose comb ination 
(FDC) of efavirenz, emti· icitabine , and tenofovi r disoproxi l fumarate 
(EFV /FTCffDF) regime n is associated with higher unannounced pi[INVESTIGATOR_727398] n-one pi [INVESTIGATOR_4382], once-dai ly [Poste r]. 17th Confe rence on Reti·ov irnses 
and Opport unistic Infectio ns (CROI); 2010 Febrnaiy 16-19; San Francisco, CA. 
Capeau J. Premat ure Aging and P remat ure Age-Related Comorb idities in HIV-Infected Patients: 
Facts and H ypotheses. Clin Infect Dis 2011;53 (11): 1127-9 . 
Dejesus E, Young B, Mora les-Rami rez JO, Sloan L, Wai·d DJ, Flaherty JF, et al. Simplificat ion 
of antireh'oviral therapy to a single-tablet regime n consisting of efavirenz, 
emti· icitabine , and tenofovi r disoproxi l fumai·ate versus unmodified antireti·ov iral 
therapy in virolog ically suppressed HIV-I -infected patients. J Acquit· hnm une 
Defic Synch· 2009 ;51 (2):163 -74. 
Depaiime nt of Health and Human Services (DHHS), Panel on AntiI·eu-oviI·al Therapy and 
Med ical Manageme nt of HIV-Infected Chil ch·en. Guidelines for the Use of 
Antireti·ov iral Agents in Pediati-ic HIV Infection. Available at 
https: //aidsinfo.n ih.gov/guidelines. [Repo1i] Last Updated: May 22. 2018 . 
EMTRIV A®, [COMPANY_009] Sciences Inc. EMTRIV A® ( emu-icitab ine) capsule, for oral use. 
EMTRIV A® ( emu-icitab ine) oral solution. US Prescribing Infonnatio n. Foste r 
City, CA. Revised November. 2012: 
[COMPANY_009] Sciences Inc. VIREAD® (tenofovii· disoprox il fumarate) Tablets and Powder for oral use. 
US Prescrib ing Info1mat ion. F oster City, CA. Revised August 2012: 
Hodder SL, Mounzer K, Dejes us E, Ebrahimi R, Gr imm K, Esker S, et al. Patient- Repo 1ied 
Outcomes in Vii·o logically Suppressed , HIV-I-Infected Subjects After Switc hing 
to a Simp lified, S ingle-Tablet Regimen of Efavii·enz, Emu-icitab ine, and 
Tenofovii· DF. AIDS Patient Cai·e STDS 2010;24 (2):87 -96. 
Joint United Natio ns Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Available at: 
http://www .unaids.org/s ites/default/files /media_asset/UNAI DS_FactSheet _en.pdf . 
2016. 
Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gai·galianos P, et al. Chang ing patterns of 
mo1iality across Europe in patients infected with HIV-1. EuroSIDA Study Group. 
Lancet 1998;352 (9142):1725 -30. 
CONFIDENT IAL Page 99 21 Febrna1y 2020 
EVG /COBI/FfCffAF 
Protoco l GS-US-292 -0106 
[COMPANY_009] Sciences , Inc. Final 
Amendment6 
Palella FJ, Delaney KM, Moo1ma n AC, Loveless MO, Fuhrer J, Satten GA, et al. Decl ining 
Morbidity and Mortality Amo ng P atients With Advanced Human 
Immu nodeficiency Vims Infectio n. N Eng J Med 1998;338 (13):853 -60. 
Panel on Antiretroviral Guidelines for Adults and Adolesce nts. Guid elines for the u se of 
antiretrov iral agents in HIV-I-in fected adults and adolescents. Depaiime nt of 
Health and Human Serv ices. 1-239. Available at 
http://www .aidsinfo.ni h.gov/ContentFiles / Adul tandAdolesce ntGL.pdf. Accessed 
Augu st 22. 2012. 
Panel on Antiretrov iral Therapy and Med ical Management of HIV-infected Children. G uidelines 
for the u se of antiretrovira l agents in pediatric HIV infect ion: Avai lable at: 
http://aidsinfo.ni h.gov/Conte ntFiles/PediactricGu idelines.pdf. Accessed 
Septe mber 9, 2012 . 2011: 1-279. 
Prejean J, Song R, He rnandez A, Ziebe ll R, Gree n T, Walke r F, et al. Estimated HIV incide nce 
in the Un ited States , 2006 -2009 . PLoS ONE 2011;6 (8):el 7502. 
Sax PE, Meyers J, Mu gavero M, Davis KL. Adhere nce to Antiretrov iral Treatment Regime ns 
and Co1Telation with Risk of Hospi[INVESTIGATOR_5186] n Amo ng Comme rcially Insmed HIV 
Patients in the Un ited States [Poster 0113]. 10th International Congress on D mg 
Therapy in HIV Infection; 2010 November 7-11; Glasgow , [LOCATION_006]. 
Sax PE, Wohl D, Y in MT, P ost F, DeJesus E, Saag M, et al. Tenofovir alafe namide versus 
tenofovir disoprox il fumai·ate , cofonnulated with el vitegravir , cobic istat, and 
emtr icitabine , for initial treatme nt ofHIV-1 infection: two randomised, double-
blind, phase 3, non-inferiority trials. Lancet 2015;385 :2606 -15. 
Sterne J, Hem an M, L edergerber B, Tilling K, Webe r R, Sendi P, et al. Long-te1m effective ness 
of potent an tiretroviral therapy in preve nting AIDS and death: a prospective 
coho1 i study. Lancet 2005 ;366 (9483):378 -84. 
World Health Organization (WHO). Developi[INVESTIGATOR_727399] 2 .0 Prior ities. 
Presented at: Paed iatric Antiretroviral Work ing Group.; 2011 25-26 Octobe r; 
Geneva, Switzerla nd. 
CONFIDENTIAL Page 100 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 101 21 February 202011. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6. Stage -3-Defining Opportunistic Illnesses in HIV Infection
Appendix 7. Tanner Stages
EVG/COBJ/FTC/f AF 
Protocol GS-US-292-[ADDRESS_993289] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of 
the Elvitegravir/Cobicistat/Emtricitabine/fenofovir Alafenamide (E/C/F/TAF) Single Tablet 
Regimen (STR) in HIV-1 Infected Antiretrovira l Treatment-Naive Adolescents and 
Virologically Suppressed Children 
GS-US-292-0106, Amendment 6, 21 February 2020 
This protocol bas been approved by [CONTACT_10869], lnc. The following signature 
[CONTACT_139142]. 
PD 
Name (Printed) 
PD 
Date [COMPANY_003] 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated . 
I will provide all study personnel under my supervis ion copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_279395] 102 21 February 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 103 21February 2020Appendi x 2. Study Procedures Table
Study Procedures ScreeningaBaseline 
(Day 1)Week 1
(Day 7)Week 2bIntensive 
PKcEnd of Weekb
30-Day 
Follow -
updESDDe4 8 12 16 24 32 40 48
Assent/Informed 
ConsentX
Medical History X
Adverse Events X X X X X X X X X X X X X X X
Concomitant 
MedicationsX X X X X X X X X X X X X X X
Vital Signsf X X X X X X X X X X X X X X X
Complete Physical 
ExamX X X X X
Symptom -Directed 
Physical ExamgX X X X X X X X X X
Height X X X X X X X X X X X X X X
Weight X X X X X X X X X X X X X X
Tanner Stage 
EvaluationshX X X
12-lead ECG -
performed supi[INVESTIGATOR_727400]-1 Genotypei X
Hematology Profilej X X X X X X X X X X X X X X
Chemistry Profilek X X X X X X X X X X X X X X
Full flow cytometry 
panel testingX X X X X X X X X X X X X
Metabolic 
Assessmentsl Xff Xee X X
Plasma HIV -1 RNAm X X X X X X X X X X X X X X
CCI
EVG /COBI/FfCffAF 
Protocol GS-US-292 -0106 
[COMPANY_009] Sciences, Inc. 
Serologie s X 
Urinaly sis X 
Estima ted Glomemlar X 
X 
Urine Pregnancy Testq 
Dispense Dosing Diaty 
(for Patt A s ubjects , 
inclusive of Coho tt 3) 
Review Dosing Diaty 
(For Patt A s ubjects , 
inclusive of Coho tt 3) 
Sing le PK Sampling1' 
Trough PK Samp les 
CONFIDENTIAL X X X 
X X X 
X X X 
xff X 
X 
xee xee 
X X X X X X 
X X X X X 
X X X X X 
xz X X X 
xff X 
Page 104 X X X 
X X X 
X X X 
xdd xdd 
X Final 
Amendment6 
X X 
X X 
X X 
X 
21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 105 21 February 2020Study Procedures ScreeningaBaseline 
(Day 1)Week 1
(Day 7)Week 2bIntensive 
PKcEnd of Weekb
30-Day 
Follow -
updESDDe4 8 12 16 24 32 40 48
DXA Scan (Lumbar 
spi[INVESTIGATOR_050] & Total Body)vX X X
Bone Safetyw Xff Xee Xdd X X X
Urine Renal Safetyx Xff Xee X X X X
Study Drug 
DispensationX X X X X X X X X
In-clinic Dosingy X X X X X X X
Drug Accountability X X X X X X X X X X X X
Palatability and 
Acceptability 
AssessmentXbb Xbb Xaa,bb Xaa Xaa Xaa,bb Xcc Xcc
a Evaluations to be completed within 35 days prior to Baseline (or 42 days for subjects who require repeat testing of the HIV -1genotype).
b All study visits are to be scheduled relative to the Baseline/Day 1 visit date. Visit windows are ± 2 days of the protocol-specified visit date from Week 2 through Week 8, 
± 4 days of the protocol-specified visit date from Week 12 through Week 48, , unless otherwise specified.
c Part A subjects only, inclusive of Cohort 3. The Intensive PK evaluation will occur a t the Week 4 (Cohorts 1 and 2) or Week 2 (Cohort 3) visit. For the purpose of scheduling 
the Intensive PK visit, a + [ADDRESS_993290] should be instructed to return in a fasted state within 7 days of their Week 4 (Cohorts 1 and 2) or Week 2 (Cohort 3) visit for 
the Intensive PK visit.
d Only required for those subjects not enrolling in the  phase of the study or those subjects who permanently discontinue study drug and do not continue in the study 
through atleast onesubsequent visit after theEarly Study Drug Discontinuation Visit. Forthepurpose ofscheduling a30-DayFollow -UpVisit, a ± [ADDRESS_993291] dose of study drug.
f Vital signs include blood pressure, pulse, respi[INVESTIGATOR_1487], andtemperature.
g Symptom -directed physical examinations performed as needed.
h Tanner assessments will be performed on subjects ≥ [ADDRESS_993292] r eceived the results from the Screening g enotype 
before proceeding with the Baseline visit. (Cohort 1 only)
j CBC with differential and platelet count.
k Chemistry profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect bilirubin, cystatin C (Cohorts 1 and 2; Baseline, Weeks 2 [ Cohort 1 only ], 4, 24, and 
48), total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodi um, CPK, and uric acid
l Fasting glucose andlipid panel (total cholesterol, HDL, direct LDL, triglyceride s).
Ifthesubject hasnotfasted prior tothevisit, thevisit mayproceed, butthesubject must return within 72hours inafasted state todraw blood forthemetabolic assessments.
CCI
CCI
CCI
CCI
CCI-
EVG /COBI/FfCff AF 
Protoco l GS-US-[ADDRESS_993293] s (inclu sive of Cohort 3), back -up sampl es will not be collected at Weeks I, 2, and 4 visits for Cohort I and at Week s I through 16 for Cohorts 2 and 3. For 
Pait B sub' ects back-u sam !es will be collected at all visits. r 
0 I' q ema es o c [ADDRESS_993294] at any VlSlt. 
r Cohoit I: a timed random PK samp le collected at Week 4 (Part B subjects only) and Week [ADDRESS_993295]-dose . A random PK sample collected at Week 8, 
Week 16, and Week 32. Cohoit 2: a timed PK at Week 12 between 0.25-4 hom·s post-dose. A random PK samp les at Week 8 and Week 16. Cohoit 3: a timed PK sample 
collected between 0.25 and 4 hom·s post-dose at Week 8, 12, and 16. 
s Subjects must come into the clinic without taking their dose ofE/C/F/fAF STR and subjects shou ld fast ovem ight (a minimum of8 hotu-s). A trough ([ADDRESS_993296]-dose) 
plasma PK sampl e will be collected at Weeks 1, 2, and 24 for subjects in Cohort I and 2 and Week 48 for Cohoit I only. For subjects in Cohoit 3, a trough sample will be 
collected at Weeks 4 and 24. 
Pait A subjects only, inclusive of Cohoit 3. Inten sive PK sampling will be peifonued on Week 4 (Cohoits 1 and 2) or Week 2 (Cohoit 3). For the ptupo se of scheduling the 
Inten sive PK visit a + [ADDRESS_993297] shou ld be instmcted to rettun within fotu· days for the Inten sive PK visit. If dosing non-compliance is identified on or prior to the Inten sive PK 
visit, the Inten sive PK assessments must not be completed . The subject should be coun seled regarding proper dosing and asked to rettun for the Inten sive PK visit no sooner 
than three da s followin com liant dosin and no later than Week 4 + 7 da s. Please refer to the PK/PBMC manual for sam le collection and rocessino details. r 
V 
w or o oits an , one sa ety mc u mg: 
Senllll: bicarbonate, N-telop eptide, C-t elopep tide (CDC) , osteocalcin , procollagen type 1 N-terminal propeptide (PI[INVESTIGATOR_680]) 
Urine : bicarbonate , N-telop eptide 
For all cohoits , bone safety including : 
Senllll: bone specific alkaline phosphatase , parathyroid hormone (PTH) , 25OH Vitaniin D and 1, 25OH Vitaniin D 
x Urine Renal Safety including: m-ine chemi stry, retinol binding protein , and beta-2-microglobulin . 4 and 48 (± IO days).-
y All subjects will be given their dose ofE/C/F /fAF STR with food. For those subjects that take their medication in the evening , the in-clinic dosing will not be pe1foimed . 
z Cohoit I Pait B subjects only 
aa To be pe1foimed for all Cohoit 1 subjects ctm·ently on stt1dy at their next schedu led visit. 
bb To be peifoimed at Baseline and Week 4 for all Cohoit 2 subjects and at Baselin e, Weeks 4, 24, and 48 for all Cohort 3 subjects enrolled . 
cc To be peifoimed at ESDD or 30-Day Follow -Up visit for either Cohort 1 or 2, as applicable . 
dd Cohoit I subjects only 
Cohoit I and 2 subjects only 
Cohoit 3 sub'ects 
CONFIDENTIAL Page 106 21 Febrna1y 2020 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 107 21 February 2020Appendix 3. Management of Clinical an d Laboratory Adverse Events
'f 
l\:la..- COil'DDUf 
dosing at th:e 
discretion of die 
inn:stig, to Grade . 
H confi1,ne,d and poss.ib11 1.,-au ot probably reb1ted! to 
in'loies:rigati ou,'ll ml'dkiinal p1roouc,5: Repeat fab t, o 
confirm tm:ici.n· 
grade • 
l. \'\iit:hhoM im.-e-stigational medir.inall p1·oduets UIJrtil •Gt· .:1de • 
' Restm . 1 al] inwsrn:ganou.,~ tnedicinai pl'Oducts at full d'O& e 
H Grade J, or 4 t'ecunenee that i.~ confirmed and. po~ilily 01· 
pll!ibably 1-d:ited fu i.m·e.srtigntion:ii l mediri.nal p1roducts, . dm:-on:tinue 
all m\'·~tigati onal mem.ci.rutl produr~ dosing petil!lllmenth· Gnule3 
,. 
Repe, t Jnb to 
con.firm tm:k:it'> 
g1·ade · 
If ,tonfi.nm-d au.d um.\fbU,ed to 
i.nn-sn;gational mtsdicin:al . prmb1tis, 
dosing may , c,ontinuts , a,t tihe 
dhtntion of the in11"e:stigat ,or ff c.onfumed aml 
possih ,~-or pmbab~· 
I_. nL,ted ro 
im,<' ligati-on,d 
mt'.dici.na:t pt"Oducts 
distmuinue 
iu. w liga.ti-onall 
mt'mdnaJ prnduc s 
dosing pe1110m1enrtly 
and follow at pe1riodic 
inren-als at i1east 
weekh' unfil a, trefurn 
to bas~line or is 
otil'mwe npbined 
li Grad1e 3 01· 41·ecun 1ence ~il'm. t is ,i:rnns.iderod um·efoted 1to 
inn-stigationru medicinal p1"0d11ct continue all! ioxes ·tigati.on.,~ 
lllfldicmal products ar the _ ,m.e dose at thi' disere,ti ,ou. of the 
im-estigat or 
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 108 21 February 2020Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Version: 18 June2012
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5 to 10.0 g/dL 85 to 100 g/L 7.5 to 8.5 g/dL 75 to 85 
g/L6.5 to 7.5 g/dL 65 to 75 
g/L6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days10.0 to 10.9 g/dL 100 to 109 
g/L OR
Any decrease from Baseline
2.5 to 3.5 g/dL 25 to 35 
g/L9.0 to 10.0 g/dL 90 to 100 
g/L OR
Any decrease from Baseline
3.5 to 4.5 g/dL 35 to 45 
g/L7.0 to 9.0 g/dL 70 to 90 
g/L OR
Any decrease from Baseline
4.5 g/dL
45 g/L7.0 g/dL
70 g/L
Infant, 36 –56 Days (HIV 
POSITIVE OR NEGATIVE )8.5 to 9.4 g/dL 85 to 94 g/L 7.0 to 8.5 g/dL 70 to 85 
g/L6.0 to 7.0 g/dL 60 to < 70 
g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days (HIV 
POSITIVE OR NEGATIVE )9.5 to 10.5 g/dL 95 to 105 g/L 8.0 to 9.5 g/dL 80 to 95 
g/L7.0 to 8.0 g/dL 70 to 80 
g/L7.0 g/dL
70 g/L
Infant, 1 –21 Days (HIV 
POSITIVE OR NEGATIVE )12.0 to 13.0 g/dL 120 to 130 
g/L10.0 to 12.0 g/dL 100 to 
120 g/L9.0 to 10.0 g/dL 90 to 100 
g/L9.0 g/dL
90 g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric,
7 Days1000 to 1300/mm3
1.00 to 1.30 GI/L750 to 1000/mm3
0.75 to 1.00 GI/L500 to 750/mm3
0.50 to 0.75 GI/L500/mm3
0.50 GI/L
Infant , 2 –7 Days 1250 to 1500/mm3
1.25 to 1.50 GI/L1000 to 1250/mm3
1.00 to < 1.25 GI/L750 to 1000/mm3
0.75 to < 1.00 GI/L750/mm3
< 0.75 GI/L
Infant , 1 Day 4000 to 5000/mm3
4.00 to 5.00 GI/L3000 to 4000/mm3
3.00 to < 4.00 GI/L1500 to 3000/mm3
1.50 to < 3.00 GI/L1500/mm3
< 1.50 GI/L
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 109 21 February 2020HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 300 to 400/mm3200 to 300/mm3100 to 200/mm3100/mm3
13 Years 300 to 400/μL 200 to 300/μL 100 to 200/μL 100/μL
Absolute Lymphocyte Count 
HIV NEGATIVE ONLY
Adult and Pediatric
13 Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100 to 125 GI/L50,000 to 100,000/mm3
50 to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25 GI/L
WBCs 2000/mm3 to 2500/mm3
2.00 GI/L to 2.50 GI/L1,500 to 2,000/mm3
1.50 to 2.00 GI/L1000 to 1,500/mm3
1.00 to 1.50 GI/L1000/mm3
1.00 GI/L
Hypofibrinogenemia 100 to 200 mg/dL
1.00 to 2.00 g/L75 to 100 mg/dL
0.75 to 1.00 g/L50 to 75 mg/dL
0.50 to 0.75 g/L50 mg/dL
0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600 mg/dL — —
ULN to 6.0 g/L 6.0 g/L — —
Fibrin Split Product 20 to 40 μg/mL
20 to 40 mg/L40 to 50 μg/mL
40 to 50 mg/L50 to 60 μg/mL
50 to 60 mg/L60μg/mL
60 mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN
International Normalized 
Ratio of prothrombin time 
(INR)1.[ADDRESS_993298] >1.[ADDRESS_993299] >2.[ADDRESS_993300] >3.[ADDRESS_993301]
Activated Partial 
Thromboplastin Time (APTT) 1.00 to 1.66 ULN 1.66 to 2.33 ULN 2.33 to 3.00 ULN 3.00 ULN
Methemoglobin 5.0 to 10.0% 10.0 to 15.0% 15.0 to 20.0% 20.0%
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 110 21 February 2020CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L
130 to <LLN mmol/L125 to 130 mEq/L
125 to 130 mmol/L121 to 125 mEq/L
121 to 125 mmol/L121 mEq/L
121 mmol/L
Hypernatremia 146 to 150 mEq/L
146 to 150 mmol/L150 to 154 mEq/L
150 to 154 mmol/L154 to 159 mEq/L
154 to 159 mmol/L159mEq/L
159mmol/L
Hypokalemia 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to 3.0 mEq/L
2.5 to 3.0 mmol/L2.0 to 2.5 mEq/L
2.0 to 2.5 mmol/L2.0 mEq/L
2.0 mmol/L
Hyperkalemia 5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0mEq/L
7.0mmol/L
Hypoglycemia
Adult and Pediatric
1 Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to 55 mg/dL
2.20 to 3.03 mmol/L30 to 40 mg/dL
1.64 to 2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant, 1 Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50 mg/dL
2.2 to 2.8 mmol/L30 to 40 mg/dL
1.7 to 2.2 mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116 to 160 mg/dL
6.42 to 8.91 mmol/L160 to 250 mg/dL
8.91 to 13.90 mmol/L250 to 500 mg/dL
13.90 to 27.79 mmol/L500 mg/dL
27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia (corrected for 
albumin if appropriate*)
Adult and Pediatric
7 Days Infant, 7Days7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L
6.5 to 7.5 mg/dL
1.61 to 1.88 mmol/L7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L6.1 to 7.0 mg/dL
1.51 to 1.74 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L6.1 mg/dL
1.51 mmol/L
5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected for 
albumin if appropriate*) 
Adult andPediatric 7Days>ULN to 11.5 mg/dL
>ULN to 2.88 mmol/L11.5 to 12.5 mg/dL
2.88 to 3.13 mmol/L12.5 to 13.5 mg/dL
3.13 to 3.38 mmol/L13.5 mg/dL
3.38 mmol/L
Infant, 7 Days 11.5 to 12.4 mg/dL
2.86 to 3.10 mmol/L12.4 to 12.9 mg/dL
3.10 to 3.23 mmol/L12.9 to 13.5 mg/dL
3.23 to 3.38 mmol/L13.5 mg/dL
3.38 mmol/L
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 111 21 February 2020CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia (ionized) 3.0 mg/dL to LLN
0.74 mmol/L to LLN2.5 to < 3.0 mg/dL
0.62 to 0.74 mmol/L2.0 to 2.5 mg/dL
0.49 to 0.62 mmol/L2.0 mg/dL
0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL
ULN to 1.50 mmol/L6.0 to 6.5 mg/dL
1.50 to 1.63 mmol/L6.5 to 7.0 mg/dL
1.63 to 1.75 mmol/L7.0mg/d L
1.75 mmol/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq/L
0.58 to <LLN mmol/L1.04 to 1.40 mg/dL
0.9 to 1.2 mEq/L
0.43 to 0.58 mmol/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.28 to 0.43 mmol/L0.67 mg/dL
0.6 mEq/L
0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14 Years
Pediatric 1 Year– 14 Years
Pediatric 1 Year2.0 to < LLN mg/dL
0.63 to LLN mmol/L
3.0 to 3.5 mg/dL
0.96 to 1.12 mmol/L
3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.0 mg/dL
0.31 mmol/L
1.5 mg/dL
< 0.47 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Hyperbilirubinemia
Adult and Pediatric
14 Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN
Infant, 14 Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL 342 to 428 
μmol/L25.0 to 30.0 mg/dL
428 to 513 μmol/L30.0 mg/dL
513 μm ol/L
Infant, 14 Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL 342 to 428 
μmol/L25.0 mg/dL
428 μm ol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL
>ULN to 597 μmol/L10.0 to 12.0 mg/d L
597 to 716 μmol/L12.0 to 15.0 mg/d L
716 to 895 μmol/L15.0 mg/dL
895 μm ol/L
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 112 21 February 2020CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypouricemia 1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to 1.5mg/d L
57 to 87 μm ol/L0.5 to 1.0mg/d L
27 to 57 μm ol/L0.5mg/dL
27 μm ol/L
Creatinine 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL
265 to 530 μmol/L6.00 mg/dL
530 μm ol/L
Bicarbonate 16.0 mEq/L to LLN
16.0 mmol/L to LLN11.0 to 16.0 mEq/L
11.0 to 16.0 mmol/L8.0 to 11.0 mEq/L
8.0 to 11.0 mmol/L8.0 mEq/L
8.0 mmol/L
Triglycerides (Fasting) NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL
(Fasting)130 to 160 mg/dL
3.35 to 4.15 mmol/L>160 to 190 mg/dL
>4.15 to 4.92 mmol/L190mg/dL
>4.92 mmol/LNA
Pediatric >2 to <18 years 110 to 130 mg/dL >130 to 190 mg/dL 190mg/dL NA
2.84 to 3.37 mmol/L >3.37 to 4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia (Fasting) 200 to 239 mg/dL
5.16 to 6.19 mmol/L239 to 300 mg/dL
6.19 to 7.77 mmol/L300mg/dL
7.77 mmol/LNA
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to 6.0 ULN 6.0 to 10.0 ULN 10.0 to 20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
EVG/COBI/FTC/TAF
Protocol GS -US-292-[ADDRESS_993302] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin 3.0 g/dL to LLN 30 g/L to 
LLN2.0 to 3.0 g/dL 20 to 30 
g/L2.0 g/dL
20 g/LNA
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 114 21 February 2020URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) See 
Note below
Females>ULN -10 RBC/HPF 10-75 RBC/HPF 75RBC/HPF NA
Males 6-10 RBC/HPF 10-75 RBC/HPF 75RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour 
Collection
Adult and Pediatric
10 Years200 to 999 mg/24 h >999 to 1999 mg/24 h >1999 to 3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to
< 10 Years201 to 499 mg/m2/24 h >499 to 799 mg/m2/24 h >799 to 1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes:
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assigned to Dipstick 
Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or G rade 3), select the higher of the two grades for the 
AE.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 115 21 February 2020CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general) Asymptomatic AND No Asymptomatic AND Non - Symptomatic, non -life- Life-threatening arrhythmia
(By [CONTACT_10871]) intervention indicated urgent medical intervention threatening AND Non -urgent OR Urgent intervention
indicated medical intervention indicated
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia (stable 
angina) OR Testing consistent 
with ischemiaUnstable angina OR Acute 
myocardial infarction
Hem orrhage (significant NA Symptomatic AND No Symptomatic AND Life-threatening hypotension
acute blood loss) transfusion indicated Transfusion of 2 units OR Transfusion of 2 units
packed RBCs (for children packed RBCs indicated (for
10 cc/kg) indicated children 10 cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140– 159 mmHg systolic OR
90–99 mmHg diastolic159– 179 mmHg systolic OR
99–109 mmHg diastolic179 mmHg systolic OR
109 mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other 
than ER visit) indicated
Pediatric 17 Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥ 95th percentile adjusted for 
age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small effusion 
requiring no interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences
(eg, tamponade) OR Urgent 
intervention indicated
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 116 21 February 2020CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV block 
OR Ventricular pause
3.0 secCom plete AV block
Pediatric [ADDRESS_993303] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV block Com plete AV block
Prolonged QTc
Pediatric 16 YearsAsymptomatic, QTc interval
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval
0.450 to 0.464 secAsymptomatic, QTc interval
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval
0.465 to 0.479 secAsymptomatic, QTc interval
0.50 sec OR Increase in 
interval 0.06 sec above 
baseline
Asymptomatic, QTc interval
0.480 secLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filt er, 
invasive procedure)Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure)Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus)
Vasovagal Epi[INVESTIGATOR_1865] 
(associated with a procedure 
of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms OR 
Worsening symptomatic CHFLife-threatening CHF
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 117 21 February 2020RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 
69%FEV1 or peak flow  25% to 
49%Cyanosis OR FEV1 or peak 
flow 25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activitiesDyspnea on exertion causing 
greater than minimal 
interference with usual social 
& functional activitiesDyspnea at rest causing 
inability to perform usual 
social & functional activitiesRespi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_422258]/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis 
OR Medical intervention 
indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in 
affected eye(s)
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing 
greater than minimal 
interference with usual social 
& functional activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in 
affected eye(s)
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 118 21 February 2020SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by [CONTACT_10874] (for 
disabled adults)Thinning or patchy hair loss 
detectable by [CONTACT_110106] –Rash Localized macular rash Diffuse macular, Diffuse macular, Extensive or generalized
maculopapular, or maculopapular, or bullous lesions OR Stevens -
morbilliform rash OR Target morbilliform rash with Johnson syndrome OR
lesions vesicles or limited number of Ulceration of mucous
bullae OR Superficial membrane involving two or
ulcerations of mucous more distinct mucosal sites
membrane limited to one site OR Toxic epi[INVESTIGATOR_111082] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions)
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or minimal 
interference with usual social 
&functional activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activitiesNA
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 119 21 February 2020GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated 
with decreased oral intake 
without significant weight 
lossLoss of appetite associated 
with significant weight lossLife-threatening consequences 
OR Aggressive intervention 
indicate d [eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND 
Intervention indicated (eg, 
diuretics or therapeutic 
paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation)
Constipation NA Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemasObstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea
Adult and Pediatric
1 YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3 stools over 
baseline/24 hrPersistent epi[INVESTIGATOR_727401] 4 –6 stools over 
baseline per 24 hrs.Bloody diarrhea OR Increase 
of 7 stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences
(eg, hypotensive shock)
Pediatric 1 Year Liquid stools (more unformed 
than usual) but usual number 
of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 120 21 February 2020GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
Mucositis/Stomatitis (clinical 
exam)
See also Proctitis, Dysphagia -
OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerationsConfluent pseudom embranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences (eg, aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24 hours) or 
intermittent nausea with no or 
minimal interference with oral
intakePersistent nausea resulting in 
decreased oral intake for 24 –
48 hoursPersistent nausea resulting in 
minimal oral intake for
48 hours OR Aggressive 
rehydration indicated
(eg, IV fluids)Life-threatening consequences
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis
(functional -symptomatic) 
Also see Mucositis/Stomatitis 
for Clinical ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater 
than minimal interference 
with usual social & functional 
activities OR Medical 
intervention indicatedSymptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicatedLife-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or minimal 
interference with oral intakeFrequent epi[INVESTIGATOR_10815]-threatening consequences
(eg, hypotensive shock)
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 121 21 February 2020NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, depression, 
mania, psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activitiesAlteration causing greater 
than minimal interference 
with usual social & functional 
activitiesAlteration causing inability to 
perform usual social & 
functional activitiesBehavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psyc hosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no or 
minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activitiesDisabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder)Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Instit utionalization indicated
CNS Ischemia (acute) NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_727425] a developmental 
screening tool appropriate for 
the settingModerate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the settingSevere developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the settingDevelopmental regression, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 122 21 February 2020NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or 
other neurologic fu nction
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy)Asymptomatic with decreased 
strength on exam OR Minimal 
muscle weak -ness causing no 
or minimal interference with 
usual social & functional 
activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activitiesDisabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respir atory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or minimal 
paresthesia causing no or 
minimal interference with 
usual social & functional 
activitiesSensory alteration or 
paresthesia causing greater 
than minimal interference 
with usual social & functional 
activitiesSensory alteration or 
paresthesia causing inability 
to perform usual social & 
functional activitiesDisabling sensory alteratio n 
or paresthesia causing 
inability to perform basic self -
care functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control (eg, refractory 
epi[INVESTIGATOR_002])
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 123 21 February 2020NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing)
For Worsening of Existing 
Epi[INVESTIGATOR_727402]-
existing seizures (non-
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality)Seizures of any kind that are 
prolonged, repetitive (eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control (eg, refractory 
epi[INVESTIGATOR_002])
Seizure
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting
< 5 minutes with < [ADDRESS_993304] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with
< [ADDRESS_993305] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting
20minutesSeizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated with 
a procedure)NA Present NA NA
Vertigo Vertigo causing no or minimal 
interference with usual social 
& functional activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activitiesVertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 124 21 February 2020MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia Joint pain causing no or Joint pain causing greater Joint pain causing inability to Disabling joint pain causing
See also Arthritis minimal interference with than minimal interference perform usual social & inability to perform basic
usual social & functional with usual social & functional functional activities self-care functions
activities activities
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing greater than minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0BMD t -score or z- score
–2.5Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences
Pediatric 21 Years BMD z -score
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater 
than minimal interference 
with usual social & functional 
activitiesMuscle pain causing inability 
to perform usual social & 
functional activitiesDisabling muscle pain 
causing inability to perform 
basic self -care functions
Osteonecrosis NA Asymptomatic with 
radiographic findings AND 
No operative intervention 
indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic
self-care functions
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 125 21 February 2020SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
ReactionLocalized urticaria (wheals) 
with no medical intervention 
indicatedLocalized urticaria with 
medical intervention indicated 
OR Mild angioedema with no 
medical intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue Malaise Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6 C
99.8F to 101.5 F38.7C to 39.3 C
101.6 F to 102.8 F39.4C to 40.5 C
102.9 Fto 104.9 F40.5C
104.9 F
Pain-Indicate Body Site See 
also Injection Site Pain, 
Headache, Arthralgia, and 
MyalgiaPain causing no or minimal 
interference with usual social 
& functional activitiesPain causing greater than 
minimal interference with 
usual social & functional 
activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Unintentional Weight Loss NA 5% to 9% loss in body weight 
from baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR Aggressive 
intervention indicated [eg, 
tube feeding or total 
parenteral nutrition]
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 126 21 February 2020INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched)Pain/tenderness causing no or 
minimal limitation of use of 
limbPain/tenderness limiting use 
of limb OR Pain/tenderness 
causing greater than mini mal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing 
inability to perform basic self -
care function OR 
Hospi[INVESTIGATOR_059] (other than 
ER visit) indi cated for 
management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 YearsErythema OR Induration of 5 
5 cm to 9 9 cm (or 2581 
cm2)Erythema OR Induration OR 
Edema 9 cm  any diameter 
(or 81 cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pediatric 15 Years Erythema OR Induration OR 
Edema present but 2.5 cm 
diam eterErythema OR Induration OR 
Edema > 2.5 cm diameter but
< 50% surface area of the 
extremity segment (eg, upper 
arm/thigh)Erythema OR Induration OR 
Edema involving 50% 
surface area of the extremity 
segment (eg, upper arm/thigh) 
OR Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pruritis Associated with 
Injection
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 48 h 
treatmentItching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h treatmentGeneralized itching causing 
inability to perform usual 
social & functional activitiesNA
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 127 21 February 2020ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back of 
neck, breasts, abdomen)Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_727426][INVESTIGATOR_10820]-threatening consequences 
(eg, ketoacidosis,
hyperosmolar non -ketotic 
coma)
Gynecomastia Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_143376] & functional 
activities OR Thyroid 
suppression therapy indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater 
than minimal interference 
with usual social & functional 
activities OR Thyroid 
replacement therapy indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss from 
the face, extremities, 
buttocks)Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_727427]/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 128 21 February 2020GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding Spotting observed by [CONTACT_727428]
(IMB) participant OR Minimal greater in duration or amount greater in duration or amount life-threatening hypotension
blood observed during than usual menstrual cycle than usual menstrual cycle OR Operative intervention
clinical or colposcopic exam indicated
Urinary Tract obstruction (eg, 
stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing
life-threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other than Localized, no systemic Systemic anti micro bial
treatmentSystemic anti micro bial 
treatmentLife-threatening
HIV infection) antimicro bial treatment 
indicatedindicated OR Symptoms indicated AND Symptoms consequences
AND Symptoms causing no causing greater than minimal causing inability to perform (eg, septic shock)
or minimal interference with interference with usual social usual social & functional
usual social & functional & functional activities activities OR Operative
activities intervention (other than
simple incision and drainage)
indicated
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transporta tion, pursuing a hobby, etc.
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 129 21February 2020Appendix 5. Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postme nopausal state when they  are >
54years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_10822] a female subj ect of an y age.
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of E/C/F/TAF STR have demonstrated 
that a clinically  relevant interaction with contraceptive steroids was observed or sus pected. If 
used, a hormonal contraceptive should contain at least 30 mcg of ethin yl estradiol. In addition, 
non-clinical toxicity  studies of E/C/F/TAF STR have demonstrated no adverse effect on fertility  
or embry o-fetal development. However, there is no cl inical data of E/C/F/TAF STR in pregnant 
women. Please refer to the latest version of the investigator’s brochure for additional 
information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of child bearing potential requires using at least an acceptable 
effective contraceptive measure. They  must have a negative serum pregnancy  test at Screening 
and a negative pregnancy test on the Baseline/Day 1 visit prior to randomization. I n the event of 
a delay edmenstrual period (over one month between menstruations), a pregnancy  test must be 
performed to rule out pregnancy . This is applicable also for women of childbearing potential 
with infrequent or irregular periods. They  must also agree to one of the followi ng Screening until 
the last dose of study  drug.
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 130 21 February 2020Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure®micro -insert s ystem (provided confirmation of success 3 months after procedure)
Vasectom y inthe male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Barrier methods (one female barrier and one male barrier must be used in combination)
■ Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
■ Male barriers: Male condom (with or without spermicide)
Hormonal methods (including Intrauterine hormone-releasing s ystem (IUS)) must be 
used with barrier methods described above. The hormonal contraceptive shoul d contain at
least [ADDRESS_993306] study  drug dose. 
3)
Contraception Requirements for Male Subjects
During the study , male subject s with female partners of childbearing potential should use
condoms when engaging in intercourse of reproductive potential. Male subjects must also refrain
from sperm donation during treatment and until at least the end of the protocol -defined
posttreatmen t period.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg ,calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenor rhea method (LAM). A female condom and a male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within [ADDRESS_993307] report the information to 
the investigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy
 outcome 
are outlined in Section [IP_ADDRESS] .
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 131 21 February 2020Appendix 6. Stage - 3-Defining Opportunistic Illnesses in HIV Infection
Bacterial infections, multiple or recurrent* Candidiasis of bronchi, trachea, or lungs Candidiasis 
of es ophagus
Cervical cancer, invasive†
Coccidioidomy cosis, disseminated or extrapulmonary  Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month’s duration)
Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month 
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y attributed to HIV§
Herpes simplex: chronic ulcers (>1 month’s duration) or bronchitis, pneumonitis, or esophagitis 
(onset at age >1 month)
Histoplasmosis, disseminated or extrapulmonary  Isosporiasis, chronic intestinal (>1 month’s 
duration) Kaposi sarcoma
Lym phoma, Burkitt (or equivalent term) Ly mphoma, immunoblastic (or equivalent term) 
Lym phoma, primary , of brain
Mycobacterium avium complex or Mycobacterium kansasii , disseminated or extra pulmonary  
Mycobacterium tuberculosis 
of any  site, pulmonary†, disseminated, or extrapulmonary  
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary  
Pneumocystis jirovecii (previously  known as “ Pneumocystis carinii ”) pneumonia 
Pneumonia, recurrent†
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent Toxoplasmosis of brain, onset at age >1 month 
Wasting sy ndrome attributed to HIV§
* Only among children aged <6 years.
† Only among adults, adolescents, and children aged ≥6years.
§ Suggested diagnostic criteria for these illnesses, which might be particularly important for HIV encephalopathy and HIV 
wasting syndrome, are described in the following references: CDC. 1994 Revised classification system for human 
immunodeficiency virus infection in children less than 13 years of age.
MMWR 1994;43(No. RR -
12). CDC. 1993 Revised classification system for HIV infection and expanded surveillance case 
definition for AIDS among adolescents and adults. MM WR 1992;41(No. RR-17).
EVG/COBI/FTC/TAF
Protocol GS -US-292-0106 Final
[COMPANY_009] Sciences, Inc. Amendment 6
CONFIDENTIAL Page 132 21 February 2020Appendix 7. Tanner Stages
1.Pubic hair (m ale and female)
Tanner I no pubic hair at all (prepubertal Dominic state)
Tanner IIsmall am ount of long, dow ny hair with slight pi[INVESTIGATOR_648449] 
(males) or on the labia majora (females)
Tanner III hair becomes more coarse and curly, and begins to extend laterally
Tanner IV adult -like hair quality, extending across pubis but sparing medial thighs
Tanner V hair extends to medial surface of the thighs
2.Genitals (male) (One standard deviation around m eanage)
Tanner I Testes, scrotum, and penis about same size and proportion as in early childhood
Tanner IIEnlargement of scrotum and testes; skin of scrotum reddens and changes in texture; little or no 
enlargement of penis (10.5 -12.5)
Tanner III Enlargement of penis, first mainly in length; further grow th of testes and scrotum (11.5 -14)
Tanner IVIncreased size of penis with grow th in breadth and development of glans; further enlargement of 
testes and scrotum and increased darkening of scrotal skin (13.5 -15)
Tanner V Genitalia adult in size and shape
3.Breasts (fem ale)
Tanner I no glandular tissue: areola follow s the skin contours of the chest
Tanner II breast bud forms, with small area of surrounding glandular tissue; areola begins to widen
Tanner IIIbreast begins to become more elevated, and extends beyond the borders of the areola, w hich 
continues to widen but remains in contour with surrounding breast
Tanner IVincreased breast size and elevation; areola and papi[INVESTIGATOR_141878] a secondary mound projecting from 
the contour of the surrounding breast
Tanner Vbreast reaches final adult size; areola returns to contour of the surrounding breast, w ith a 
projecting central p api[INVESTIGATOR_9387].